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INVESTIGATIONS OF NOVEL MECHANISMS OF ACTION FOR ANTI-BACTERIAL 
AND ANTI-CANCER AGENT DEVELOPMENT 
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of Philosophy at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2014. 
Major Director: Keith C. Ellis 
Assistant Professor, Department of Medicinal Chemistry 
 
 
The development of drugs and therapeutic agents for combating infections and human 
malignancies continues to be a forefront area in both academic and industrial research. 
This is driven by the rapid emergence of multi-drug resistant bacterial strains and 
accumulating mutations in cancer targets that is quickly rendering our current arsenal of 
drugs ineffective for these therapies. Unless new drugs with novel mechanisms of action 
  
 
are identified and developed at a faster pace, we face a losing battle in managing these 
diseases. 
The first part of this work concerns with the natural product Simocyclinone D8 (SD8). 
Simocyclinone D8 is an angucyclinone antibiotic that inhibits DNA gyrase with a novel 
mechanism of action that has been termed competitive inhibition. Simocyclinone D8 was 
found to inhibit the growth of both Gram-(+ve) and Gram-(–ve) organisms and also inhibit 
a fluoroquinolone resistant mutant of DNA gyrase. Inspired by the structure and novel 
mechanism of action that SD8 displays, we synthesized analogues based on the co-
crystal structure of SD8 with DNA gyrase. These compounds were found to inhibit DNA 
gyrase, albeit by a different mechanism of action than that of SD8. We also conducted 
studies towards the total chemical synthesis of SD8 and made three out of the four 
fragments in SD8 in decent yields. 
The second part of this work is focused on the development of a substrate-competitive 
covalent inhibitor for protein kinase B (AKT). AKT is a valid target for cancer research 
with two compounds currently in late stage clinical trials. Developing substrate- 
competitive inhibitors for kinases is a novel approach in targeting them, with very few 
examples in the literature. This mechanism has been postulated to overcome common 
resistance mutations that cancer targets harbor. A major drawback in this approach is the 
low binding affinity for peptide substrates by kinases. We circumvented this problem of 
affinity by utilizing a covalent mode of binding and synthesized a potent non-peptide 
active-site directed irreversible compound that inhibits AKT. Further studies on this 
compound are underway and are expected to yield a compound that can be used as a 
therapeutic agent or as a probe for AKT.     
xvi 
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CHAPTER 1: FLAVONE BASED ANALOGUES INSPIRED BY SIMOCYCLINONE D8 
(SD8) 
1.1: Critical need for New Anti-Bacterial agents  
The discovery of anti-bacterial agents has been one of the most significant scientific 
achievements of the past century. Their influence has not only revolutionized the 
treatment of infectious diseases, but also many advanced surgical procedures would not 
have been possible without them. However, bacterial resistance has evolved to every 
anti-bacterial that has been commercially introduced and most pharmaceutical 
companies have already exited this area of drug discovery1. 
The introduction and discovery of anti-bacterials is the most prototypical incident in the 
archives of medicinal chemistry research. It could be argued that the discovery of the first 
synthetic anti-bacterial agent, Salvarsan (Arsphenamine), by Paul Ehrlich in 1909 was 
the first documented instance of lead optimization by systematic chemical modifications 
for biological activity. In fact, the term “magic bullet” was first introduced in drug discovery.  
Salvarsan was discovered form the lead Atoxyl (Arsanilic acid) and was used for the 
treatment of syphilis and was the world’s first blockbuster drug until the discovery of 
penicillin and sulfonamides. These compounds heralded a new era in medicine, where 
the concept of the “magic bullet” came closer to reality2. 
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Currently there are many anti-bacterial agents that have been introduced to the market. 
Broadly they can be classified into synthetic and natural scaffolds. The synthetic scaffolds 
consist of the sulfonamides, diaminopyridines, quinolones and oxazaolidinones and the 
natural scaffolds consist of β-lactams, tetracyclines, macrolides, aminoglycosides and 
glyco and lipo peptides. However, these compounds target a very limited number of 
clinically relevant targets: DNA gyrase and topoisomerase IV, ribosomal function 
inhibition and inhibition of cell wall biosynthesis. Most compounds currently in the pipeline 
of pharmaceutical companies are derivatives of the above mentioned chemical scaffolds, 
but there already exists microbes with underlying resistance mechanisms in clinical 
settings that have built resistance to all these chemical classes. Derivatizing these already 
existing chemical scaffolds might temporarily improve efficacy of the drug, but the binding 
interaction with the target remains unchanged; hence, development of resistance to the 
scaffold is just a matter of time3.  
Drug resistance is mostly seen in gram-positive and gram-negative organisms, both in 
hospital and community based settings. The majority of these organisms that cause 
infections and are effectively resistant to most of the current drugs have been collectively 
termed as the “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa and 
Enterobacter species). In addition to these, there are reports of increasing infection and 
death rates in hospitals due to methicillin-resistant S. aureus (MRSA), vancomycin-
resistant E. faecium (VRE) and fluoroquinolone-resistant P. aeruginosa. Due to the 
increasing immunocompromised patient population consisting of geriatrics, patients 
undergoing surgery, chemotherapy and neonatal units, infections due to these antibiotic 
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resistant pathogens are rising rapidly and are of significant concern in the medical 
community4. 
There are various factors that lead to the slow development of anti-bacterials. The overall 
time line, success rate and investment required to launch a novel broad-spectrum 
antibacterial is staggering as compared to other therapeutic areas. Scientifically, it is also 
an exhaustive challenge considering that bacterial cells are quite different from human 
cells, so the general rules used in drug discovery for e.g. Lipinsky’s “rule of 5” does not 
translate into antibiotics. 
The advent of the genomic era in the 1990’s followed by the complete sequencing of the 
Haemophilus influenza genome changed the focus of drug discovery from chemical 
modification of already existing molecules to discovery of newer targets and molecules in 
the pharmaceutical industry. High throughput screens (HTS) were run with isolated 
enzyme or protein targets and whole cells, but these did not translate well into lead 
molecules. Most molecules that progressed into the lead optimization stage did not make 
it through Phase 1 testing. The difficulties were attributed to less diversity in compound 
libraries screened, multiple pathogens that have to be inhibited by a broad-spectrum 
compound, both Gram-positive and Gram-negative species with different molecular 
targets, membrane permeabilities, metabolic pathways and an acceptable and 
convenient pharmacokinetic and dynamic profile. After the failure of this earlier genomic 
based approach for anti-bacterial drug discovery, the current approach in industry has 
been shifting to a renewed focus on novel chemical scaffolds, concentrating on already 
validated targets, exploring new binding modes and including more diversity in chemical 
screens5.  
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There is a critical and unmet need for the development of newer anti-bacterials. This is 
driven by the emergence of bacterial strains that have the capacity to mutate over a time 
period of hours compared to the years required to develop antibiotics, rendering our 
current arsenal of antibiotics ineffective. The discovery of anti-bacterials was one of the 
biggest discoveries in medicine, but unless newer anti-bacterials are developed at a faster 
pace, we face a losing battle.    
1.2: DNA-Gyrase as a drug target. 
DNA Topoisomerases are enzymes that change the topology of DNA in both prokaryotic 
and eukaryotic cells. They catalyze changes in the topology of DNA at various steps in 
the replication cycle. The helical intertwined nature of DNA presents a problem during 
replication and transcription, where DNA gets overwound ahead of the replication fork. 
To overcome this tension, topoisomerases either bind to one strand or both strands of 
DNA and nick the phosphate backbone. This process removes supercoils of DNA and 
after the process, the DNA strand is resealed, so these enzymes remove catenanes and 
knots in DNA. Topoisomerases are classified into type I and type II based on whether 
they catalyze the transient breakage of one strand or both strands of DNA6.  
DNA gyrase is a type II topoisomerase that can also introduce negative supercoils in 
DNA. It is the only known topoisomerase enzyme that can generate negative supercoils 
as well as relax positive and negative DNA supercoils; however, generating negative 
supercoils appears to be the primary function of gyrase in the cell.  The enzyme uses the 
hydrolysis of ATP to carry out this process. Prokaryotic DNA gyrase consists of two 
subunits A and B. In the active enzyme, these associate to form an A2B2 complex. The 
E. coli gyrase has a molecular weight of 97 and 90 KDa for its A and B subunits, 
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respectively. The A subunit interacts with DNA and has the active site tyrosine that 
catalyzes the DNA cleavage. The B subunit consists of the ATP binding site and catalyzes 
the ATPase activity. 
DNA gyrase is an important anti-bacterial drug target due to its important function in the 
cell.  The mechanism by which the enzyme supercoils DNA is complex and multistep and 
this offers an avenue for its inhibition at various steps in the process. A model called the 
“two – gate mechanism” has been proposed for how gyrase supercoils DNA and is 
supported by structural and biochemical data7, 8. DNA gyrase consists of three interfaces 
that interact with DNA, and they can either exist in an open or closed conformations 
(Figure 1). The “N–gate” is the N–terminal domain of GyrB, “DNA gate” is the GyrA–
GyrB–DNA interface that cleaves DNA and the “C–gate” is the C–terminal area of coils 
where DNA exits the enzyme. The supercoiling reaction progresses in the following 
fashion: the first step (step 1, Figure 1) involves DNA (named as the G-segment) 
association with the unliganded enzyme at the GyrA and GyrB interface that is between 
the TOPRIM domain of GyrB and the N–terminal domain of GyrA dimer. This leads to 
conformational changes and the formation of the DNA gate (step 2, Figure 1), following 
which about 130 base pairs of DNA wrap around the enzyme in a right handed supercoil. 
Wrapping of DNA around the C–terminal domain of gyrase facilitates the T–segment of 
DNA (the segment that will be passed through the cleaved DNA) to reach the N gate and 
is placed over the G segment (the segment that forms the DNA gate, step 3, Figure 1). 
ATP binding dimerizes GyrB allowing the trapping of the T segment and cleaving the G 
segment at the DNA gate (step 4, Figure 1). The cleavage site in double stranded DNA 
occurs 4 base pairs apart and results in the G segment covalently attaching itself to the 
 6 
 
GyrA subunit of DNA gyrase. The T segment is passed through the DNA gate and the 
cleaved G segment and finally through the exit gate. The translocation of the T segment 
is allowed by the rotation of GyrB, due to the hydrolysis of one molecule of ATP. The next 
step is the religation of the G segment, which introduces two negative supercoils in DNA 
(step 5, Figure 1). The hydrolysis of a second molecule of ATP opens the N-gate and the 
enzyme is ready for the next supercoiling cycle and resets to step 2. One gyrase cycle 
introduces two negative supercoils into DNA at the expense of two ATP molecules. The 
supercoiling reaction is a complex cycle and the exact order and mechanism of the steps 
are not unambiguously known, however due to the multiple number of steps, there exists 
enough opportunity for disruption of this cycle with inhibitors. 
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Figure 1: Model for the catalytic reaction of topoisomerase II. ATPase domain is shown 
in yellow, domain in red forms the DNA gate and the domain in blue has the catalytic 
tyrosines9.   
There are multiple points of intervention in the supercoiling cycle that inhibitors act on i.e. 
DNA binding, DNA cleavage, strand passage and ATP hydrolysis. There are two main 
mechanisms by which inhibitors act on DNA gyrase. The first one involves the inhibition 
of the enzymatic activity of gyrase and the second is the stabilization of the covalent 
enzyme DNA adduct or otherwise known as gyrase poisoning.  
1.3: Quinolones 
The origin of Quinolones can be traced to the discovery of nalidixic acid, a by–product 
formed during the preparation of chloroquine (an anti–malarial). Systematic chemical 
modifications lead to the discovery of the fluoroquinolones: norfloxacin, ciprofloxacin, 
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levofloxacin and gemifloxacin (Figure 2). These compounds have been significantly used 
as broad spectrum antibiotics in the treatment of both Gram positive and Gram negative 
infections10. 
 
Figure 2: Structure of Quinolones 
Based on the type of organism and the quinolone, topo IV has also been indicated as a 
target in addition to gyrase. Bacteria harbor resistance genes to fluoroquinolones and the 
site of point mutations that give quinolone resistance is called the quinolone resistance–
determining regions or QRDR. Fluoroquinolone resistance has been reported in 
pneumonia, influenza, MDR/XDR tuberculosis and respiratory tract diseases.  
Quinolones stabilize the covalent gyrase DNA complex, where DNA gyrase is covalently 
bound to the 5’ ends of the cleaved DNA. Crystal structures of the fusion protein involving 
C–terminal of GyrB with the N–terminal of GyrA, show that the DNA gate is in the closed 
conformation, suggesting that opening of this gate is not required for quinolone binding. 
The aromatic rings of the quinolone are found to be stacked against the DNA bases at 
 9 
 
the site of cleavage. This interaction can cause a misalignment of DNA on either side of 
where cleavage happens and difficulty in joining the broken DNA11.  
Quinolones in vivo display both bacteriostatic and bactericidal activities. The quinolone–
gyrase (or quinolone–topo IV) complex formed can stall the replication fork and lead to a 
bacteriostatic effect. The bactericidal effect mechanistically happens through two distinct 
pathways; first one dependent on protein synthesis and the second on in its absence, 
which depends on the particular type of quinolone. The ultimate consequence of a 
quinolone–stabilized gyrase (or topo IV) complex with DNA is cell death that occurs 
through chromosome fragmentation, induction of SOS response and eventually cell 
fragmentation that could involve reactive oxygen species. 
It has been hypothesized that the mode of action that the quinolones employ for gyrase 
(or topo IV) inhibition is the most effective. Relatively only a low occupancy of inhibitor 
bound to the target is required to cause enough chromosome fragmentation for cell death 
to occur. 
1.4 Aminocoumarins 
The aminocoumarins are characterized by their 3-amino–4,7-dihydroxycoumarin ring. 
Further substitutions on the ring or groups attached to the amine or phenol make up the 
diversity in this class of compounds. The prototypical aminocoumarins: novobiocin and 
clorobiocin (Figure 3) were extracted from Streptomyces species. These compounds 
were used once to treat methicillin resistant S. aureus (MRSA), but they have been 
withdrawn from clinical use because of their toxicity and poor pharmacokinetic 
parameters12. 
 10 
 
 
Figure 3: Structure of Novobiocin and Clorobiocin 
Aminocoumarins bind tightly to the B subunit of DNA gyrase and they work 
mechanistically by inhibiting the catalytic activity of DNA gyrase. They compete with ATP 
for binding to the GyrB domain; hence, the ATPase reaction of gyrase is inhibited. Their 
binding site overlaps the ATP binding site in GyrB that is a 24–KDa amino–terminal 
subdomain in GyrB and is named as the aminocoumarin binding site. This binding 
prevents ATP binding to the site and thus inhibits the supercoiling reaction from 
proceeding13. 
Naturally occurring resistance to the aminocoumarins has been observed in DNA gyrase 
and these involve mutations in the aminocoumarin binding site (Arg136 and Gly164, E. 
coli numbering). However, due to the proximity of this site to the ATP binding site, these 
mutants show a loss in enzymatic activity due to impaired ATPase activity.  
In vitro aminocoumarins are potent inhibitors of DNA gyrase, but they display poor activity 
against Gram negative bacteria. Additionally, their mammalian toxicity and poor 
bioavailability have precluded their use clinically and they have been most commonly 
used to study the ATP–binding site of DNA gyrase. 
1.5: New Bacterial Topoisomerase Inhibitors (NBTIs) 
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NBTIs are a new class of synthetic anti-bacterials, which have a non-quinolone scaffold 
but bind to topoisomerase II class of enzymes in a similar fashion as that of the 
quinolones. They have a mechanism of action distinct from that of the quinolones and 
currently are being pursued by the pharmaceutical industry because they are not affected 
by mutations that affect fluoroquinolone binding14. 
One of the most studied compounds is the quinolone based drug candidate NXL101, 
licensed by Novexel (Figure 4). NXL101 displayed a preference for inhibition of topo IV 
over DNA gyrase in E. coli and displayed the opposite trend when it came to S. aureus. 
This preference in targets was the opposite to that displayed by fluoroquinolones. NXL101 
displays the ability to inhibit mutant forms of gyrase that are resistant to fluoroquinolones 
and the mutations that render the drug ineffective were found to be outside the QRDR 
domain region in DNA gyrase. One of the mutations that confers fluoroquinolone 
resistance is Ser84 in GyrA (S. aureus numbering), whereas for NXL101 was Asp83 (S. 
aureus numbering), which highlight the differences in binding of NXL101 as compared to 
fluoroquinolones. Nonetheless, the lack of co–crystal structures of DNA gyrase with 
NBTIs has made determination of the precise binding site impossible. However, in 2009, 
the development of NXL101 was discontinued due to QT prolongation in Phase I 
studies15. 
In 2010, GSK reported the crystal structure of the compound GSK299423 (Figure 4) with 
DNA and S. aureus gyrase. They isolated the precleaved complex of mutant S. aureus 
gyrase (Tyr123 to Phe) and observed that the cyano–quinoline region of the compound 
intercalates DNA, midway between the two gyrase active sites and arrests the complex 
before the double strand is cleaved. The compound does not directly inhibit the DNA 
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cleavage and religation process like quinolones do, but it stabilizes the pre-cleavage 
complex and prevents strand separation. This binding site is distinct from the 
fluoroquinolone binding site and the compound was active against MRSA and 
fluoroquinolone resistant strains. But no further studies on this compound have been 
reported16.  
 
Figure 4: Structures of NXL101 and GSK299423 
1.6 Simocyclinone D8 (SD8) 
Simocyclinone D8 is an antibiotic that belongs to the family of angucyclinones. It was first 
reported in 2000 by Fiedler et al. after they isolated it from Streptomyces antibioticus Tu 
604017. Screening of metabolites from the novel Streptomyces strain that was isolated 
from a soil sample in Argentina, lead to the discovery of SD8. Simocyclinone D8 was 
found to have antibiotic activity against Gram positive bacteria (S. aureus, Bacillus brevis, 
Bacillus subtilis and Streptomyces viridochromogenes) and cytostatic effect on tumor 
cells lines, but no significant activity against Gram negative organisms (E. coli). The 
authors also optimized the fermentation conditions and reported that various partially 
substituted analogues of SD8 can be obtained by varying the carbohydrate source in the 
medium18.  The SD8 molecule consists of three subunits: an aminocoumarin similar to 
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that present in novobiocin and clorobiocin, a tetraene linker that is present in the 
veterinary antibiotic fumagillin and an angucyclinone, which is comprised of an olivose 
sugar bound by a C–glycosidic bond to a highly substituted benz[a]anthracene system 
(Figure 5)19. This angucyclinone system is very similar to that present in the natural 
product aquayamycin. The biosynthetic gene cluster of SD8 was cloned by Heide et al. 
in 200220. The authors reported that the gene cluster consists of several genes with high 
similarity to that of the aminocoumarin class of antiobitics, however in contrast with the 
aminocoumarins, the SD8 gene cluster doesn’t have an obvious resistance gene, 
hindering the identification of a possible target. They also proposed a biosynthetic 
pathway of how SD8 is synthesized in the microorganism21. 
 
Figure 5: Structure of SD8 
The first report that garnered attention for SD8 in the scientific community was published 
by Maxwell et al. in 200519. The authors test the compound for inhibition of DNA gyrase 
because of its chemical similarity to the aminocoumarin antibiotics. They found that SD8 
inhibits gyrase supercoiling reaction with an IC50 of 0.1 µM as compared to novobiocin 
with an IC50 of 0.25 µM and 0.7 µM for ciprofloxacin. SD8 also inhibited the DNA relaxation 
activity of gyrase with an IC50 of 0.5 to 1.0 µM. To determine the possible mode of binding, 
they tested whether the observed inhibition was dependent on ATP and report that SD8 
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does not compete with ATP unlike novobiocin. Assaying SD8 with a ciprofloxacin resistant 
DNA gyrase (Ser83 to Trp) for supercoiling activity increased the IC50 10-fold, whereas 
for ciprofloxacin increased 30-fold. This established that SD8 does not share the same 
binding site on DNA gyrase as novobiocin and there might be an overlap of binding 
regions with quinolones. SD8 also did not form linear DNA from supercoiled DNA in the 
presence of gyrase and it also abolished DNA–DNA gyrase cleavage complex formation 
in the presence of ciprofloxacin, suggesting that it had a distinct mechanism of action 
from the quinolones by inhibiting the enzyme prior to DNA cleavage. 
Binding studies by SPR indicated that SD8 prevented DNA from binding to gyrase, while 
isothermal calorimetric studies showed that SD8 bound to the GyrA subunit in a ratio of 
1:1. This mechanism of inhibition has been termed as catalytic and SD8 is the first and 
only molecule reported to date as a catalytic inhibitor of DNA gyrase.  
In 2009 the first co-crystal structure of SD8 was reported with the N-terminal domain of 
GyrA (GyrA59) at 2.6 Å resolution (Figure 6)22. This crystal structure also assigned the 
absolute stereochemistry of SD8. The crystal structure reveals a homotetramer of two 
A59 dimers cross-linked by four molecules of SD8. Each GyrA subunit has two distinct 
pockets for the aminocoumarin and the polyketide moieties. The tetraene subunit, about 
10 Å long, displays no interaction with the enzyme and holds the two binding moiety’s 
apart. The stoichiometry remain consistent (1:1), as reported earlier by the ITC studies.  
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Figure 6: GyrA59 dimer with two molecules of SD8. The catalytic Tyr122 on both 
subunits are labeled (PDB ID: 2Y3P). 
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Figure 7: Residues interacting with SD8 in GyrA59 structure (PDB ID: 2Y3P). 
Also, the SD8 molecule can be modeled in a bent conformation that bridges between the 
aminocoumarin and polyketide binding pockets within the same subunit. This could place 
the tetraene linker possibly interacting with the α-helix 4 of GyrA.  Nanoelectrospray 
ionization mass spectrometry experiments reveal that the most probable binding 
conformation is a single SD8 molecule bound to the aminocoumarin and polyketide 
pockets within the same subunit. SD8 at high concentration causes tetramerization of 
GyrA by bridging the homodimers, but at pharmaceutically relevant concentrations, the 
dimeric form of GyrA exist bound to one or two SD8 molecules. 
Analysis of the crystal structure reveals some interesting observations for both the 
pockets. The aminocoumarin and polyketide both bind in separate pockets and the 
tetraene linker and olivose sugar are not seen interacting with any residues. In the 
aminocoumarin pocket there is a halogen bond between the 8-position chlorine on the 
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coumarin ring with the carbonyl oxygen of Gly170. In the polyketide pocket, Arg121 and 
Tyr122 in the active site interact via water molecules to a Mg2+ that is bound to the diols 
on the polyketide fragment. On a similar basis His80 makes a water-mediated interaction 
with the second Mg2+ ion that coordinates to the angular diols on the polyketide ring. His80 
also π stacks with the phenol on the angucyclinone. The tetra-substituted epoxide on the 
angucyclinone ring interacts with the guanidine group on the side chain of Arg32 (Figure 
7).   
Mutations in the aminocoumarin and polyketide pockets result in significant abrogation of 
supercoiling activity. Also, QRDR mutations in the α-helix 4 region of GyrA result in 
resistance to SD8, despite none of these amino acids making direct contact with SD8. It 
might be possible that mutating the residues in the α-helix 4 might impede the 
conformation of the linker and affect bridging of the aminocoumarin and polyketide 
binding sites. 
Further mass spectrometry studies with GyrA and SD8 reveal that the binding is a function 
of both aminocoumarin and polyketide groups on SD8, and comparison with free 
aminocoumarin and polyketide groups reveal that the polyketide fragment binds with five 
times more affinity than the aminocoumarin fragment, but these individual fragment 
interactions are much weaker than bifunctional SD823. Furthermore, binding of SD8 
induces a strong allosteric cooperativity between the two binding sites, where occupancy 
in the first pocket strongly promotes binding in the second pocket. A >20-fold increase in 
affinity of binding the aminocoumarin subunit is seen after binding of the first polyketide 
unit. Edwards et al. report that the only binding mode supported by this data is that where 
both binding sites on a single monomer are bound by a single molecule of SD8. Based 
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on the binding constants of aminocoumarin and polyketide fragments, they hypothesize 
that: polyketide fragment binds first, increasing the local concentration of the 
aminocoumarin fragment followed by its binding. This bent over conformation of SD8 
induces a strain in the tetraene linker that results in small structural changes in GyrA, 
which then results in the positive cooperativity upon binding of SD8. 
In 2010, protein melting studies were reported to characterize the interaction of SD8 with 
DNA gyrase24. The circular dichorism profile of DNA gyrase indicates that both the A2B2 
heterodimer and individual subunits (GyrA and GyrB) were established in presence of 
SD8 at various temperatures. For the GyrA subunit, as expected, a compound mediated 
shift of Tm was recorded and by plotting Tm vs SD8 concentrations, a cooperative 
conformational change was noticed. Unexpectedly, however binding of SD8 with the 
GyrB47 domain induced a change in Tm. The GyrB47 domain is also involved in DNA 
binding and the GyrA site displays much higher affinity than that of the GyrB domain. SD8 
also changed the proteolytic pattern of GyrB digestion by trypsin, which also indicates a 
binding site on GyrB.  
In 2014, a new crystal structure of SD8 was published with GyrA55 at 2.05 Å resolution 
(Figure 8)25. This 55 kDa fragment lacks the crucial residues that stabilize the tetrameric 
state of GyrA, hence obtaining a better picture of SD8 binding in physiological 
concentrations. The conformation of bound SD8 in this structure is different from that in 
the earlier reported crystal structure. The polyketide moiety binds at the interface of the 
two GyrA monomers, displaying interactions with 5 residues, out of which Asp87 and 
Met120 are from the adjacent monomer. The aminocoumarin pocket is the same as 
earlier, but the orientation of the AC moiety in the pocket is different. The tetraene in this 
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structure is distant from the α-helix and does not interact with it, although it is seen to 
have hydrophobic interactions with Val44 and His78. No Mg2+ ions were found in the 
polyketide pocket (Figure 9). 
 
 
Figure 8: GyrA55 dimer with SD8 (displayed as spheres) bound in “bent-over” 
conformation (PDB ID: 4CKL). 
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The report also reevaluates the mutation data that was published in the original GyrA59-
SD8 paper and the crystal structure explains all the observed data for GyrA mutants. Also 
to validate the intra-dimer binding mode of SD8 in the GyrA55-SD8 complex, three 
mutants were made: Met120 to Pro (PK pocket), Lys42 to Ala (AC pocket) and Ala84 to 
Arg (α-helix 4). The first two resulted in 60- and 50-fold increases in resistance to SD8, 
but the Ala84 to Arg mutant showed very little increase in resistance to SD8. The authors 
explain this by asserting that the Arg84 side chain adopting a conformation that does not 
impinge on the SD8 binding site. Based on this recent crystal structure, they also 
hypothesize a mechanism by which SD8 blocks DNA binding to gyrase: SD8 positions 
itself on the dimer interface and “staples” the dimer closed and preventing the DNA gate 
from opening for strand passage and also interfering with the conformational changes 
required in the DNA gate for DNA binding. The interaction of Asp87 and Gly81 with SD8 
will prevent movement of α-helix 4, interaction of Met120 and SD8 will prevent the loop 
having the catalytic tyrosine (Tyr122) from orienting itself with DNA, and binding of Arg91 
on α-helix 4 with the AC will prevent it from stabilizing the GyrA-DNA complex. 
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Figure 9: Residues interacting with SD8 in GyrA55 structure (PDB ID: 4CKL). 
ITC studies of SD8 with GyrA and GyrB43 (N-terminal GyrB) and GyrB47 (C-terminal 
GyrB), yielded a substantially higher affinity of SD8 for GyrA over GyrB (1000 fold). The 
authors conclude that GyrA is the primary target for SD8 and the interaction with GyrB is 
an in vitro artifact manifested in the absence of GyrA.   
Because most gyrase inhibitors also inhibit topo IV, SD8 was tested for its in vitro and in 
vivo profiles of enzyme inhibition26. The in vitro activity was accessed by determining the 
sensitivity of E. coli and S. aureus type II topoisomerases to SD8 and in vivo activity was 
studied using microarray analysis for cellular responses. The IC50 (supercoiling assay) for 
E. coli gyrase (Gram -ve) and S. aureus gyrase (Gram +ve) were 0.41 µM and 1.45 µM, 
respectively, whereas for E. coli topo IV and S. aureus topo IV they were 270 µM and 
14.5 µM respectively. These results show that SD8 is much more selective for DNA 
gyrase as compared to topo IV. Transcriptional responses of E. coli to SD8 treatment are 
similar to the profile of gyrase inhibition; i.e., upregulation of gyrase genes and 
downregulation of the topo I gene. SD8 treatment does not induce an SOS response, 
unlike the response to quinolones. The compound also displayed an enhanced activity 
against E. coli cells that lacked the AcrB multidrug efflux pump, thus explaining why, in 
spite of SD8 being a potent inhibitor for DNA gyrase, it displays no activity against Gram 
negative bacterium. Because SD8 was initially reported as possessing cytostatic activity 
against tumor cells, it was tested against malignant mesothelioma (MM) and non-small 
cell cancer (NSCLC) cell lines and displayed an IC50 ranging from 75-125 µM27. Further 
assays revealed that the target in human cancer cells was human topo II with an IC50 of 
100 µM. Later, it was found that SD8 can also inhibit human topo I with an IC50 of 60 ± 15 
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µM. Hence, SD8 is a dual catalytic inhibitor of human topo I and II28. Although the affinity 
of SD8 for these enzymes is low and the concentrations required for growth inhibition are 
not feasible in vivo, further structural modification might allow for analogues that display 
better anti-cancer activity. 
A recent publication also demonstrated that SD8 was highly active against E. coli clinical 
isolates and also moderately effective against K. Pneumoniae. The authors explain this 
unexpected result because earlier laboratory E. coli isolates were used for testing, and 
these lab strains have reduced cellular uptake of the antibiotic in comparison to clinically 
present strains29.       
1.7: Rationale for the work 
DNA gyrase is a validated drug target for developing anti-bacterials. Currently, the only 
drugs in the market that target DNA gyrase are the quinolones. The quinolones have 
enjoyed widespread success since their introduction and are widely used in the clinic 
because of their broad-spectrum activity. However, due to the prevalent use of quinolone 
antibiotics, resistance to them has already emerged in community and clinical settings30-
33. To counter the threat of these fluoroquinolone-resistant infections, compounds that 
inhibit DNA gyrase by a mechanism of action other than the quinolones is required.  
The natural product simocyclinone D8 is one such compound that potently inhibits DNA 
gyrase (IC50 = 0.4 µM, supercoiling activity) by a different mechanism of action than the 
quinolones. Unlike quinolones, which stabilize the cleavage complex formation of DNA 
gyrase with DNA, SD8 acts as a competitive inhibitor for DNA, by binding to the GyrA 
domain of DNA gyrase and effectively blocking the catalytic apparatus.  The mode of 
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inhibition of DNA gyrase by SD8 has been termed catalytic inhibition and SD8 is the only 
reported compound to exhibit such a mechanism. Also, SD8 inhibits a ciprofloxacin 
resistant mutant, demonstrating that this novel mechanism can be used to combat 
fluoroquinolone resistance19. SD8 was also been shown to be active against Gram 
positive and Gram negative bacteria in clinically relevant concentrations. Taken together, 
all of this data show that the competitive inhibition mechanism of SD8 is a valid mode of 
action that can be used to develop new anti-bacterials and SD8 can be used as an ideal 
lead for further compound development. 
The SD8 molecule has three subunits: an aminocoumarin, a tetraene linker and an 
olivose sugar bound to a highly substituted benz[a]anthracene system by a C-glycosidic 
linkage (Figure 5). 
The GyrA59-SD8 crystal structure reveal that GyrA has 2 separate binding pockets that 
can accommodate the AC and the PK moieties. The tetraene linker and the olivose sugar 
do not make any contacts with the enzyme. Based on the report published by Maxwell et 
al.22, the only known structure activity relationships for SD8 and reported analogues are 
as follows: Simocyclinone D8 (SD8, compound 1) has an IC50 of 0.4 µM, Simocyclinone 
D4 (SD4, compound 2), which is a biosynthetic intermediate of SD8 and does not have 
the chlorine on the coumarin ring, has an IC50 of 1.6 µM. Simocyclinone C4 (SC4, 
compound 3); an intermediate from the biosynthesis of SD8 that lacks the aminocoumarin 
and the tetraene linker has an IC50 of 70 µM and MGD8N2A (compound 4), a 
semisynthetic intermediate obtained from the hydrolysis of SD8 and lacks the angucyclic 
polyketide fragment, has an IC50 of 50 µM (Figure 10). This data underscores the 
importance that both the fragments of SD8 are required for optimal activity. 
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Figure 10: Structures of SD8, SD4, SC4 and MGD8N2A 
The goal is to design simplified analogues of SD8 as antibacterial agents where in the 
simplest pharmacophore (extracted from the GyrA59-SD8) would be two binding 
elements separated by a linker (Figure 11). In the crystal structure, the tetraene linker 
and the olivose sugar do not seem to make any potential interactions with the enzyme, 
merely serving as a bridge to place the AC and PK moieties in their respective pockets. 
 
Figure 11: Simplest pharmacophore extracted from GyrA59-SD8 
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We decided to use a flavone moiety as a suitable replacement for the aminocoumarin. 
Flavones have previously been used as isosteric replacements for coumarins in Hsp90 
inhibitors34. The 2-phenyl ring of the flavone could potentially occupy a hydrophobic cleft 
formed by Leu98, Gly170 and Tyr266 that lie beside the AC binding site and potentially 
create more hydrophobic interactions (Figure 12).    
For the flavone, we chose to use quercetin because of its commercial availability, and for 
the ease of synthesis of the linker, we chose a flexible linker comprised of pimelic acid 
and glycine. The linker length of 15 Å was chosen based on the modeled binding 
geometry of SD8 in the GyrA59 crystal structure. Also in the recent GyrA55-SD8 crystal, 
where SD8 was crystallized in its “bent over conformation”, the distance from the residue 
that interacts with the carbonyl oxygen of the amide (His45, AC fragment) to the residue 
that interacts with the phenol (His80, PK fragment) is ~15 Å (Figure 13).  
 
Figure 12: Binding pocket for the SD8 coumarin on GyrA59 (PDB ID: 2Y3P). The 
angucyclinone aglycone has been omitted for clarity22. 
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Figure 13: Distance for the linker chosen (PDB ID: 4CKL)25. 
To potentially create interactions in the PK binding site, we chose to couple substituted 
anilines to the linker. We envisioned that the aromatic ring of the anilines can π-stack with 
the His80, located 15 Å away. This has been proved to be a critical residue by 
crystallography and mutation studies. Based on the interactions of the highlighted diol 
with Tyr122 and Arg121 through a Mg2+ ion and water, we decided to substitute the meta- 
and para- positions of the aniline. Because the hydrogen bond distances are long in the 
GyrA59-SD8 structure, we decided to extend the diol and use a more acidic substituent 
(carboxylic acid). To probe the space available at the para- position of the aniline, we 
decided to use a range of substituents from hydrogen to isopropyl group. To probe the 
electronics of the aromatic ring, we used a para chloro and a para methoxy substituent 
(Figure 14). 
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Figure 14: Design of quercetin-pimelic acid-glycine linked aniline analogues 
Our aims in designing these analogues were to find simpler compounds that could bind 
to the AC and PK pockets of GyrA and also to determine a synthetically accessible 
scaffold that could potentially bind to the PK pocket, thus obviating the need to make 
structurally complex analogues of the SD8 angucyclinone. 
1.8: Synthesis of flavone-based analogues of SD8 
To begin our work, we protected commercially available quercetin 5 with benzyl bromide 
in DMF, using potassium carbonate as a base to give tribenzyl quercetin 6 in 50% yield. 
Pimelic acid 7 was selectively protected as the mono-tertbutyl ester by a standard peptide 
coupling protocol using tert-butanol, N-(3-dimethylaminopropyl)-N’-(ethylcarbodiimide) 
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hydrochloride (EDCI) and 4-(dimethylamino)pyridine  
(DMAP)  as the base in chloroform to obtain the mono protected tert-butyl ester of pimelic 
acid 8 in 44% yield (Figure 15).  
 
Figure 15:  Synthesis of 6 and 8 
Tribenzyl quercetin 6 was esterified using the acid 8 and the peptide coupling reagent 
EDCI in THF, with stoichiometric amounts of Hunig’s base and catalytic DMAP in THF to 
obtain the ester 9 in quantitative yield. The tert-butyl ester was removed using 
trifluoroacetic acid (TFA) in DCM with triethylsilane as a cation scavenger to afford the 
compound 10 in 76% yield (Figure 16).  
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Figure 16: Synthesis of compound 10 
Suitably protected anilines 11a – 11j were coupled to N-phthaloyl-glycine acid chloride in 
THF with triethylamine as the base under reflux conditions. The obtained aniline-glycine-
phthalimide compounds were sufficiently pure to be used for the next step. The 
phthalimide protecting groups were removed using hydrazine hydrate in ethanol under 
reflux conditions. The deprotected primary amines 12a – 12j were purified on silica and 
were obtained in 60-80% overall yields (Figure 17).  
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Figure 17: Synthesis of compounds 12a to 12j 
These obtained compounds 12a – 12j were coupled to the acid 10 using standard peptide 
coupling procedures with EDCI as the coupling reagent, 1-hydroxybenzotriazole as the 
promoter and N-methyl morpholine as the base in DMF to offer the amides 13a – 13j in 
77 to 95% yield (Figure 18).  
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Figure 18: Preparation of compounds 13a to 13-j 
From the obtained amides, the aniline protecting groups were initially removed, followed 
by removal of the benzyl ethers. The silyl protecting groups were removed using 
tetrabutylammonium fluoride in THF, which gave the alcohols in moderate yields (69% 
for compound 14b and 65% for compound 14h, Figure 19). Tert-butyl ester was removed 
using TFA and the cation scavenger triethylsilane in DCM to give the carboxylic acid 15c 
in quantitative yield (Figure 20). The acetonide protecting group was removed using HCl 
in THF, obtaining the diol 14i (Figure 21) in 36% yield. The benzyl ethers were removed 
by hydrogenation using hydrogen at 1 psi (balloon pressure) and palladium on charcoal 
as the catalyst to obtain the benzyl deprotected quercetin derivatives 15a – 15j in yields 
ranging from 33% - 57% (Figure 19 – Figure 22).  
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Figure 19: Synthesis of compounds 15b and 15h  
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Figure 20: Synthesis of compound 15c  
 
Figure 21: Synthesis of compound 15i 
 
Figure 22: Preparation of compounds 15a, 15d-g, 15j   
As a control compound, we prepared a flavone based analog 15k without the aniline 
fragment. Tribenzyl-quercetin 6 was esterified with mono-methyl sebacic acid, to give the 
ester 14k. The ester was hydrogenated to obtain quercetin-sebacic acid methyl ester 
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analog 15k (Figure 23). This compound lacks the aromatic ring that would bind to the PK 
pocket. 
 
Figure 23: Synthesis of compound 15k  
 
1.9: Biological activity of flavone-based analogues 
To assess the ability of the flavone analogues to inhibit E. coli DNA gyrase we performed 
a supercoiling activity assay26. Briefly, the assay uses the relaxed plasmid PBR 322 and 
E. coli gyrase. The DNA gyrase supercoils the plasmid DNA, which is shown as a band 
of topoisomers into the supercoiled form that moves faster on the gel. Upon addition of 
the compound, if gyrase is inhibited, the amount of supercoiled plasmid is reduced.  The 
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assay was performed in the presence of varying concentrations of these flavone 
analogues and the 50% inhibitory concentration (IC50) was determined (Table 1). 
Compounds 15d – 15g and 15j were not soluble in the assay medium, so we could not 
determine any further data from these compounds.  
Table 1: Activity of compounds against E. coli DNA gyrase 
Compound Supercoiling assay 
IC50 (µM) 
15a 48.6 ± 0.8 
15h 84.7 ± 5.5 
15b >200 
15c >200 
15i >200 
15k >200 
SD8 0.41 
 
Next, to determine whether these compounds inhibit E. coli DNA gyrase by a catalytic 
mechanism similar to SD8, they were tested for their ability to disrupt binding of DNA 
gyrase to DNA by surface Plasmon resonance (SPR)19. Neither compounds was active 
in this assay nor was disruption of the DNA –enzyme interaction observed (Figure 24).  
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Figure 24: Sensogram of compound 15a  
To further investigate the mechanism of how these compounds inhibited DNA gyrase, we 
tested the effect of these compounds on the DNA cleavage activity of E. coli DNA gyrase 
(Table 2)26. Topoisomerases cause changes in DNA topology by cleaving and religating 
strands. When quinolones inhibit this religation process, they form linear DNA that makes 
covalent complexes with the enzyme. Formation of linear DNA is quantified to determine 
whether the compound works as a topoisomerase poison.  
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Table 2: DNA cleavage assay for compounds 
Compound DNA cleavage 
(Fold – stimulation) 
15a 7.8 
15h 5.0 
15b 3.0 
15c 1.8 
15i 1.9 
15k >1 
SD8 >1 
 
So, determining that these compounds inhibit DNA gyrase, but with a mechanism different 
than that of SD8, we tested them against human Topo II27, 28. We first evaluated the effect 
of these compounds on the decatenation activity of human Topo II and also on the DNA 
cleavage activity of Human Topo II (Table 3).  
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Table 3: Effect of flavone analogues on Human topo II 
Compound Decatenation assay 
IC50 (µM) 
DNA Cleavage 
(Fold – Stimulation) 
15a 149 ± 3.2 2.7 
15h >200 2.4 
15b >200 2.1 
15c >200 <1 
15i 78.9 ± 1.4 <1 
15k >200 <1 
SD8 100  
Since quercetin can intercalate into DNA35, 36 and the compounds 15a, 15h and 15b have 
the quercetin moiety in them, we decided to examine if these compounds can intercalate 
into DNA by using a DNA unwinding assay. We also used quercetin as a control, to 
compare the level of intercalation that occurs (Figure 25).  If the compound intercalated 
into DNA (in this case plasmid PBR 322), after treatment with gyrase, it forms relaxed or 
underwound DNA that converts into supercoiled DNA. The presence of supercoiled DNA 
indicates DNA intercalation has happened. The extent of intercalation of a compound can 
be measured as the level of negative supercoils introduced into the covalently closed, 
relaxed circular substrate DNA37. 
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Figure 25: (A) Intercalation of compounds 15a – 15k. (B) Intercalation of compound 
15a as compared to intercalation by quercetin 
1.10: Conclusions and Discussion 
Based on the structure and competitive mechanism of action of SD8 against DNA 
gyrase19, we designed and synthesized ten flavone based analogues. We prepared 
compounds using the flavone quercetin as the AC binding element and various 
substituted anilines to bind to the PK pocket of DNA gyrase linked by a flexible glycine-
pimelic acid linker in modest yields. 
Initially, we tested the ability of these flavone-based compounds to inhibit E. coli DNA 
gyrase supercoiling by a supercoiling activity assay. Compounds 15a and 15h displayed 
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modest inhibitory effects on the supercoiling activity of gyrase with IC50 values of 48.6 ± 
0.8 µM and 84.7 ± 5.5 µM, respectively, but the other compounds were not active (i.e., 
IC50 values greater than 200 µM). The activities of these compounds for DNA gyrase were 
significantly lower than that of SD8 (IC50 = 0.41 µM) and quercetin alone (IC50 value of 
0.14 µM), but similar to that of the coumarin-linker subunit of SD8 (MGD8N2A, IC50 = 50 
µM). Compound 15k, the flavone-based analog most similar to MGD8N2A was inactive, 
suggesting that the aniline fragment is required for activity against DNA gyrase.  
To determine the mechanism of DNA gyrase inhibition by these compounds we 
performed an SPR assay. SD8 binds to DNA gyrase and inhibits the catalytic activity of 
the enzyme by preventing DNA from binding to the enzyme and this mechanism has been 
termed catalytic inhibition. SPR has been used to analyze this disruption of DNA binding 
to the enzyme by SD819.  Neither compound 15a nor 15h was active in this assay and no 
disruption of DNA-enzyme interaction was observed. This data suggested that the 
observed inhibition of DNA gyrase by the flavone analogues 15a and 15h were by a 
different mechanism than that of SD8. 
Quinolones inhibit DNA gyrase by stabilizing the enzyme-DNA cleavage complex, thereby 
preventing religation and exit of DNA from the enzyme11. To investigate whether the 
flavone analogues inhibited E. coli DNA gyrase by a similar mechanism, we carried out a 
DNA cleavage assay. All compounds except 15k modestly stimulated gyrase-catalyzed 
cleavage, with compounds 15a and 15h displaying the highest levels of stimulation (7.8-
fold and 5.0-fold stimulation in generation of linear DNA at 200 µM, respectively). The 
extent of generation of linear DNA by compounds 15a and 15h tallies up with their 
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inhibition of supercoiling activity for E. coli gyrase. This suggests that compounds 15a 
and 15h inhibit the activity of DNA gyrase by poisoning it. 
SD8 was found to be a dual inhibitor of human topo II and topo I28. Human topoisomerase 
inhibitors are used for cancer chemotherapy. To determine the potential toxicity of these 
compounds, we screened them against human topo II. Initially, the effect of these 
compounds on the decatenation activity of human topo II was assessed and it was found 
that compounds 15a and 15i exhibited modest activities with IC50 values of 149 ± 3.2 µM 
and 78.9 ± 1.4 µM. It is interesting to note that compound 15a inhibited both E. coli DNA 
gyrase and human Topo II, whereas compound 15i inhibited only human topo II and 
compound 15h inhibited only E. coli DNA gyrase. To determine the mechanism of action 
of these compounds on human topo II, we assessed their activity on DNA cleavage by 
human topo II. Similar to the results obtained for E. coli DNA gyrase, compounds 15a and 
15h displayed the highest level of poisoning activity against human Topo II, although the 
extent of DNA cleavage stimulation for Topo II were lower than that of E. coli DNA gyrase. 
Hence, the compounds 15a and 15h appear to inhibit the activity of topoisomerases by 
poisoning, as quercetin does. But, interestingly, compound 15i exhibited modest inhibition 
of human topo II without poisoning it, suggesting a different mode of action for compound 
15i. 
Since quercetin35, 36 and also quinolones38 can intercalate into DNA, we tested the DNA 
intercalation ability of these flavone based analogues by a DNA unwinding assay. Some 
of these compounds were found to intercalate into DNA and their levels of intercalation 
varied. Compound 15a displayed the highest level of intercalation and the level of 
intercalation was similar to that of quercetin. Compound 15h displayed a modest level of 
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intercalation but the level of intercalation of other compounds were limited. Compounds 
15a and 15h displayed the highest level of poisoning activity among these compounds 
against both E. coli gyrase and human Topo II, indicating that these compounds might 
inhibit topoisomerases by their ability to intercalate into DNA. 
In conclusion, we prepared flavone-based analogues inspired by the natural product 
simocyclinone D8. While two of these compounds do inhibit DNA gyrase, they do not act 
as catalytic inhibitors as SD8 does. The flavone based analogues 15a and 15h were 
determined to be topoisomerase poisons and DNA intercalators.      
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CHAPTER 2: SYNTHETIC STUDIES TOWARDS THE TOTAL SYNTHESIS OF 
SIMOCYCLINONE D8 (SD8) 
2.1 Introduction 
Natural products have long been a source for antibiotics and it is reasonable to expect 
new natural products to serve as promising leads for new antibiotic drug discovery. An 
overwhelming majority (69%) of antibacterial drugs FDA approved between 1981 and 
2006 were either natural products or developed from natural products39. Antibacterial drug 
discovery from natural products has been more fruitful as compared from small molecule 
libraries because of the chemical diversity natural products afford and also due to their 
different physiochemical properties as compared to small molecules40.  
The fluoroquinolones are broad spectrum antibiotics that are able to treat both Gram-(+) 
and Gram-(-) infections6. They are the only class of drugs used clinically that inhibit DNA 
gyrase. However, mutations in DNA gyrase that confer resistance to the fluoroquinolone 
drugs like ciprofloxacin have emerged both in clinic and community settings. 
Fluoroquinolone resistance has been reported in pneumonia, influenza, MDR/XDR 
tuberculosis and pseudomonas respiratory infections. To counter this threat from 
fluoroquinolone-resistant bacterial strains, compounds that can inhibit drug-resistant DNA 
gyrase mutants must be developed30-32. One potential source of compounds that can 
inhibit fluoroquinolone-resistant mutants are compounds that can inhibit DNA gyrase by 
a novel mechanism.  
SD8 is one such natural compound that inhibits DNA gyrase by a novel mechanism of 
action as compared to the fluoroquinolones. SD8 inhibits DNA binding to the enzyme and 
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has been termed competitive inhibition compared to fluoroquinolones that trap the DNA-
DNA gyrase complex. SD8 was shown to inhibit both wild-type and a ciprofloxacin-
resistant mutant in a supercoiling assay proving that the competitive mechanism of action 
can be exploited to overcome fluoroquinolone resistant mutants19, 22. 
The structure of SD8 is highly modular, consisting of three subunits: an aminocoumarin, 
tetraene linker and an angucyclinone aglycone comprised of an olivose sugar bound to a 
highly substituted benz[a]anthracene system by a C-glycosidic bond. SD8 belongs to the 
angucyclinone family of natural products, which are characterized by the 
benz[a]anthracene ring system and its angular A ring. Angucyclines are categorized along 
with tetracyclines and anthracyclines as antibiotics with a carbotetracyclic skeleton. SD8 
is further categorized as belonging to the aquayamycin sub-type of angucyclinones. This 
sub-type is defined by molecules that incorporate both a C-glycoside and angular, tertiary 
diols at C4a and C12b in the aglycone (Figure 26)41-43.  The structure is highly modular 
and this will be exploited while designing synthetic routes towards its total synthesis. 
 
Figure 26: Structure of Angucycline antibiotics and Aquayamycin subtype Angucyclines 
2.2: Review of literature 
2.2.1: Prior synthetic efforts towards the Angucyclinone fragment 
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Various synthetic strategies have been reported for the synthesis of angucyclinone 
antibiotics, that either form the B, C or D rings as the key step. Most commonly reported 
methodologies for the key ring formation include Hauser cycloaddition, radical cyclization, 
Friedel-Craft cyclization, Michael addition and biomimetic reactions41, 42. 
The only reported total synthesis of an aquayamycin-type angucyclinone is of 
aquayamycin itself44. The study reported in 2000, uses a Hauser annulation between the 
3-(phenylsulfonyl) phthalide fragment 16 and the optically active cyclohexanone fragment 
17 to construct the BCD ring fragment (Figure 27). This synthesis uses a Lewis acid 
catalyzed C-glycosidation to install the olivose sugar in fragment 16. The stereochemistry 
of the angular C4a alcohol was derived using enzymatic resolution by Candida antartica 
lipase of a racemic tertiary alcohol in the preparation of the fragment 17. The 
stereochemistry at C4a is used to control the stereochemistry of the C12b alcohol during 
construction of the A ring by pinacol coupling44-46. This report provides precedent for 
construction of the A ring and control of stereochemistry while installing the angular diols. 
 
Figure 27: Total synthesis of Aquayamycin 
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Little synthetic work has been done on angucyclinones having epoxides. Sulikowski has 
reported an epoxidation on a benz[a]anthracene ring system in work towards the 
synthesis of angucycline SF 2315B (Figure 28)47. The epoxide of compound 22 was 
installed using radical oxidation by oxygenating a solution of the quinone 21 in THF in the 
presence of tetrabutylammonium fluoride and it was reported that only the α-epoxide is 
formed due to steric hindrance on the β-face by the A ring. This breaks the conjugated 
quinone system, and Sulikowski then performs a chelation-controlled syn-reduction of the 
C12 quinone ketone of 23 using tetramethylammonium triacetoxyborohydride to get 24. 
These conditions are chemoselective and the β-hydroxyketone can be reduced in 
presence of an epoxide and a ketone. This report offers the precedent of achieving 
chelation-controlled syn-reduction of a β-hydroxyketone in the presence of an epoxide 
and a ketone. 
 
Figure 28: Sulikowsky synthesis of SF 2315B  
Suzuki et al. report the selective substitution of the C3’ alcohol of olivose over the C4’ in 
the total synthesis of the antibiotic C104 (Figure 29)48, 49. TBS protection of the less 
hindered C3’ alcohol 25 occurs more readily and is followed by the installation of the 
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dienone ester at C4’ by Yamaguchi esterification to give 26. This report provides the 
precedent of selective reactivity of the C3’ alcohol over the C4’ alcohol in olivose.  
 
Figure 29: Selective reactivity of the C3’-OH over C4’-OH in the olivose sugar 
2.2.2:  Retrosynthetic Analysis of SD8 
The structure of SD8 is highly modular, which we plan to exploit in our total synthesis. 
Our first disconnection is at the olivose-tetraene bond (Figure 30). We plan to install the 
coumarin-tetraene subunit 27 selectively at the C3’ of the olivose sugar of the aglycone 
28 by a Yamaguchi esterification following the precedent of Suzuki48, 49. 
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Figure 30: Retrosynthesis of SD8 
The aglycone 28 will be prepared from the quinone 31 by a stereoselective epoxidation, 
chelation-controlled reduction of the C7 ketone, Suzuki coupling to install the A ring side 
chain and pinacol coupling to install the A ring. The BCD ring system 31 will be assembled 
by a Hauser annulation of the isobenzofuranone 33 and the α,β-unsaturated ketone 32  
will be prepared by stereoselective Rubottom-type α-hydroxylation (Figure 31). 
 
Figure 31: Retrosynthesis of the aglycone fragment 28 
Our proposed synthesis begins with the glycosidation of the sugar 34 and the 
isobenzofuranone 35 (Figure 32). The sugar can be installed using a well-precedented 
Lewis acid or protic acid catalyzed C-glycosylation reaction50, 51. Protection of the triol as 
the tri-benzyl ether completes the synthesis of the isobenzofuranone 33. 
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Figure 32: Synthesis of fragment 33 
We plan to synthesize the α,β-unsaturated ketone 32 as described in Figure 33. Using 
4-OTBS-cyclohex-2-en-1-one 36, which can be prepared on a large scale by multiple 
chemical or enzymatic routes as reported52-55, we plan to install the hydroxymethyl at Cα’ 
in a non-stereoselective manner to afford 37. On this substrate, we plan to carry out an 
asymmetric α-hydroxylation using Rubottom-type conditions56, which is well-precedented 
in the literature using Davis’ chiral oxaziridine57, Shi epoxide catalyst/Oxone58, Mn(salen) 
complexes/NaOCl59 and Sharpless Asymmetric Epoxidation (SAE)60, 61. The silyl enol 
ether is more electron rich than the olefin of the α,β-unsaturated ketone 37 and will react 
preferentially under these conditions62. We expect to isolate the triol 38 after a global 
deprotection using TBAF and reprotect the primary and tertiary alcohols as the acetonide 
and the secondary alcohol as the TBS ether to afford the compound 32.  
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Figure 33: Synthesis of the cyclohexanone fragment 32 
Hauser cycloaddition of 33 and 32 under basic conditions (LiHMDS) followed by acidic 
neutralization using the procedure of Hauser63 will afford the quinone 31 (Figure 34). We 
plan to install the epoxide in the next step. The timing of epoxide installation (early vs. 
late) was made after consideration of the stereochemical outcome of epoxidation of the 
early-stage and late-stage substrates (Figure 35). We predict that epoxidation on the 
early-stage substrate 31 will afford the desired β-epoxide 31’’. The protected C4a-OH 
and C6-OTBS groups in this intermediate will sit in the axial positions in the half-chair 
conformation, blocking the α-face and leaving the β-face sterically accessible for the 
approach of mCPBA. Epoxidation of the late-stage substrate 43, wherein the A ring is 
already formed, might lead to poor facial selectivity and yield because both the α- and β- 
faces are sterically hindered. Thus, we will install the epoxide at this earlier point in the 
route. Treatment of the epoxide with TBAF will remove the C6-OTBS protecting group 
and will set the stage for the next chelation-controlled syn-reduction on the substrate 39. 
 
Figure 34: Preparation of fragment 40 
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Figure 35: Epoxidation on early vs. late substrate  
The C6-OH in 39 will provide the directing group for the stereoselective syn-1,3-chelation-
controlled reduction of the C7 ketone64. Several reagents have been reported to offer high 
diastereoselectivity in similar systems including LiAlH(OtBu)3, DIBAL-H, LiBH4 and Luche 
reduction conditions65-68. Under chelation with the metal, the β-hydroxyketone 39 will 
adopt a half-chair conformation due to the stereochemistry of the C6 alcohol (Figure 36). 
The hydride will be delivered axially on the β-face to afford the C7-α-alcohol. The β-
hydroxyketone can be reduced preferentially in the presence of the ketones at C11 and 
C12b and the epoxide. Both the newly formed alcohols will be protected as the O-TBS 
ethers 40 for the next step (Figure 34).  
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Figure 36: Chelation-assisted syn-reduction 
Acetonide 40 will be deprotected using dilute acid to afford the diol and this will be treated 
with triphenylphosphine and DIAD to obtain the epoxide (Figure 37). The epoxide will be 
opened with iodide to give the alkyl iodide 41. We plan to use this alkyl iodide in a Suzuki 
coupling reaction using the conditions reported by Fu and Zhou69 with the vinyl boronate 
42 to obtain the extended alkyl chain in compound 43. Vinyl boronate 42 can be prepared 
by hydrozirconation/methylation of a 1-alkynylboronate according to literature 
procedures70. Alternatively, we can swap the coupling partners for the Suzuki reaction by 
using vinyl halide and an alkyltrifluoroboronate instead. Conditions for Suzuki coupling 
using alkyltrifluoroboronates and aryl halides have been reported by Molander et al.71, 72. 
The alkyltrifluoroboronate can be prepared by alkylation of the enolate by iodomethyl 
pinacolboronate and hydrolyzing the pinacol ester to the potassium trifluoroboronate by 
using KHF2. We will prepare the vinyl iodide required for the Suzuki coupling as reported 
by literature procedures73. 
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Figure 37: Synthesis of compound 28 
Following the extension of the side chain by Suzuki coupling, we will install the A ring 
using an intramolecular pinacol coupling similar to the one used for the preparation of 
aquayamycin. Hydrolysis of the ketal 43 with dilute acid will generate the aldehyde, which 
will be subjected to Pedersen conditions (VCl3(THF)3 and Zn in DMF) in a chelation-
controlled pinacol coupling74. The stereochemistry of the C4a quaternary carbon will force 
approach of the aldehyde from the top β-face of the C12b ketone in the chelation complex 
with the metal (Figure 38). Similar to the aquayamycin total synthesis, we expect to obtain 
a mixture of epimers at C1. Oxidation of the C1 alcohol will result in the desired single 
diastereomer 44. Synthesis of the aglycone will be completed by removal of the three 
benzyl protecting groups by catalytic hydrogenation and selective protection of the phenol 
as the O-TBS ether giving 28, which will complete the synthesis of the aglycone. 
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Figure 38: Pinacol coupling to form the A ring 
We will make the coumarin-tetraene fragment 27 by an EDCI coupling (Figure 39). The 
amide coupling with aminocoumarins using EDCI is well precedented by the work of 
Blagg et al.75. The coumarin-tetraene fragment 27 will be unified with the C3’ alcohol of 
olivose 28 by an ester bond using Yamaguchi coupling as described earlier. This will be 
followed by a global silyl-ether deprotection using either TBAF or HF/pyridine to give SD8. 
 
Figure 39: Final steps toward SD8 
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2.3: Progress towards the total synthesis of SD8 
2.3.1: Synthesis of the tetraene linker 
 
Figure 40: Synthesis of the tetraene linker 
We prepared the mono-tert butyl protected tetraene linker through multiple synthetic 
routes (Figure 40). Initially, we synthesized mucodialdehyde 46 by a double Wittig76 
reaction of glyoxal trimer dihydrate 44 and the Wittig reagent 
(triphenylphospharanylidene) acetaldehyde 45 to give the compound 46 in 64% yield. 
This di-aldehyde was subjected to a mono Horner-Wardsworth-Emmons reaction with the 
HWE reagent tert-Butyl diethylphosphonoacetate 47 using barium hydroxide as the base 
to obtain the compound 48 in 42% yield. The yield of this reaction was unoptimized. The 
mono-aldehyde 48 was subjected to an HWE reaction with diethylphosphonoacetic acid 
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49 using n-BuLi as the base to obtain the tetraene-mono tert-buyl ester 50 in quantitative 
yield. 
The tetraene di-carboxylic acid 30 is a component of the veterinary antibiotic fumagillin B 
51 that is commercially available in gram quantities as a beekeeping antibiotic. We 
obtained the diacid 30 in 90% yield by base hydrolysis77 of fumagillin 51 obtained after 
removal of excipients for the formulation by sodium bicarbonate wash.  
We also prepared the mono-tert-butyl ester of fumagillin 52 in 60% yield using tert-butyl 
bromide and caesium carbonate as the base in DMF. The fumagillol fragment was 
removed using base hydrolysis to afford the compound 50 in quantitative yield. 
 2.3.2: Synthesis of the olivose sugar 
 
 
Figure 41: Synthesis of compound 57 
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Figure 42: Synthesis of compound 62 
6-Deoxysugars such as D-olivose are commonly found in antibiotics produced by the 
Streptomyces bacteria. The classic route reported in literature towards 2-deoxysugars 
involve hydration of glycals under acidic conditions78. We chose to use the method of 
O’Doherty and co-workers to prepare the olivose sugar79-81. The first step involves a 
transfer hydrogenation from formic acid and triethylamine under Noyori reduction 
conditions using the catalyst (R)-Ru(η6-mesitylene)-(R, R)-TsDPEN A of 53 to 54 (Figure 
41). To prepare the pyran scaffold of olivose, an Achmatowicz reaction was carried out 
on the furan 54 to give the dihydropyranone 55 in 45% yield. We attribute this low yield in 
the initial two steps to the use of the commercially available ligand in preparation of A as 
compared to the recrystallized ligand used by O’Doherty, leading to unconverted starting 
material in the initial reduction. The separation of this unreacted material 53 was difficult 
leading to the reduced yield in the Achmatowicz reaction. 
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To separate the epimers on silica formed by the Achmatowicz reaction, the epimeric 
alcohol was protected as a Boc ether, and the β-epimer was purified (1:1, α:β, 24% of β, 
56). This was followed by a protecting group swap for the Boc to a benzyl using 
Bis(dibenzylideneacetone)palladium(0) in 95% yield to give 57. Luche reduction on the 
pyranone 57 gives a mixture of the diasteromeric alcohols 58 in 79% yield (Figure 42). 
This mixture was not separated and was subjected to an allylic transposition reaction 
using 2-nitrobenzenesulfonyl hydrazide (NBSH) as the nucleophile, affording the olefin 
59 in 97% yield. Mechanistically, this is a Mitsonobu reaction on the allylic alcohol using 
NBSH as the nucleophile, which forms the N-allylic sulfonylhydrazine derivative that at 
room temperature forms the allylic diazene intermediate. The diazene intermediate is 
unstable and results in the sigmatropic elimination of dinitrogen followed by the 
transposition of the olefin82. 
This olefin was dihydroxylated using OsO4 to give the diol 60 in 80% yield. However, the 
stereochemistry of the C4’-OH obtained is opposite of what is desired (3S vs. 3R), hence 
this was inverted using a Mitsonobu reaction using para-nitrobenzoic acid to afford the 
compound 61. The reaction had significant amount of impurities, which could not be 
removed entirely to obtain the pure product. Hence, a partially purified reaction mixture 
was subjected to TBSOTf and 2,6-lutidine as the base in DCM to give the 4-OTBS ether 
of D-olivose 62 in 30% yield (2 steps).   
2.3.3: Synthesis of the coumarin 
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Figure 43: Synthesis of the compound 68 and 71 
The synthesis of 3-amino-8-chloro-4,7-dihydroxy-coumarin has not been reported in the 
literature. Generally, there are two common synthetic approaches to coumarins: Friedel-
Crafts reaction of substituted phenols and cyclization of substituted 2-hydroxy-
acetophenone with base and diethylcarbonate. We used the acetophenone route to 
synthesize 3-amino-4,7-dihydroxy-coumarin and explored a late stage chlorination 
approach to install the 8-chloro on the ring. 
Starting from 2,4-dihydroxyacetophenone 63, the 4-OH group was protected using para-
methoxybenzyl chloride to afford the 4-PMB protected acetophenone 64 in 46% yield 
(Figure 43). This compound was cyclized into the coumarin using sodium hydride as the 
base in toluene and dimethyl carbonate as the electrophile to afford the coumarin 65 in 
quantitative yield. The most commonly reported method for introducing the nitrogen at the 
C3 position of the coumarin involves using concentrated nitric acid as the electrophile. 
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However, we decided to install the nitrogen using the electrophilic nitrogen source 
bis(Troc) azodicarboxylate83 66 to afford the compound 67 in quantitative yield. The 
decision to use this reagent was taken based on the high yielding electrophilic amination 
using this reagent and the ease in reaction workup and purification. Reduction of the 
hydrazide to the amine was carried out using zinc and acetone in acetic acid to afford the 
coumarin 68 in 46% yield. Acetone in this reaction forms the hydrazone from the 
hydrazide that is reduced readily by metallic zinc under these conditions83. We see a 
complete conversion of the starting material to the product by TLC and HPLC however; 
recovery of the polar amino alcohol 68 is difficult. Optimization of the workup conditions 
of this reaction will allow better recovery of the product. 
We explored conditions for the late-stage installation of the chlorine on 4,7-dihydroxy-3-
nitro-coumarin 70. This compound was prepared in one step from commercially available 
4-hydroxy,7-methoxy-3-nitro-coumarin 69 using dodecane thiol, KOtBu in DMF in 88% 
yield. Treatment of compound 70 with chloramine-T in refluxing dioxane/water affords a 
1:1 mixture of the product 71 and the starting material 70 in quantitative yield. Reduction 
of the nitro group84 and TBS protection will afford the desired coumarin 29. 
2.3.4: Suzuki coupling and model system 
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Figure 44: Synthesis of compound 76 and 79 
To prepare the A ring of the aglycone 43, we plan to install the side chain required for 
formation of the A ring by Suzuki coupling of an alkyl iodide and a vinyl boronate. To 
develop and optimize reaction conditions for the coupling, we decided to use the model 
system having a tetralone scaffold. 6-methoxy tetralone 72 was hydroxymethylated at its 
Cα position using 1H-benzotriazole-methanol under basic conditions (LiTMP) to give the 
α-hydroxymethyl-  derivative85 73 in 65% yield (Figure 44). This compound was 
hydroxylated at its alpha position under Rubottom conditions using m-CPBA as the 
oxidant. Briefly, the di-OTBS ether derivative was made using TBSOTf and, after reaction 
workup, the silanol-ether was oxidized using m-CPBA and 1,2-dichloroethane as the 
solvent. Use of 1,2 DCE simplifies the workup as after oxidation the 3-chlorobenzoic acid 
byproduct precipitates out of solution and after filtration the di-OTBS ether is obtained86. 
The compound was stirred with TBAF in THF to get racemic (±)-74 in 65% overall yield. 
To prepare the alkyl iodide, compound 74 was subjected to intramolecular Mitsonobu 
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reaction conditions with tributylphosphine and DIAD to obtain the epoxide 75 in 97 yield. 
The epoxide was opened with iodine and BF3(OEt)2 as the Lewis acid87 to obtain the 
iodide (±)-76 in 64% yield. 
We decided to swap the Suzuki coupling partners in case the reaction did not work with 
the alkyl iodide. Compound 78 was prepared by a procedure reported by Molander et al.. 
Alkylation of 6-methoxy tetralone 72 with iodomethylpinacol boronate 77 using LiHMDS 
as the base gave compound 78 in 55% yield. The potassium trifluoroboronate was 
prepared by using a saturated solution of KHF2. After continuous Soxhlet extraction 
overnight using acetone, compound 79 was obtained in quantitative yield71, 72.         
2.3.5: Synthesis of the isobenzofuranone 
 
Figure 45: Synthesis of the Isobenzofuranone 84 
The Isobenzofuranone coupling partner for the Hauser reaction was prepared in 6 steps 
from 3-hydroxybenzoic acid 80 (Figure 45). Commercially available 3-hydroxybenzoic 
acid was converted to N,N-diethyl-3-methoxybenzamide 81 via the acid chloride in an 
overall yield of 92% for two steps. The N,N-diethylamide was synthesized in order to 
direct lithiation using s-BuLi at the ortho position. The lithium anion formed using s-BuLi 
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was quenched using DMF to give the compound 82 in 67% yield. This was followed by a 
protecting group swap from 3-O-methyl to 3-O-benzyl, initially deprotecting the methoxy 
group using the Lewis acid BBr3 to give the phenol 82’ in 87% yield and alkylating the 
phenol with benzyl bromide, using sodium hydride as the base to give the compound 83 
in 76% yield. The compound was cyclized to the furan using TMSCN and catalytic KCN 
and quenching with acetic acid to provide the product 84 in 68% yield. 
2.3.6: Model reactions for the Olivose Sugar-Aglycone coupling (C-glycosidation) 
 
Figure 46: Model reactions for C-glycosidation 
To demonstrate the feasibility of acid catalyzed C-glycosidation, we ran the reaction using 
two different conditions using 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 as the glycosyl 
donor and 1-naphthol 85 and estrone 88 as the glycosyl acceptor (Figure 46). These 
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reactions were run only once and the yields were not optimized. Under these reaction 
conditions, first the phenolic oxygen attacks the anomeric carbon on the glycosyl donor 
forming an O-glycoside bond that rearranges to form the more stable C-glycoside.  The 
first reaction between 85 and 86 involved protic acid conditions, using trifluoromethane 
sulfonic acid as the protic acid in DCM giving the C-glycoside 87 in 37% yield51. The 
second set of conditions involved the Lewis acid TMSOTf and silver perchlorate50 as the 
promoter with 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 as the glycosyl donor and 1-
naphthol 85 and estrone 88 as the glycosyl acceptor. 1-Naphthol glycoside 87 was 
obtained in 32% yield and estrone glycoside 89 was obtained in 37% yield. 
2.3.7: Model reactions for Coumarin-Tetraene and Tetraene-Olivose Sugar coupling 
 
Figure 47: Model reactions for EDCI amidation and Yamaguchi reactions 
To demonstrate the feasibility of the planned coupling of tetraene with the coumarin (EDCI 
amidation)75 and with the Olivose sugar (Yamaguchi esterification), we have performed 
the reaction on a model system with the commercially available coumarin 90, alcohol 93 
and sorbic acid 91 (Figure 47).  
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The amidation was done on commercially available 3-aminocoumarin 90 and sorbic acid 
91 using the conditions reported by Blagg75 and coworkers to give the amide 92 in 59% 
yield. Once the target aminocoumarin 29 is available, this reaction condition can be used 
to synthesize the aminocoumarin-tetraene amide 27. 
To demonstrate that the Yamaguchi esterification48, 49 will work on a similar substrate, we 
used the alcohol 93 as a surrogate for the sugar Olivose. Yamaguchi coupling proceeds 
through a mixed-anhydride intermediate. 2,4,6-trichlorobenzoyl chloride forms the mixed 
anhydride with sorbic acid 91 in the presence of triethylamine. This intermediate mixed-
anhydride is treated with the alcohol and DMAP to form the ester. Compound 94 was 
isolated in 51% yield. 
2.4: Conclusion 
The structure of SD8 is highly modular, consisting of four distinct fragments – 
aminocoumarin, tetraene, olivose and the angucyclinone. We have proposed a synthetic 
route to the highly substituted and complex angucyclinone fragment in SD8. We also have 
identified and worked out synthetic routes to the aminocoumarin, tetraene and the olivose 
sugar. Although none of these reactions were optimized, we have prepared these 
fragments in a minimal number of steps and obtained modest overall synthetic yields 
(Table 4). We have identified and worked out various fragment-linking chemistries on 
model substrates like EDCI amidation for the Coumarin-tetraene fragment and 
Yamaguchi esterification for the Tetraene-Olivose fragment. We have also prepared the 
substrates for the Suzuki reaction for forging the A ring on model systems. Completion of 
synthetic work towards the angucyclinone fragment will help identify and synthesize 
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various analogues of SD8 that potentially will have better activity towards DNA gyrase 
and other fluoroquinolone resistant DNA gyrase mutants. 
Table 4: Fragments of SD8 prepared and overall yield 
Fragment synthesized  Total Synthetic Steps  Overall yield (%) 
8-chloro-4,7-dihydroxy-3-
nitrocoumarin 
2 69 
(2E,4E,6E,8E)-10-(tert-
butoxy)-10-oxadeca-2,4,6,8-
tetraenoic acid 
2 80 
D-Olivose 9 59 
7-(benzyloxy)-3-oxo-1,33-
dihydroisobenzofuran-1-
carbonitrile 
(Isobenzofuranone) 
6 82 
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  CHAPTER 3: DESIGN AND SYNTHESIS OF A SUBSTRATE-COMPETITIVE 
COVALENT INHIBITOR FOR PROTEIN KINASE B (AKT) 
3.1: Introduction 
3.1.1: AGC Kinases 
Phosphorylation is an important reversible covalent modification that regulates the 
function of proteins in cells. Enzymes that carry out phosphorylation in cells are called 
protein kinases. They transfer a phosphate group from ATP to their substrates by mostly 
attaching them to Serine (76-90%), Threonine (10-20%) or Tyrosine (0.05-4%) residues. 
Other residues found to be less frequently phosphorylated are histidine, aspartic acid and 
glutamic acid88. Protein kinases are classified into 8 major groups: AGC (PKA, PKG, 
PKC), CAMK (Ca-Calmodulin dependent protein kinases), CMGC (CDK, MAPK, GSK3, 
CLK), TK (Tyrosine Kinases), TKL (Tyrosine Kinase Like Kinases), STE (homologs of 
yeast kinases), RGC (Receptor Guanylate Cylases) and CK1 (Casein Kinase 1)89.     
AGC kinases belong to the subgroup of Ser/Thr protein kinases that by sequence 
alignments were found to have a similar catalytic kinase domain as cAMP-dependant 
protein kinase 1. The AGC family has 60 out of the 518 protein kinases identified. 
Structurally, most of them consist of the kinase core and other functional domains that 
mediate membrane or substrate interaction90.   
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A common structural feature seen in AGC kinases is a bilobal kinase fold that consists of 
an amino-terminal small lobe (N-lobe) and a carboxy-terminal large lobe (C-lobe) 
sandwiching one molecule of ATP. Activation in many AGC kinases requires 
phosphorylation of two highly conserved regulatory motifs: the activation segment (T-
loop) and the hydrophobic motif. The activation segment is found in the C-lobe, beside 
the ATP binding site, and is connected to the N-lobe by an αC helix. Phosphorylation in 
this activation segment leads to conformational changes in the αC helix that are required 
for the catalytic activity of the enzyme. The αC helix also forms a part of the hydrophobic 
pocket in the N-lobe and is necessary for regulatory interactions of the N-lobe with the 
hydrophobic motif. The hydrophobic motif extends from the tail of the C-lobe, wraps 
around the N-lobe, and inserts into the hydrophobic motif pocket, thus stabilizing the 
active conformation of the αC helix. The turn motif is located at the C-terminal end, before 
the hydrophobic motif, and consists of a phosphorylation site required for full kinase 
activity. A groove near the active site of the kinase is involved in substrate binding and 
the sequence specificity is determined by residues forming this site. The structures of 
activated AGC kinases are quite similar, but those of inactive AGC kinases have revealed 
a range of conformations indicating that the domains are highly flexible and disordered. 
Phosphorylation locks the kinase in an ordered conformation required for its activity 
(Figure 48)90. 
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Figure 48: AKT2 in its active conformation (PDB ID:1O6K). pThr309 and the ATP 
analog are shown in stick representation. DFG-in denotes the active conformation of the 
DFG motif that is ordered in the activated kinase. 
3.1.2: Protein Kinase B (AKT) 
AKT serine/threonine kinase (protein kinase B) is a member of the AGC kinase family 
and is an important signaling molecule in eukaryotic cells. The AKT gene is the cellular 
homolog of the oncogene v-AKT and was first identified in 1977 by Staal et al. and named 
c-AKT91. In 1991, the AKT kinases were cloned and identified by three independent 
research groups92-94. There are 3 isoforms of AKT: AKT1 (PKBα), AKT2 (PKBβ) and 
AKT3 (PKBγ), all encoded by different genes. AKT1 is expressed ubiquitously throughout 
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all tissues, AKT2 is expressed in insulin sensitive tissues that include the liver, skeletal 
muscle and adipose tissue and AKT3 is mostly expressed in the brain and testes95.  
The three isoforms of AKT share similar structures: a N-terminal regulatory domain that 
includes a pleckstrin homology (PH) domain, a hinge region that connects the PH domain 
to the kinase domain and a C-terminal region required for kinase activity. The catalytic 
domain of AKT is quite similar to other PKA and PKC members (Table 5). 
Table 5: Sequence Similarity (in %) between AKT isoforms96 
PAIR PH domain LINK 
region 
Catalytic 
domain 
C-terminal 
extension 
AKT1/AKT2 80% 46% 90% 66% 
AKT1/AKT3 84% 40% 88% 76% 
AKT2/AKT3 76% 17% 87% 70% 
 
3.1.3: Regulation of AKT 
3.1.3.1: Regulation by phosphorylation 
One of the ways AKT can be activated is by the receptor PDGFR (Platelet Derived Growth 
Factor Receptor β) through the enzyme PI3 kinase97. The tyrosine kinase receptor 
PDGFR undergoes dimerization on activation and leads to auto-phosphorylation of its 
tyrosine residues: Tyr740 and Tyr751. This recruits PI3 kinase to the plasma membrane 
through the Src homology 2 (SH2) domains in their regulatory subunit and the phospho-
tyrosine residues on the receptor. PI3 kinase then generates D3 phosphorylated lipids by 
the phosphorylation of phosphoinositides at the plasma membrane. This forms PIP2 and 
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PIP3. PIP3 binds to AKT at its PH domain, which results in the translocation of AKT to 
the plasma membrane. In addition to this PIP3 binding, phosphorylation of Thr308 in the 
T-loop and Ser473 within the hydrophobic motif are required to fully activate the enzyme. 
AKT is maintained in its inactive state by the interaction of the PH domain with the kinase 
domain. Once phosphoinositides bind to the PH domain, the conformation is changed 
and this allows subsequent phosphorylation events to occur90. 
PDK1, a serine/threonine kinase, also contains a PH domain and a kinase domain97. The 
PH domain binds to PIP3 at a higher affinity than that of AKT. Under physiological 
conditions, PDK1 is present as constitutively active at the plasma membrane of non-
stimulated cells. Once the concentration of PIP3 at the cell membrane increases by the 
stimulation of PI3K, AKT is shuttled from the cytoplasm to the plasma membrane. 
Following binding of the PH domain of AKT to PIP3, PDK1 phosphorylates Thr308 at the 
kinase domain in AKT. The enzyme that phosphorylates Ser473 within the hydrophobic 
motif had been elusive for a long time; in 2005 this was identified as the mTOR complex-
2 (mTORC2). mTORC298 directly phosphorylates Ser473 in vivo and also enhances the 
phosphorylation of AKT by PDK1. Other kinases such as DNA-PK and ILK1, are also 
capable of phosphorylating Ser473, but this may happen in a cell or context-dependent 
manner.  The mTORC2 complex consists of the kinase mTOR bound to: the mTOR-
interacting proteins rapamycin insensitive companion of TOR (RICTOR), SAPK-
interacting protein (SIN1), mammalian lethal with SEC13 protein 8 (mLST8), protein 
observed with RICTOR1 (PROTOR1) and PROTOR2. In addition to this AKT is 
constitutively phosphorylated at Thr450 in its turn motif, which stabilizes it and protects 
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the hydrophobic motif from dephosphorylation. Phosphorylation at the turn motif happens 
soon after AKT is synthesized, but it is unclear which kinase participates in it.   
Other miscellaneous ways in which AKT gets activated though PI3 kinase include 
Integrin-mediated99 and B cell antigen receptor (BCR)100 mediated stimulation. When 
cells get attached to fibronectin receptors in the extracellular matrix through integrin 
receptors on the cell surface Focal Adhesion Kinase (FAK), a tyrosine kinase in the 
cytoplasm gets activated and results in the phosphorylation of PI3 kinase. This activates 
PI3 kinase and activates AKT signaling through phosphoinositides. BCRs also play a role 
in activation of AKT though PI3 kinase. 
AKT must be phosphorylated on both the hydrophobic motif (Ser473) and at the activation 
loop (Thr308) to be fully active. Phosphorylation of only the hydrophobic motif or the 
activation loop results in an enzyme with just 10% of kinase activity compared to the 
doubly phosphorylated enzyme. Phosphorylation of the activation loop orders the catalytic 
domain and forms the substrate and ATP binding site101.  
AKT is mainly negatively regulated by dephosphorylation aided by the activity of various 
phosphatases. Protein phosphatase 2A (PP2A)102 is a serine/threonine heterotrimeric 
phosphatase that is present in the cytosol. It dephosphorylates Thr308 and returns AKT 
to its inactive conformation in the cytosol. Dephosphorylation of Ser473 is carried out by 
the PH domain leucine-rich repeat protein phosphatase (PHLPP), which belongs to a 
class of protein phosphatases 2C (PP2C) family103. 
PTEN (Phosphatase and Tensin Homologue deleted on chromosome 10) is a tumor 
suppressor gene, also referred to as MMAC1 (Mutated in Multiple Advanced Cancer 1) 
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and its mutation leading to loss of function has been implicated in many forms of cancers 
such as glioblastomas, prostate cancer and melanomas. The PTEN protein consists of a 
tensin-like domain and a catalytic domain similar to that of protein tyrosine phosphatases. 
PTEN has been found to have lipid phosphatase activity that preferentially 
dephosphorylates phosphoinositide substrates. It dephosphorylates PI(3,4,5)P3 to 
PI(4,5)P2; hence, PTEN negatively regulates levels of PIP3 in cells and regulates the 
AKT pathway. In addition to dephosphorylation of phosphoinositides, several reports 
demonstrate dephosphorylation of FAK by PTEN, leading to inhibition of cell migration 
and focal adhesion. PTEN only inhibits basal PKB activity, not affecting the pathway when 
stimulated by growth factors (Figure 49)104. 
 
Figure 49: Model of AKT regulation 
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The SHIP (SH (Src homology)-2 containing Inositol 5’ Phosphatase) phosphatases are 
lipid phosphatases with specific 5’ phosphatase activity105, 106. They break down 
PI(3,4,5)P3 to PI(3,4)P2, removing phosphates form the 5-position rather than the 3-
position. SHIP1 is present in haematopoietic cells and SHIP2 in non-haematopoietic cells. 
SHIP inhibits the AKT pathway when stimulated by growth factors. Activated PI3-kinase 
phosphorylates SHIP and it then translocates to the plasma membrane, leading to its 
phosphatase activity. Although both PTEN and SHIP regulate the level of PIP3 in cells, 
PTEN has the primary responsibility of controlling the mitogenic ability of these 
phosphoinositides because it dephosphorylates at the 3’ position and this has been 
demonstrated in knockout mice107, 108. Phosphorylation at the 3’ position is a necessity for 
binding to the PH domain of AKT. 
3.1.3.2: Redox Regulation 
AKT displays an intramolecular redox sensitive disulfide bond between Cys296 and 
Cys310 in its activation loop. Formation of this disulfide bond inactivates the enzyme that 
has been doubly phosphorylated at Thr308 and Ser473, suggesting that AKT is a redox-
regulated protein. A crystal structure of inactive AKT2 with this disulfide bond has been 
reported. Formation of this disulfide bond changes the conformation of the activation loop 
and sterically hinders both substrate and ATP binding. It also promotes the 
dephosphorylation of Thr308 by PP2A. Under conditions of oxidative stress, AKT forms 
the disulfide bond and targets the protein for inactivation by PP2A. Also this 
intramolecular disulfide bond can be reduced by glutaredoxin in vitro, restoring AKT to its 
active, functional conformation109. 
3.1.4: Downstream substrates of AKT 
 75 
 
The minimal substrate sequence for AKT has been found to be R-X-R-X-X-S/T-B, where 
X represents any amino acid and B represents bulky hydrophobic residues110. A 
representation of the most common downstream substrates is shown in Figure 50. These 
substrates are phosphorylated by AKT leading to either their activation or inhibition. 
Regulation of these substrates by AKT-mediated phosphorylation leads to the control of 
various cellular processes111. 
 
Figure 50: Substrates of AKT in the cell. AKT mediated phosphorylation of these 
substrates lead to their activation (green arrow) or inhibition (red blocking arrow) 
3.1.4.1: Cell survival 
AKT enhances cell survival by inhibiting the function of various proteins that participate in 
apoptosis: e.g. AKT phosphorylates the pro-apoptotic BH3-only protein BAD112, which is 
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a member of the Bcl-2 gene family and inhibits it. When BAD is phosphorylated by AKT, 
it forms a homodimer and releases Bcl-2 to inhibit cytochrome c-mediated apoptosis. AKT 
also phosphorylates the transcription factors FOXO113 and p53114. Phosphorylation of 
FOXO by AKT results in its exclusion from the nucleus thereby prevents transcription of 
its target genes that mediate apoptosis, cell-cycle arrest and metabolic processes. AKT 
promotes cell survival by phosphorylating MDM2115, an E3 ubiquitin ligase that is 
responsible for degradation of p53, resulting in its translocation into the nucleus. Two 
important transcriptional targets of p53 are the BH3-only proteins Puma and Noxa that 
are important in p53 mediated apoptosis. AKT also phosphorylates GSK3, inhibiting the 
enzyme. An important target for GSK3 is the Bcl-2 family member MCL-1, which is found 
to enhance cell survival. Human pro-caspase-9 has been found to be phosphorylated by 
AKT and this correlates with the decrease in protease activity of caspase-9 in vitro116. 
3.1.4.2: Cell Growth 
AKT plays a significant role in promoting cell growth (i.e. increase in cell mass) through 
activation of mTOR complex 1 (mTORC1 or the mTOR-raptor complex)117. This complex 
is regulated by both nutrients and growth factor signaling. AKT-mediated phosphorylation 
inhibits TSC2 (tuberous sclerosis complex 2) function and TSC2 is a negative regulator 
of mTORC1 signaling. This allows RHEb-GTP to activate mTORC1 signaling, which 
initiates translation and ribosome biogenesis. 
The AKT substrate PRAS40118 has also been found to be involved in mTORC1 regulation. 
PRAS40 associates with mTORC1 and negatively regulates mTORC1 signaling. 
Phosphorylation of PRAS40 by AKT results in its dissociation from mTORC1. 
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3.1.4.3: Cell Proliferation 
Phosphorylation of p27 cyclin-dependent kinase inhibitor by AKT leads to its cytosolic 
sequestration and thus prevents its localization to the nucleus119. This negates its cell-
cycle inhibitory effects. AKT also phosphorylates the cyclin dependent kinase p21, 
thereby inhibiting it120.  
GSK3 phosphorylates the G1 cyclins cyclin D and cyclin E and the transcription factors 
c-jun and c-myc, thus marking them for proteosomal degradation. These proteins play a 
critical role in the G1-to S- phase cell-cycle transition, and their enhanced stability by the 
inhibition of GSK3 by AKT increases the rate of cell proliferation. mTORC1 is a critical 
regulator of cell proliferation and the phosphorylation of TSC2 and PRAS40 by AKT 
regulates cell proliferation. 
3.1.4.4: Angiogenesis 
AKT signaling plays an important role in angiogenesis in both endothelial cells and tumor 
cells. In endothelial cells the pathway is activated by vascular endothelial growth factor 
(VEGF)121. The phosphorylation of the above-mentioned targets contributes to 
endothelial cell survival, growth and proliferation. In addition to this, AKT phosphorylates 
endothelial nitric oxide (NO) synthase (eNOS). The activated eNOS releases nitric oxide 
and this results in stimulation of vasodilation, vascular remodeling and angiogenesis122.  
Also through mTORC1 dependent translation, AKT leads to the increased production of 
hypoxia inducible factor α (HIF1α and HIF2α)123. This leads to expression and secretion 
of VEGF and other angiogenic factors124. Also, AKT1 in endothelial cells is required for 
proper endothelial cell migration. 
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3.1.4.5: Cellular Metabolism 
AKT signaling regulates nutrient uptake and metabolism by its action on a variety of 
downstream targets. AKT acutely stimulates glucose uptake in response to insulin by 
associating with glucose transporter 4 (Glut4)-containing vesicles on insulin stimulation 
of adipocytes, and this leads to Glut4 translocation to the plasma membrane125. The 
protein Rab-GAP AS160126 also known as TBC1 domain family member 4 (TBC1D4) is 
an important target that is phosphorylated by AKT in response to insulin. Phosphorylation 
of AS160 inhibits its GAP activity, allowing Glut4 vesicle translocation. Glut1 is the main 
glucose transporter in most cell types and AKT mediated activation of the mTORC1 
pathway leads to increased transcription of the Glut1 gene, through HIFα-mediated 
transcription.  
AKT activation also alters glucose and lipid metabolism in cells. It stimulates the 
association of hexokinase isoforms with the mitochondria where they more readily 
phosphorylate glucose to glucose-6-phosphate. Inhibition of GSK3 by AKT activates 
glycogen synthase leading to increased glycogen synthesis. AKT activation also 
increases the rate of glycolysis due to its ability to promote expression of glycolytic 
enzymes through HIFα. FOXO1 promotes glucose production in hepatocytes and 
regulates the differentiation of cells involved in metabolic control. AKT-mediated inhibition 
of FOXO1 also contributes to glucose homeostasis127.  
GSK3 promotes the degradation of sterol regulatory element-binding proteins (SREBPs) 
that are transcription factors, which turn on the genes involved in cholesterol and fatty 
acid biosynthesis. AKT-mediated inhibition of GSK3 increases SREBP stability and 
increases lipid production128.   
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3.1.5: Rationale for inhibiting AKT 
The hyperactivation of AKT is commonly seen in many cancers and through multiple 
cellular mechanisms results in tumor cell survival and enhanced resistance to apoptosis. 
The most frequent mechanism by which AKT is hyperactivated involves loss or 
downregulation of the PTEN tumor suppressor104, 107, 108, 129. Various reasons for targeting 
AKT for anti-cancer therapeutics are as follows; 
1. Expression of PTEN in Jurkat T cells inhibited AKT activation and increased 
apoptosis130. Introduction of wt-PTEN into tumor cell lines (glioblastoma, renal cell 
carcinoma, breast and prostate cell) that are mutant for PTEN resulted in either 
cell cycle arrest or apoptosis131, 132. Expression of AKT protected cells from 
apoptosis mediated by PTEN130. 
2. Antisense AKT2 RNA expression in PANC-1 cells reduced their tumorigenicity in 
nude mice133. 
3. Expressing a kinase-dead (KD) AKT mutant in tumor cells expressing activated 
AKT induced apoptosis. This did not affect normal cells or tumor cells with low 
levels of activated AKT. On a similar note, expression of PTEN induced apoptosis 
in several tumor cells that lack PTEN expression, but not in cells having wt-PTEN 
or normal cells. These results suggest that inhibition of AKT signaling would not 
be toxic to normal cells134. 
4. In neural cells, expression of constitutively-active AKT enhances IGF-1-mediated 
survival, but expression of a dominant-negative allele of AKT increased 
apoptosis135. 
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5. Introduction of anti-AKT-1 single chain antibodies into tumor cells resulted in 
reduced phosphorylation of GSK3α/β, leading to apoptosis in three cell lines with 
constitutive AKT activity, and inhibited tumor growth in a transgenic mouse 
model136. 
6. A peptide that binds to AKT, “AKT-in”, inhibited cellular proliferation and anti-
apoptosis in vitro and also tumor growth in vivo137. 
7. Reintroduction of a phosphatase PHLPP (PH domain/leucine-rich repeat protein 
phosphatase) that directly dephosphorylates AKT into a glioblastoma cell line 
caused suppression of cell growth138. 
8. Lung and breast cancer cell lines displayed inhibition of AKT signaling on treatment 
with the PI-3 kinase inhibitors  Wortmannin and LY 294002139, 140. 
9. Studies indicate that blocking AKT activation is the key reason for the therapeutic 
efficacy seen with the drugs Gleevec141, Trastuzumab142, Gefitinib104 and Tarceva. 
Frequent alterations seen with the AKT pathway in human cancer include the activation 
of growth factor receptors (GFRs) by ligand stimulation, or by overexpression/mutation of 
the receptor, leading to upregulation of AKT signaling. Activation of oncoproteins in the 
pathway like AKT itself, RAS, PI3-K, EIF4E by overexpression or activating mutations are 
seen in many cancers. Loss or inactivation of tumor suppressors such as NF1, VHL, 
PTEN, TSC2/1, LKB1 also contribute to deregulation of the pathway and subsequent 
tumor formation. Multiple human cancers that include carcinomas, glioblastomas and 
various hematological malignancies all display aberrant AKT activation97, 129, 143, 144 (Table 
6) 
Table 6: AKT activation in human cancers129 
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Tumor type % Tumors 
with active 
AKT 
Glioma ~55 
Thyroid carcinoma 80-100 
Breast carcinoma 20-55 
Small-cell lung carcinoma ~60 
NSCLC 30-75 
Gastric carcinoma ~80 
Gastrointestinal stromal tumors ~30 
Pancreatic carcinoma 30-70 
Bile duct carcinoma ~85 
Ovarian carcinoma 40-70 
Endometrial carcinoma >35 
Prostate carcinoma 45-55 
Renal cell carcinoma ~40 
Anaplastic large-cell lymphoma 100 
Acute myeloid leukemia ~70 
Multiple myeloma ~90 
Malignant mesothelioma ~65 
Malignant melanoma 43-67 
 
3.1.6: Inhibitors of AKT 
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Based on the strong rationale for targeting AKT, development of inhibitors for AKT is an 
active field of research in both the pharmaceutical industry and academia. Currently, there 
are multiple compounds that inhibit AKT in clinical trials, with two of them in phase-2 
studies (MK2206 and GSK2141795). This underscores the importance of developing 
inhibitors for targeting AKT145. 
AKT has multiple binding pockets where binding of inhibitors would block its downstream 
effects. One of the most studied pockets is the PI(3,4,5)P3 pocket on the PH domain. The 
PH domain binds to PI(3,4,5)P3 and PI(3,4)P2. The interactions are mostly charge-driven 
through the D3 and D4 phosphates, with lysines and arginines in the pocket. Compounds 
that block the binding of phosphoinsositides with the PH domain have been shown to 
inhibit the growth of transformed cells. Their mode of inhibition will prevent AKT 
translocation to the plasma membrane and subsequent activation, but compounds in this 
class have problems with solubility, pharmacokinetics and potency and remain largely as 
probe compounds to study kinase activity.  In the kinase domain, the most studied is the 
ATP binding pocket. However, given the high homology of the ATP pocket with other 
kinases, it is quite difficult to design compounds that bind selectively to the ATP pocket in 
AKT. 
3.1.6.1: Phosphatidylinosotol Analogues 
The lead compound in this class was DPI (Figure 51), which has an IC50 of 35 µM in  the 
HT-29 colon cancer cells146. This compound is an analogue of phosphatidyl-myo-inositol, 
while members of the class lack the 3-position hydroxyl group, which was removed so 
that it cannot be phosphorylated by PI-3 Kinase. Further analogues of this compound led 
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to removal of the two labile ester groups to ether linkages resulting in DPIEL that has an 
IC50 of 2.1 µM in the HT-29 colon cancer cell line147. 
The analog PIA5 was found to have an IC50 of 4.13 µM in the H1603 cell line. Analogues 
of this class of compounds inhibited phosphorylation targets downstream of AKT. They 
also increased apoptosis in cells with higher levels of constitutive AKT activity148.  
The compound Perifosine, KRK-0401 (licensed to Aeterna Zentaris) has an IC50 = 4.7 µM 
against AKT and a GI50 = 5 µM in the PC-3 prostate carcinoma cell line. It was shown to 
be active in phase-2 trials as a combination therapy in colorectal cancer and multiple 
myeloma. But it has been withdrawn from phase-3 trials145, 149, 150.  
 
Figure 51: Structures of Phosphatidylinositol analogues 
3.1.6.2: ATP-Competitive Inhibitors 
There is a high degree of homology in the ATP binding pocket among AKT, PKA and 
PKC. Hence, compounds that bind to the ATP binding site in AKT have to be tested for 
PKA and PKC binding as a measure of selectivity. 
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High-throughput screening of the Abbott compound collection led to the identification of 
3,5-disubstituted pyridine analogues that bind to the ATP binding pocket of AKT and these 
compounds have been classified as ATP-competitive, reversible pan-AKT kinase 
inhibitors that inhibit AKT activity in vitro and in vivo (Figure 52)151. Compound 95 has an 
Ki of 5 µM against AKT1. The chlorine atom was removed, the pyridine was replaced with 
an indazole and the methyl group was substituted with a 3-indole to give compound 96 
that had a potency of 0.00016 µM and was 40-fold selective over PKA. Compound 96 
displayed a dose dependent decrease in cell growth and lowered AKT mediated 
phosphorylation of downstream targets. It displayed an IC50 = 0.1 µM in MiaPaCa-2 
human pancreatic cancer cells and decreased tumor growth in mouse xenograft models, 
however this compound displayed poor pharmacokinetic properties and displayed QT 
prolongation and hypotension152. Compound 96 was further modified to give 97, which 
displayed a Ki = 0.0006 µM but with a lowered selectivity profile towards PKA. Despite a 
lowered potency and selectivity towards AKT, compound 97 exhibited no statistically 
significant hypotension when dosed orally in mice153. 
 
Figure 52: Structures of Abbott’s 3,5-disubstituted pyridine analogues 
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In 2008 GSK described a series of AKT inhibitors analogued from the oxadiazole leads 
98 and 99154. Using molecular modeling and co-crystalization the preclinical candidate 
100 (GSK690693) was identified (AKT1 IC50 = 0.002 µM, AKT2 IC50 = 0.013 µM, AKT3 
IC50 = 0.009 µM, Figure 53). The compound 100 inhibited GSK3β phosphorylation in cells 
and displayed a dose dependent reduction in tumor volume in BT474 breast carcinoma 
xenograft mice155. The compound was withdrawn from phase-1 clinical trials while testing 
an IV formulation of the agent for undisclosed reasons145. 
 
Figure 53: Structures of ATP competitive inhibitors from GSK 
3.1.6.3: Allosteric inhibitors 
Compounds 101 and 102 were identified from high throughput screening (Figure 54). 
Kinetic analyses indicated that neither compound competed with ATP nor the peptide 
substrate, also they were not active against AKT3, mutants lacking the PH domain or 
other closely related AGC kinases156.   
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Figure 54: Allosteric inhibitors of AKT  
Further work showed that these inhibitors prevented phosphorylation of Thr308157 by 
PDK1. This led to a description of a model for this novel mode of inhibition wherein the 
inhibitors only bind to a site that exists in presence of the PH domain, and stabilize AKT 
in a closed conformation that is not capable of being activated by PDK1. This has been 
proved by further studies that show the residue Trp80 in the PH domain forms a cavity in 
AKT1, but is absent in AKT3. Also in vivo FRET data shows that compound 102 locks 
AKT into its inactive conformation preventing its activation by phosphorylation. 
Merck, in 2005, identified the compound 103 (Figure 55), a dual AKT1/2 allosteric 
inhibitor from the lead 102158. Compound 103 displayed PH-domain dependent inhibition 
and it inhibited AKT and AKT dependent phosphorylation in a mouse pharmacodynamics 
assay. Due to the poor physical properties of compound 102, further work consisted of 
replacing the 2,3-diphenyl-quinoxaline core with a quinoline core to give compound 
104158. This analog displayed better physical properties, but to reduce molecular weight 
and increase basicity, the quinoline core was truncated to a pyridine to give compound 
105, a potent AKT1/AKT2 inhibitor with excellent aqueous solubility at pH 4.5159. 
Furthermore, chemical manipulation of the scaffold followed trying to improve aqueous 
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solubility, balancing biochemical and cell based activity and removing hERG liabilities, 
leading to the compound [1,2,4]triazolo[3,4-f][1,6]napthypyridine 106160.  
 
Figure 55: Allosteric inhibitors of AKT from Merck 
Merck also disclosed their recent allosteric AKT inhibitor MK-2206 (Figure 56), which is 
based on the triazolone-napthypyridine core. It also has an allosteric mode of action and 
currently is in phase-2 studies161. 
 
Figure 56: Structure of MK-2206 
3.1.6.4: Covalent inhibitors 
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A high-throughput screening effort in 2007 led to the discovery of the 
pyanonaphthquinone lactones 107 and 108 (Figure 57). These compounds were found 
to be highly potent and selective inhibitors of AKT162. 
 
Figure 57: Structure of PNQ lactones 
The mechanism of inhibition was found to be irreversible, with an adduct being formed 
with the pyanonaphthquinone and Cys310 and or Cys296 present in the T-loop of AKT1. 
A bioreductive alkylation mechanism was proposed wherein the quinone gets reduced 
under in vitro and in vivo conditions and forms a quinone methide 109’ that acts as a 
Michael acceptor. This reacts with the nucleophilic cysteine 310 in the T-loop of AKT and 
forms the adduct 110. The formation of this activated quinone methide 109’ by reduction 
is essential for the activity of these compounds (Figure 58). Analogues that lack this 
lactone ring are inactive as AKT inhibitors up to concentrations of 20 µM163.  
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Figure 58: Bioreductive alkylation mechanism postulated for PNQ lactones 
3.1.6.5: Substrate-Mimetic Inhibitors 
These compounds are more selective than all the earlier mentioned classes of inhibitors 
due to the natural selectivity filter of the kinase substrate binding pocket to recognize only 
a limited number of substrates. The substrate binding site offers potential for a large 
number of interactions for small molecules that can mimic a peptide.  
Activated AKT2 has been crystallized with the GSK3β 10 residue substrate sequence 
(3GRPRTTSFAE12) and a non-hydrolysable ATP analog (AMP-PMP)164. A similar 
shortened sequence 111 (GRPRTSSF), was reported by Alessi et al. to have a Km of 8 
µM110. This shortened sequence was used by Hamilton et al. to develop substrate-
mimetic inhibitors of AKT165. 
Initially, they substituted the serine, which can be phosphorylated, for a valine to give 
compound 112. More rigidity was introduced into the sequence by substituting Thr-Thr 
with para-aminobenzoic acid and a hydrophobic group; benzyl was added to the C-
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terminal Phe to get compound 113 (Figure 59). This was followed by removal of the N-
terminal GRP- sequence to obtain the compound 114. Compound 114 displayed a 3-fold 
decrease in affinity compared to 113, but Hamilton et al. were able to shorten the chain 
by 3 residues. Further optimization led to the extension of the linker between the para-
aminobenzoic acid and the guanidine group and addition of an N-benzyl acetamide group 
to fill the pocket that was occupied by threonine side chain to get compound 115. 
 
Figure 59: Peptidomimetic analogues   
Livnah et al. prepared the novel heptapeptide inhibitor 116 (Figure 60), which was found 
to have more than 50-fold selectivity for AKT over PKA166. Peptide 116 selectivly killed 
prostate cancer cells where in AKT was upregulated but not normal cells or cancer cells 
in which AKT was not activated. Also, the compound was effective in two prostate cancer 
mouse models.   
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Figure 60: Livnah Heptapeptide inhibitor 
Based on the structure of compound 115 and the 10 residue GSK3β peptide sequence 
(3GRPRTTSFAE12), Hamilton et al. designed compound 117 using the docking software 
GOLD (Figure 61)167. The compound was designed based on their observation that the 
N-terminal Gly3, Arg4 and Pro5 are not needed, the Thr7 and Thr8 are replaced with a 
p-aminobenzoic acid scaffold, and addition of a benzyl to the C-terminal Phe10 moiety 
increased affinity. The C-terminal dibenzyl group mimics Phe10 and the benzyl group 
from compound 115. Addition of a phenyl substituent to the 3-position of the p-
aminobenzoic acid scaffold gave 118 with an IC50 = 84 µM. Further rounds of analoguing 
led to the substitution of the C-terminal dibenzyl with a di-p-cyanobenzyl group, and gave 
the compound 119 that displayed a fourfold increase in inhibition. Substitution of a 
naphthyl group on the 3-position of the p-aminobenzoic acid gave compound 120, and 
replacement of the ethylamine-linker with a glycine linker led to the compound 121 with 
about an eightfold increase in inhibition as compared with the computationally designed 
lead 117. This work provides the example that the substrate binding site of AKT can be 
targeted with small molecule peptide mimetics. 
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Figure 61: Structures of substrate-competitive peptidomimetics 
Following the above mentioned work, Valle et al. reported synthesis of GSK3β peptide 
small molecule mimetics168. They used the lead GSK3β peptide (3GRPRTTSFAE12) as a 
lead and replaced the Thr7-Thr8 residues with a bicyclic-carbamate scaffold consisting 
of a proline, a 6-membered carbamate ring as a dipeptide surrogate and removed the N-
terminus 3GPR5 segment (Figure 62). Also they introduced the Val-Phe-NHBn fragment 
at the C-terminus as reported earlier by Hamilton et al. Further optimization led to the 
compound 122, which is ~5 fold more potent than compound 121.  
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Figure 62: Peptidomimetic reported by Valle et al.168.   
3.2 Rationale for the work 
3.2.1 Utilizing the Substrate Binding Pocket of AKT 
AKT is a widely expressed Ser/Thr kinase that phosphorylates various substrates in the 
cell that are involved in regulation of cellular functions such as cell proliferation, 
transcription, migration, apoptosis, cellular differentiation and metabolism. Persistent 
activation of the AKT pathway leads to human oncogenesis. Disregulation of AKT kinase 
activity is seen in many human cancers such as ovarian, breast, thyroid and colon 
cancers129, 143. Suppression of this aberrant AKT signaling by using small molecules that 
target AKT kinase has been shown to increase apoptosis and reduce cell proliferation in 
tumor cells that in particular express high levels of activated AKT. The development of 
small molecules that target AKT kinase is currently a highly active area of research with 
many such compounds currently in clinical trials169.           
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The majority of the small molecule AKT kinase inhibitors use the ATP binding site for 
binding to the kinase. The problem with such an approach is achieving selectivity with 
other homologous members in the AGC kinase family such as PKA and PKC. Selective 
binding in the ATP pocket of kinases is challenging, as this pocket is highly conserved 
among other kinases, and achieving specificity requires utilizing the subtle differences in 
residues lining these pockets. Hence, these inhibitors tend to compete with other 
enzymes that utilize ATP having similar binding regions and also with high cellular 
concentrations of ATP. This competition with millimolar concentrations of ATP in the cell 
explains why ATP mimetics require much higher concentrations for tumor growth 
inhibition compared to recombinant enzyme assays170.  
One significant problem with using kinase inhibitors that target the ATP pocket is the 
development of drug resistance. This is because the mutations that accumulate in the 
ATP binding site of the kinase, as was observed in patients with CML undergoing 
treatment with Imitinib. The mutated residues found in the ATP binding site were highly 
conserved among kinases, so use of the substrate binding pocket potentially may obviate 
that problem. Such a strategy has already been used sucessfully for targeting 
Extracellular signal Regulated Kinase (ERK), Polo-like Kinase 1, Abl kinase, Insulin-like 
growth factor-receptor 1 (IGF-RI) and AKT170-172.   
Substrate-mimetic inhibitors offer a new paradigm in the targeting of protein kinases by 
blocking phosphorylation, and thus not competing with ATP. The enzyme substrate 
binding site has evolved to recognize specific substrate sequences in contrast to the ATP 
binding site. These sites are adapted individually for each kinase to recognize a particular 
substrate sequence in the cell. Therefore, they offer a large number of specific potential 
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interactions that could be used for designing a small molecule to target these sites, 
compared to the corresponding ATP pocket. Hence, exploiting the substrate specificity of 
these sites will allow the design of a more specific inhibitor for AKT kinase170. 
3.2.2: Utilizing a Covalent Mode of Inhibition 
The problem with using the substrate binding site is the large binding pocket and the 
extended binding conformation that many of the substrates use. This creates a problem 
where a large binding space has to be targeted for the design of an effective and specific 
inhibitor. Although the substrate peptides possess high selectivity and specificity in 
binding to the kinase, these sequences are poor inhibitors due to their lack in potency. 
The usual approaches used to increase potency with these peptides involve screening 
combinatorial libraries of peptides173, incorporation of unnatural amino acids166, 174 and 
bisubstrate approaches that link the peptide to an ATP pocket binder175. We chose to 
develop a covalent substrate competitive binding approach to increase potency. 
Covalent mechanisms of binding to proteins has been traditionally shunned in drug 
development because these compounds were thought to form highly reactive metabolites 
and cause drug allergies. But, about 30% of the drugs on the market that target an 
enzyme do act through a covalent mechanism176. The risk of toxicity by covalent inhibitors 
can be minimized by optimization of the non-covalent binding interactions and by 
modulation of the reactivity of the electrophile. This would lead to more target specificity 
and mitigate unwanted side reactions with nucleophiles in vivo177. 
The advantages of a covalent mechanism of action include an improved biochemical 
efficiency due to irreversible binding, less frequency of dosing due to longer duration of 
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action, increased efficacy due to the lower concentrations required, and the potential to 
avoid drug resistance due to continuous suppression of the target. Also, targets with 
shallow binding sites could be inhibited. There has been a recent surge in the 
identification of covalent inhibitors with compounds from the programs targeting EGFR, 
BTK, FAAH and MetAP2 progressing to phase II and III clinical trials172, 176, 178.  
3.2.3: Identification of a Nucleophilic Residue in AKT 
The pyranonaphthoquinone (PNQ) lactone class of natural products potently and 
selectively inhibits AKT by alkylating Cys310 in the activation loop. The PNQ lactones 
have been shown to form a covalent adduct with Cys311 in AKT2 (Figure 59)162, 163. 
Other non-selective cysteine alkylating electrophiles like N-ethylmaleimide179, iodoacetic 
acid180 and 4-hydroxynonenal181 (4-HNE, a Michael acceptor) have been shown to 
alkylate Cys310 in AKT. An iodoacetamidate activity-based probe has been shown to 
alkylate Cys310 in AKT by Cravatt et al. by mass spectrometry182.   
3.2.4: Identification of an appropriate Substrate Mimetic for AKT            
The X-ray crystal structure of activated AKT2 with the GSK3β 10 residue substrate 
sequence (3GRPRTTSFAE12) and a non-hydrolysable ATP analog (AMP-PMP) was 
reported in 2002164. The peptide is phosphorylated by AKT on Ser9 and includes the 
consensus sequence for AKT (RXRXXSF). The crystal structure shows the GSK3β 
peptide to be bound in an extended conformation, with discrete sections of the β-strand 
on either side of Ser9. According to the crystal structure, Phe10 of the GSK3β peptide 
aligns adjacent to AKT Cys310 (Figure 63). The distance measure from the peptide 
backbone of GSK3β to Cys310 is ~6.0 Å. 
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Figure 63: Distance between Cys310 and peptide backbone of GSK3β peptide  
Hamilton and coworkers identified the small molecule peptidomimetic 121 of AKT  by 
analoguing from the GSK3β peptide. In order to understand the spatial relationships of 
compound 121 binding to AKT, we docked this compound using GOLD into the substrate 
binding pocket of the AKT co-crystal structure (Figure 64)167. The docking pose we 
obtained closely matches that reported by Hamilton. The docking model predicts that one 
of the two p-cyanobenzyl rings on the C-terminal end of the molecule is located ~5.5 Å 
from the thiol of Cys311 (AKT311 numbering). 
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Figure 64: Docked Structure of compound 121 
3.2.5: Initial Design of Compounds and Selection of the Electrophile 
Based on our docking model that predicts the distance of ~5.5 Å from the nucleophile of 
Cys310 in AKT to the p-cyanobenzyl group, we reasoned that we could replace this C-
terminal moiety in 121 (Figure 65) with appropriate electrophiles that would react with the 
sulphur of Cys310. To synthesize covalent inhibitors of this type, we needed to identify 
electrophiles that can be installed on the aniline nitrogen and that could inhibit AKT. As 
our initial screen we decided to screen α-haloacetamides, maleimides, epoxides, 
acrylamides and vinyl ketones. These electrophiles have been reported to alkylate 
cysteines, when used in various kinase inhibitors176-178. For the ease of synthesis and 
quick screening for inhibition of AKT activity, we initially decided to use only the C-terminal 
end or the right hand fragment of compound 121 to install the electrophiles. We reasoned 
that from the most potent compound obtained from this set, we will elaborate by adding 
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the N-terminal end of the Hamilton fragment to result in a potent and selective substrate 
mimetic covalent inhibitor for AKT. 
 
Figure 65: Design of the first set of compounds 
3.3: Synthesis and Biological evaluation of the First Set of Compounds 
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3.3.1: Synthesis of α-haloacetamides 
   
Figure 66: Synthesis of α-haloacetamides 
The α-haloacetamides were synthesized either starting from aniline 123 or from 4-
nitroaniline 124 as shown in Figure 66. The electrophiles were installed using either 
chloroacetyl chloride or bromoacetyl chloride using standard acid chloride coupling 
conditions with triethylamine as the acid-trap. Compound 131 was prepared by reductive 
amination from 4-nitroanilline and 4-cyanobenzaldehyde using the acid stable sodium 
triacetoxborohydride as the reductant. The iodo-acetamides 127, 128 and 133 were 
prepared using a Finkelstein reaction by refluxing the chloro-acetamides 125, 126 and 
132 with excess sodium iodide in acetone. 
3.3.2: Synthesis of acrylamides 
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Figure 67: Synthesis of the acrylamides 
The acrylamides 135, 136 and 137 were prepared form aniline 123, 4-nitroaniline 124 
and compound 131 using acryloyl chloride by acid coupling conditions using triethylamine 
as the base (Figure 67). Acrolyl chloride was added at 0 0C to the reaction and they were 
allowed to react overnight at room temperature.  
3.3.3: Synthesis of Epoxide 
 
Figure 68: Synthesis of compound 138 
The compound 138 was synthesized from the acrylamide 135 by refluxing it with the 
oxidant m-CPBA in dichloromethane (Figure 68).  
3.3.4: Synthesis of Maleimides 
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Figure 69: Synthesis of the maleimides 141, 144 and 145 
The maleimides 141 and 145 were synthesized from the iodo-acetamides 127 and 133 
according to Figure 69. Maleimide itself cannot be used in a base catalyzed reaction 
because of its reactive Michael-acceptors. Hence it was protected using furan in a hetero-
Diels Alder cyclization to give compound 139. This compound was then reacted with 
compounds 127 and 133 in an SN2 reaction with potassium carbonate as the base to 
obtain the intermediates 140 and 145’. The furan protecting group was removed using a 
retro Diels-Alder reaction by heating the compounds 140 and 145’ in anisole at 160 0C 
for four hours to give the maleimides 141 and 145. 
Compound 143 was prepared by a SNAr reaction using 2-aminoethanol as the nucleophile 
and 142 as the electrophile. The primary alcohol was substituted with maleimide in a 
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Mitsonobu reaction to give the compound 144. Mitsonobu reactions use much milder 
conditions and allow the use of unprotected maleimide itself as the nucleophile. 
3.3.5: Synthesis of Vinyl ketones  
 
Figure 70: Synthesis of Vinyl ketones 148 and 151 
The vinyl ketone 148 was prepared starting from Boc-Phe-OH 146, which was converted 
to the Weinreb amide 147 using EDCI as the coupling reagent and HOBt to prevent 
racemization (Figure 70). The Weinreb amide was reacted with the Grignard reagent 
vinyl magnesium bromide to obtain the vinyl ketone 148. The vinyl ketone was found to 
be both acid and base labile, hence the N-Boc protecting group was removed by first 
reducing the ketone using sodium borohydride in methanol to obtain a diastereomeric 
mixture of alcohols 149. From this compound 149, the N-Boc group was removed using 
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a mixture of TMSOTf and 2,6-lutidine. The primary amine was coupled to p-nitrobenzoic 
acid to give a diasteromeric mixture of alcohols 150. The secondary alcohol was oxidized 
using Dess Martin reagent in dichloromethane to give the vinyl ketone 151. 
3.3.6: Biochemical evaluation of the compounds 
We evaluated the first set of compounds in a biochemical fluorescence assay (Z’-LYTE 
kinase assay, Ser/Thr kit 6, Invitrogen) using commercially available recombinant AKT1 
(Invitrogen, P2999). This assay uses a proprietary peptide substrate that contains the 
AKT1 consensus sequence and is labeled with a coumarin on one end and fluorescein at 
the other. During the kinase reaction, the peptide substrate is phosphorylated by AKT1. 
After the reaction is stopped, the FRET signal between the coumarin and fluorescein is 
detected only on the phosphorylated peptide. Unphosphorylated peptide is cleaved by a 
site-specific protease when the reaction is developed, disrupting the FRET signal from 
the unphosphorylated substrate. Addition of compounds to the assay that inhibit 
phosphorylation of the substrate by AKT1 results in a decrease of the FRET signal. This 
assay detects functional inhibitors of AKT1 independent of mechanism of action. 
Compounds 125 to 151 were evaluated by this assay in triplicate over a concentration 
range of 8 nM to 100 µM. The data we obtained is shown in Table 7. 
Table 7: Evaluation of compounds against AKT1 
Compound 
AKT1 IC50 
(µM) 
Compound 
AKT1 IC50 
(µM) 
125 >100 141 1.55 
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129 10.59 144 1.79 
127 3.25 145 1.97 
128 2.33 138 >100 
133 1.11 148 0.58 
135 >100 151 0.32 
 
Based on the above IC50 data, the epoxide 138, acrylamide 135 and the α-chloro 
acetamide 125 were inactive as AKT1 inhibitors with IC50 > 100 µM. The α-bromo 129 
and α-iodo acetamides 127, 128, 133 and the maleimides 141, 144 and 145 were all 
active in the low-micromolar range of concentrations. However, the vinyl ketones 148 and 
151 inhibited AKT in the submicromolar range of concentration, with an IC50 of 0.58 µM 
and 0.32 µM. 
Among the α-haloacetamides, the inhibition was dependent on the reactivity of the 
electrophile. The α-chloro acetamides 125 were inactive, and the iodo-acetamides 127, 
128, 133 were ~4 fold active, as compared to the bromo-acetamide 129. Among the iodo-
acetamides, compound 133 was twice as active as compared to 127 and 128. This can 
be explained by the additional interactions made by the p-cyanobenzyl moiety. 
Among the maleimides 141, 144 and 145, there were no differences in IC50s among the 
compounds with these variations in structure. This suggests that the interactions were 
mostly covalent binding and the addition of more binding elements did not make any 
difference in the IC50. 
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The most potent compounds in this series were the vinyl ketones 148 and 151. The most 
potent compound 151 has the p-nitrobenzyl group instead of the N-Boc group. This is the 
fragment present in the Hamilton compound 121, which can be elaborated on to add the 
N-terminal end of the compound.  
3.3.7: Synthesis and biochemical evaluation of the reduced analogues and with the 
alkyne handle 
Having identified the most potent compound in the series, we decided to confirm that the 
mechanism of inhibition was covalent. We inactivated the vinyl ketone electrophile by 
reducing it to the ethyl ketone using catalytic hydrogenation over palladium on charcoal 
to give the compounds 152 and 153 (Figure 71). 
 
Figure 71: Synthesis of 152 and 153 
To determine the selectivity of the compounds in a cellular context, as compared with the 
purified recombinant enzyme, we made the vinyl ketones with an alkyne handle attached 
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to the N-terminal: 156 and 161 (Figure: 72 and Figure: 73). The alkyne handle can be 
used to attach detection or purification tags to the compound in a biological sample. This 
will allow the identification of the compound-protein adduct in the sample. 
 
Figure 72: Synthesis of compound 156 
The compound 156 was synthesized starting from phenylalanine 146, to which the 
propargyl carbamate group was installed using propargyl chloroformate and sodium 
hydroxide as the base. This compound was converted to the Weinreb amide using the 
coupling reagent EDCI to give compound 155. This was reacted with the Grignard reagent 
vinyl magnesium bromide in THF to give the compound 156. 
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Figure 73: Synthesis of compound 161 
Compound 161 was synthesized starting from the mixture of the diastereomeric alcohols 
150. The nitro group was reduced to the amine using tin chloride dihydrate in refluxing 
ethylacetate to give compound 157. The secondary alcohol was then protected as the 
TBS ether using TBSOTf and 2,6-lutidine as the base to give 158. The propargyl group 
was then installed onto the amine using propargyl chloroformate and triethylamine as the 
base, followed by removal of the TBS ether using TBAF to give compound 160. The 
secondary alcohol was oxidized using Dess-Martin periodane to give compound 161. 
To confirm the covalent mechanism of action of compounds, the inactivated analogues 
152 and 153 were screened for inhibition of AKT phosphorylation using the Z-LYTE assay 
as described before. Also, to determine the selectivity of the compounds for AKT, we 
screened the alkyne analogues 156 and 161 against c-AMP-dependent protein kinase A 
(PKAα) (Table 8). PKAα is a member of the AGC kinases and is most identical to AKT, 
sharing 43% sequence identity in its kinase catalytic domain183. Hence, the fold selectivity 
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obtained for AKT over PKA is a probable measure of how selective the compound will be 
in a cellular context.  
Table 8: IC50 of compounds against AKT1 and PKAα 
Compound AKT1 IC50 (µM) PKAα IC50 (µM) 
152 >100 nd 
153 >100 nd 
148 0.58 52.6 
151 0.32 >100 
156 2.44  
161 0.82 13.47 
 
To confirm that the vinyl ketones 148 and 151 inhibit AKT by a covalent mechanism of 
action, we tested the inhibition of AKT by the inactivated analogues 152 and 153. These 
compounds have their electrophilic moiety removed by reduction of the vinyl ketone to 
the ethyl ketone. As shown in Table 8, compounds 152 and 153 are inactive towards AKT 
with IC50s > 100 µM. This confirms that the mechanism of action of these compounds is 
by covalent inactivation of AKT. 
The first step in determining the selectivity of these compounds towards AKT is by 
screening them against c-AMP-dependent protein kinase A (PKAα), which is a member 
of the AGC kinase family. As shown in Table 8, the Boc-Phe-vinyl ketone 148 inhibits 
PKAα with an IC50 of 52.6 µM, hence is ~90 fold more selective for AKT1 than PKAα, 
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whereas the p-nitrobenzoyl-Phe-vinyl ketone 151 was essentially inactive towards PKAα 
(IC50  > 100 µM) displaying a selectivity of more than ~310 fold for AKT1.  
To determine the selectivity of the compounds in a cellular context, we made the alkyne-
tagged analogues 156 and 161. These compounds were selectively and potently active 
towards AKT with 161 displaying a ~16 fold selectivity towards AKT1. 
Now that we determined the mechanism of inhibition of these compounds to be covalent, 
we wanted to determine the residue in AKT1 that is covalently modified by the vinyl 
ketones. Hence, we made the fluorescein-labeled analog of 156 by azide-alkyne 
cycloaddition as shown in Figure 74 to give the compound 165.  
 
Figure 74: Synthesis of 165 
This compound was incubated with AKT1, followed by gel electrophoresis and 
confirmation of labeling by in-gel fluorescence scanning (Figure 75). Once the AKT1 
band was confirmed to be labeled by 165, it was excised and subjected to trypsin 
digestion. The mass-spectrum was obtained on a LTQ Orbitrap Velos instrument and an 
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average 93% coverage was obtained. 165 was shown to modify the AKT fragment 
Cys310 (Table 9). Modification of other cysteines was not observed. 
 
Figure 75: Labeling of AKT1 with 165. a) Coomassie Blue Staining b) Fluorescence 
image at 488/526 nm (Lane 1: AKT1 only, Lane 2: AKT1 incubated with 165) 
 
Table 9: Mass Spectrometry Data for AKT1 Fragment Modified by 165 
  308TFCGTPEYLAPEVLEDNDYGR328 
  Mass Found Mass Calculated 
Unmodified 2389.04 2389.06 
Modified with 165 3177.33 3177.32 
 
To determine the selectivity of 165 in a cellular context, we incubated the compound with 
cell lysates from the HCT-116 cell line. HCT-116 carries two mutations that constitutively 
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activate the PI3K/AKT signaling pathway (one in the large subunit of PI3K and the other 
that constitutively activates Ras). The cell lysates were treated with increasing 
concentrations of 165 (0 – 100 µM final concentration) and incubated at room temperature 
for 1 hour. Following this, the labeling reactions were separated by gel electrophoresis on 
a 10% SDS-PAGE gel (Figure 76, A). Labeled proteins were visualized on an in-gel 
fluorescence scanner. AKT alone was detected by Western Blot with biotin-conjugated 
AKT (pan) antibody and streptavidin horseradish peroxidase (Figure 76, B). All proteins 
in the cell lysates were visualized using Coomassie stain (Figure 76, C) 
 
Figure 76: Labeling of AKT in HCT-116 cell lysates by compound 165  
Figure 76 shows that the major band labeled by the probe 165 corresponds to the 
molecular weight of AKT, as is shown by the western Blot (Figure 76, B). This shows that 
additional bands are labeled, especially at higher concentrations and that non-specific 
labeling occurs. The compound 148 displays non-specific labeling in cells lysates, hence, 
despite the vinyl ketone electrophile being highly potent and selective for AKT over PKAα, 
it cannot be used for further elaboration because of its non-selective binding to proteins.  
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3.4: Synthesis and Biological Activity of the second set of compounds 
Our approach to develop covalent inhibitors for AKT till now was to focus on identification 
of an appropriate electrophile by structural elements from the C-terminal end of the 
Hamilton compound 121. This led us to identify the vinyl ketones 148 and 151, which 
were potent inhibitors of AKT and were highly selective for AKT against PKAα. However, 
in a cellular context, we found that these compounds displayed non selective labeling of 
other proteins in the cell. To address this issue of improving selectivity for AKT over other 
proteins we chose to shift our focus from the electrophile and examine rest of the 
substrate binding site. Our new approach was:  
 Dial down the reactivity of the electrophile so that it would not react indiscriminately 
with other proteins in the cell. 
 Include additional binding elements from reported inhibitors, so that the non-
covalent interactions from the inhibitor provide more selectivity for AKT. 
We envisioned that using an electrophile that had moderate to low reactivity towards 
Cys310 in AKT would make it less susceptible for indiscriminate labelling. Compound 133 
has an IC50 of 1.11 µM towards AKT. Hence, we decided to use the α-iodoacetamide 
electrophile and also prepare and screen the α-bromo and α-chloro electrophiles. TPCK 
has been used traditionally as an active site label for serine proteases (Figure 77). It has 
been shown by mass spectrometry to label Cys310 in AKT1 and no inhibition of AKT was 
seen in vitro in concentrations up to 500 µM184, 185. Thus, we decided to use the 
phenylalanine chloromethyl ketone core as an electrophile. 
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For additional binding elements, we included the N-terminal fragment of the Hamilton 
inhibitor 121. We did not include the 3-naphthyl group from the p-amino benzoic acid 
fragment in the α-haloacetamide compounds for the ease of synthesis, rationalizing that 
this fragment can be included for later analogues if the compounds were active. For the 
α-chloromethyl ketone analogues, we used a phenyl group at that position instead 
(Figure 77).  
 
Figure 77: Rationale for second set of compounds 
As a control analog, we decided to prepare the compounds 198 and 203 (Figure 78). 
Compound 198 would give us a qualitative estimate of electrophilicity of the α-
chloromethyl ketone against AKT. Compound 203 would give clues about the non-
covalent interactions with AKT. It was designed as a hybrid, based on the GSK3β peptide 
and Hamiltons peptidomimetic 121.   
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Figure 78: Control compounds 
3.4.1: Synthesis of the α-haloacetamide compounds 
 
Figure 79: Synthesis of intermediate 172 
Our synthetic routes to these compounds was designed such that the steps were linear 
and more fragments were added from the C-terminal to the N-terminal end. This route 
would be successful only if the electrophile that would be installed in the beginning would 
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survive all the synthetic conditions leading to the product. Gratifyingly, the α-chloro 
acetamide was stable enough to be installed from the start of the synthetic route and be 
carried till the end. The more reactive α-bromo and α-iodo could be synthesized under 
Finkelstein conditions at the penultimate step in the route.   We started the synthesis of 
the α-haloacetamides from the intermediate 132 that was previously prepared (Figure 
79). The para-nitro group was reduced in refluxing tin chloride to give the aniline 166, 
which was coupled with 4-nitrobenzoic acid by acid-chloride 167, coupling to give 
compound 168. The newly introduced para-nitro group was reduced with tin chloride in 
refluxing ethyl acetate to give the aniline 169. The aniline was coupled with Fmoc-Gly-Cl 
using sodium bi-carbonate as the base in a mixture of water and chloroform to give the 
Fmoc-protected compound 170. The protecting group Fmoc was removed using base 
and the primary amine was coupled to the Diboc protected amidine reagent: N,N’-Di-Boc-
1H-pyrazole-1-carboxamidine in methanol, with triethylamine as the base to give the 
compound 172. The Diboc-protecting group was removed under acidic conditions using 
TFA to give the α-chloro acetamidate 173 (Figure 80). The α-chloro group was 
exchanged either to a bromo or iodo under Finkelstein conditions by refluxing it with 
sodium bromide or sodium iodide in acetone to give compounds 174 and 176. The Diboc-
protecting group was removed under acidic conditions to give the final compounds 175 
and 177. 
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Figure 80: Synthesis of the α-haloacetamides 173, 175 and 177 
3.4.2: Synthesis of the α-chloromethyl ketone compounds and control compounds 
To synthesize the chloromethyl ketone compounds, we had to synthesize the N-terminal 
fragment of the Hamilton’s compound 187 separately and then couple it with the C-
terminal chloromethyl ketone fragment. We tried to prepare these compounds in an 
analogous manner as that of the α-haloacetamides, but the α-chloromethyl ketone 
electrophile was too reactive and did not survive the reaction conditions.  
Our synthetic route starts with the preparation of the N-terminal binding fragment 187 
(Figure 81). Starting from 3-bromo-4-nitrobenzoic acid 178, the carboxylic acid was 
protected as a tert-butyl ester using tert-Butyl 2,2,2-trichloroacetamidate and the Lewis 
acid boron trifluoride diethyl etherate to give compound 179. Other common reaction 
conditions like tert-butanol and EDCI or tert-butyl bromide did not give any product. 
Suzuki reaction with phenylboronic acid catalyzed by palladium-
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tetrakistriphenylphosphine was carried out to give compound 180. The tert-butyl 
protecting group was removed with acid to give compound 181. Using standard acid 
chloride coupling the fragment benzyl 4-amino benzoate was coupled to the acid 181 to 
give the amide 182. The nitro group was reduced with tin chloride in refluxing ethyl acetate 
to give the aniline 183. To this intermediate N-Boc-2-aminoacetaldehyde was coupled by 
reductive amination using sodium cyanoborohydride as the reductant to give compound 
184. The N-Boc group was removed using acid and the amidine fragment was coupled 
using the reagent N,N’-Di-Boc-1H-pyrazole-1-carboxamidine with triethylamine as the 
base to give compound 186. The benzyl protecting group was removed using catalytic 
hydrogenation using palladium on carbon to get the fragment 187. 
 
Figure 81: Synthesis of the fragment 187. 
We prepared the phenylalanine chloromethylketone 189 as described in Figure 82. 
Starting from Boc-Phe-OH 146 was converted into the α-diazoketone 188 with 
diazomethane. The intermediate mixed anhydride is initially formed with isobutyl 
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chloroformate, which forms the α-diazoketone 188 in 95% on treatment with a 
diazomethane solution in ether. Compound 188 is hydrolyzed by hydrochloric acid in 
dioxane to give compound 189 in quantitative yield. 
 
Figure 82: Preparation of the α-diazoketone 189 
Much to our consternation, subsequent attempts to couple α-chloromethyl ketone 189 
with the Hamilton fragment 187 under standard peptide coupling conditions led to 
exhaustive degradation and no isolable product was detected on TLC. We tried various 
peptide coupling reagents like carbodiimides, mixed anhydrides and 
phosphonium/uronium based salts, but no reaction condition tried gave product (Figure 
83). 
 
Figure 83: Attempted amide coupling of the α-chloromethyl ketone 
We reasoned that peptide coupling reactions were not progressing because that the 
compound 189 is not stable to base due of the presence of the electrophilic α-
chloromethyl ketone moiety. Also, we did not find any reports in literature where the 
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phenylalanine chloromethylketone 189 was coupled to any small molecule carboxylic acid 
substrates except in solid phase peptide coupling procedures where 6-10 equivalents of 
189 was used. Therefore, we decided to reduce the ketone to the halohydrin, making the 
primary alkyl chloride much less reactive, and then carrying out the oxidation of the 
secondary alcohol to the ketone in the end stage to reveal the electrophile. 
As described in Figure 84, we selectively hydrolyzed the α-diazoketone to α-chloromethyl 
ketone in presence of the N-Boc group by addition of 1.5 equiv of HCl in dioxane at -200C, 
giving compound 190 in quantitative yield. The secondary alcohol was reduced using 
sodium borohydride in methanol and the N-Boc group was deprotected using 
trifluoroacetic acid to give the halohydrin 192. 
 
Figure 84: Synthesis of compound 192 
In the next step, this compound was reacted with the Hamilton fragment 187 using the 
peptide coupling reagent PyBOP and Hunigs base in dichloromethane overnight (Figure 
85). Much to our surprise, the amide 193 was obtained as a diastereomeric mixture 
epimeric at the secondary alcohol in 90% yield. The secondary alcohol was oxidized to 
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the ketone using Dess-Martin periodane and the N-Boc protecting groups on the 
guanidine were removed under acidic conditions to give 195 in quantitative yield. 
 
Figure 85: Synthesis of the α-chloromethyl ketone 195 
Bolstered by our above mentioned success in coupling the α-chloromethyl ketone, we 
prepared the control compound 198 in a similar fashion (Figure 86). 4-methoxybenzoic 
acid 196 was coupled to the halohydrin 192 using the peptide coupling reagent PyBOP 
and Hunigs base to give the compound 197 in 91% yield. This secondary alcohol was 
oxidized to the ketone using Dess-Martin periodane in dichloromethane to give 198 in 
50% yield. 
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Figure 86: Synthesis of the control compound 198 
Next, we prepared the control analog 203, which is a hybrid between GSK3β and the 
Hamilton’s compound 121 as described in Figure 87. Compound 200 was prepared by a 
standard EDCI coupling between benzylamine 199 and Boc-Phe-OH 146 to give the 
product in 75% yield. The N-Boc group was removed under acidic conditions and was 
coupled to Hamilton’s fragment 187 using the peptide coupling reagent PyBOP and 
Hunig’s base to give the amide 202 in 80% yield, following which the N-Boc protecting 
groups on the guanidine were removed under acidic conditions to give 203 in quantitative 
yield. 
 
Figure 87: Synthesis of the control analog 203 
3.4.3: Biochemical evaluation of full-length compounds and controls 
We evaluated this second set of compounds by the Z-LYTE assay for AKT inhibition as 
described earlier and the results are shown in Table 10. 
Table 10: IC50 of second set of compounds 
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Compound AKT1 IC50 (µM) 
173 >100 
175 >100 
177 >100 
195 0.578 
198 >25 
203 >25 
 
3.5: Results and discussion 
Based on the second set of compounds that were prepared and evaluated, the most 
active compound turned out to be 195 with an IC50 of 0.578 µM. This compound is derived 
from the GSK3β peptide sequence (Phe10 from 3GRPRTTSFAE12) with the N-terminal 
portion of the Hamilton non-covalent analog 121 and the chloromethyl ketone electrophile 
appended to the C-terminal phenylalanine. The compound 198, which has the 
phenylalanine chloromethyl ketone electrophile coupled with a p-methoxybenzoic acid 
has an IC50 > 25 µM. This indicates that the phenylalanine chloromethyl ketone by itself 
is not a potent inhibitor of AKT and our results are in line with the activity reported for 
TPCK for inhibition of AKT184, 185. The non-covalent control analog 203 also has an IC50 
> 25 µM, indicating that the chloromethyl ketone electrophile is necessary for inhibition. 
The α-haloacetamides 173, 175, 177 were not active with IC50s > 100 µM. This indicates 
that the 3-position phenyl substituent in the N-terminal portion is important for guiding the 
compound into the substrate binding pocket of AKT or the sequence that we used to 
attach the electrophile was not optimal.  
 124 
 
Our design and selection within the first set of compounds involved utilizing only the C-
terminal portion of the Hamilton compound 121 and screening various electrophiles. This 
led to the selection of the most potent electrophile that had only minimal fragments of the 
Hamilton compound 121 to guide selectivity. The major downfall of this approach was, 
that by including minimal binding elements of the Hamilton compound, we focused our 
identification of compounds solely based on the reactivity of the electrophile, leading to a 
compound that was potent for AKT but not selective in a cellular context. Our design 
concept for the second set of compounds synthesized involved dialing down the reactivity 
of the electrophile so that it would not display non-selective binding and including either 
most of the binding elements of the Hamilton compound 121 or a hybrid between the 
GSK3β peptide and the Hamilton compound 121. For this purpose, we used the α-
haloacetamides and the α-chloromethyl ketone as electrophiles, which are much milder 
in comparison with the vinyl-ketone, and inclusion of the whole N-terminal binding 
fragment of Hamilton’s compound 121. This led to the identification of 195 as a potent 
sub-micromolar inhibitor of AKT. Further experiments have to be done to discern the 
selectivity of this compound for AKT, but we expect 195 to be selective towards AKT in a 
cellular context because of the relatively milder reactivity of the chloromethyl ketone 
electrophile in comparison to the vinyl-ketone and inclusion of additional binding elements 
from Hamilton compound 121 and GSK3β peptide. 
3.6: Future work 
1. Compound 195 was identified as a potent sub-micromolar inhibitor of AKT. Before 
we move on to optimizing the structure and analyzing reactivity and selectivity 
patterns, we plan to confirm the mechanism of action of the compound. The IC50 
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of the inactivated electrophile (204, Figure 88), where the methyl-ketone is used 
instead, will confirm a covalent mechanism of action. Mass spectrometry with 
labeled AKT will indicate the residue that is covalently modified by 195. We expect 
Cys310 to be labeled based on the labeling of Cys310 by TPCK. 
2. To test the selectivity of the compound among other kinases especially within the 
AGC kinase family, 195 must be tested in a kinase selectivity screen assay. The 
data from this kinase panel will determine whether 195 is selective as an AKT 
inhibitor. To evaluate the cellular selectivity of 195 among other kinases we 
propose to do a protein profiling experiment. Compound 205, which has an alkyne 
functional handle substituted on the 3/4-position of the phenyl will be prepared. 
Selection of this 3-position is based on the observation that a naphthyl group in 
compound 121 increases affinity. We will incubate this compound with cell lysates 
and subject the lysates to copper-promoted click conditions using a fluorescent 
azide tag. Visualizing these lysates on a SDS-page gel will determine other 
proteins labeled by compound 205. 
3. Finally, optimizing the potency and selectivity of the compound towards AKT can 
be done by further chemical manipulation. The reactivity of the electrophile can be 
further dialed down if needed by using a fluoromethyl ketone. The affinity of the 
compound can be increased by using further binding elements from Hamilton’s 
compound 121, i.e., substituting the phenylalanine to 4-cyanophenylalanine, 
phenyl for a naphthyl, and or changing the ethylamine linker to a glycine linker. 
These optimizations are shown as compound 206, and are expected to yield a 
compound that will be more potent/selective for AKT.   
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Figure 88: Future analogues of Compound 195 to be prepared. 
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CHAPTER 4: EXPERIMENTALS 
4.1 Experimental for Flavone-based analogues inspired by the natural product 
simocyclinone D8 as DNA gyrase inhibitors. 
4.1.1 Chemistry Experimentals 
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), Alfa-
Aesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography 
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash 
chromatography was performed on TELEDYNE ISCO CombiFlash® Rf instrument using 
RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm).  1H NMR and 
13C NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated 
chloroform (CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of 
parts per million (ppm) relative to chloroform and methanol residual peaks at 7.26 and 
3.31 respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra).  
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and 
integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin 
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer. 
General procedures 
A. Procedure for N-phthalylglycine acid chloride couplings with anilines and 
deprotection 
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a. To a suspension of N-phthaloylglycine 5 (1.0 equiv) in chloroform (0.2 M) was added 
thionyl chloride (1.5 equiv). The reaction mixture was refluxed for 4 hours, after which 
the solution was concentrated in vacuo. The mixture was then taken in THF (0.4 M) 
and cooled down to 0 °C in an ice bath. To this was added a solution of the suitably 
functionalized aniline 11a-j (1.2 equiv) and triethylamine (2.0 M) in THF (0.4 M). The 
reaction mixture was then refluxed overnight, following which it was diluted with ethyl 
acetate and washed subsequently with 1 N HCl and saturated NaHCO3. The ethyl 
acetate layer was concentrated in vacuo and the crude was used in the next step 
without purification.  
b. To a solution of the crude from the previous step in ethanol (0.2 M) was added 
hydrazine hydrate (2.0 equiv). The reaction mixture was refluxed for 2 hours and the 
resulting thick suspension was filtered over celite and washed with ethyl acetate. The 
filtrate was concentrated and was purified by column chromatography (silica gel, 
methanol/dichloromethane, 10% v/v) to give the desired amine 12a-j.   
 
B. Procedure for amide couplings 
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To a solution of the acid 10 (1.0 equiv) in DMF (0.4 M) was added EDCI (1.3 equiv), HOBt 
(1.1 equiv) and NMM (2.0 equiv). The reaction mixture was stirred for 30 minutes, followed 
by addition of the amine 12a-j (1.0 equiv) in DMF (0.4 M). The mixture was stirred 
overnight, after which it was diluted with ethyl acetate and washed with excess 1 N HCl 
solution. The ethyl acetate layer was dried over sodium sulfate and concentrated in vacuo 
and was purified by column chromatography (silica gel, methanol/dichloromethane, 5% 
v/v) to give the desired amide 13a-j.  
 
C. Procedure for removal of silyl protecting groups 
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To a solution of the amide 13b, h in THF (0.1 M) was added a 1 M solution of TBAF in 
THF (3.0 equiv). The reaction mixture was stirred at room temperature overnight and was 
diluted with ethyl acetate and washed with saturated ammonium chloride solution. The 
ethyl acetate layer was concentrated in vacuo and was purified by column 
chromatography (silica gel, methanol/dichloromethane, 10% v/v) to give the desired 
alcohol 14b and 14h.   
 
D. Procedure for the removal of benzyl protecting groups 
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To a solution of the amide 13a-j in ethanol:dioxane (3:1), was added 5% Pd/C (25% w/w). 
The reaction mixture was stirred overnight in an atmosphere of hydrogen (balloon 
pressure). The mixture was then filtered over celite and was purified by column 
chromatography (silica gel, methanol/dichloromethane, 10% v/v) to give the desired 
phenol 15a, 15d-g, 15j, 14b-c, 14h-i .   
 
 
2-Amino-N-phenylacetamide (12a): Compound 12a was prepared according to general 
procedure A and was obtained in 75% overall yield (0.113 g, 0.73 mmol). 1H NMR (400 
MHz, CD3OD) δ 7.56 (d, J=7.8, 2H) 7.63 (t, 2H), 7.42 (t, 1H), 3.42 (s, 2H). 
 132 
 
 
2-Amino-N-(4-((tert-butyldiphenylsilyloxy)methyl)phenyl)acetamide (12b): 
Compound 12b was prepared according to general procedure A and was obtained in 
67% yield (0.42 g, 1.0 mmol). 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J=8, 2H), 7.45-
7.36 (m, 10H), 7.27 (d, J=8, 2H), 4.72 (s, 2H), 3.46 (s, 2H), 1.07 (s, 9H). 
 
 
tert-butyl 2-(4-(2-aminoacetamido)phenyl)acetate (12c): Compound 12c was 
prepared according to general procedure A and was obtained in 72% yield (0.319 g, 1.2 
mmol). 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J=9, 1H), 7.38 (d, J=8, 1H), 7.19 (dd, J1=8, 
J2=9, 2H), 3.59 (s, 2H), 3.49 (s, 1H), 3.43 (s, 1H), 1.44 (d, J=7, 9H). 
 
2-amino-N-(p-tolyl)acetamide  (12d): Compound 12d was prepared according to 
general procedure A and was obtained in 64% yield (0.35 g, 2.13 mmol). 1H NMR (400 
MHz, CDCl3) δ 9.31 (br. s., 1H), 7.47 (d, J = 8.30 Hz, 2H), 7.12 (d, J = 8.30 Hz, 2H), 3.43 
(s, 2H), 2.31 (s, 3H). 
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2-amino-N-(4-ethylphenyl)acetamide (12e): Compound 12e was prepared according to 
general procedure A and was obtained in 76 % yield (0.27 g, 1.51 mmol). 1H NMR (400 
MHz, CDCl3) δ 6.66 (d, J = 8.53 Hz, 2H), 6.48 (d, J = 8.53 Hz, 2H), 3.06 (s, 2H), 2.08 (q, 
J = 7.61 Hz, 2H), 0.66 (t, J = 7.53 Hz, 3H). 
 
 
2-amino-N-(4-isopropylphenyl)acetamide (12f): Compound 12f was prepared 
according to general procedure A and was obtained in 69% yield (0.31 g, 1.61 mmol). 1H 
NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.30 Hz, 2H), 7.00 (d, J = 8.28 Hz, 2H), 3.58 (s, 
2H), 2.86 (td, J = 6.93, 13.99 Hz, 1H), 1.18 (d, J = 7.03 Hz, 6H). 
 
 
2-amino-N-(4-chlorophenyl)acetamide (12g): Compound 12g was prepared according 
to general procedure A and was obtained in 73% yield (0.137 g, 0.74 mmol). 1H NMR 
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(400 MHz, CDCl3) δ 9.42 (br. s., 1H), 7.53 (d, J = 8.78 Hz, 2H), 7.26 (d, J = 8.80 Hz, 2H), 
3.44 (s, 2H). 
 
2-Amino-N-(4-(tert-butyldiphenylsilyloxy)phenyl)acetamide (12h): Compound 12h 
was prepared according to general procedure A and was obtained in 61% yield (0.3 g, 
0.74mmol). 1H NMR (400 MHz, CDCl3) δ 7.43-7.34 (m, 10H), 6.87 (d, J=9, 2H), 6.78 (d, 
J=9, 2H), 3.6 (s, 2H), 1.1 (s, 9H). 
 
 
 
2-Amino-N-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)acetamide (12i): Compound 
12i was prepared according to general procedure A and was obtained in 80% yield (0.289 
g, 1.22 mmol). 1H NMR (400 MHz, CD3OD) δ 6.99 (dd, J1=2, J2=6, 1H), 6.89 (d, J=2, 
1H), 6.86 (d, J=8, 1H), 4.87 (s, 2H), 3.57 (s, 2H), 1.52 (s, 6H).  
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2-amino-N-(4-methoxyphenyl)acetamide (12j): Compound 12j was prepared 
according to general procedure A and was obtained in 79% yield (0.175 g, 0.97 mmol). 
1H NMR (400 MHz, CDCl3) δ 9.24 (br. s., 1H), 7.52 (d, J = 9.00 Hz, 2H), 6.88 (d, J = 9.00 
Hz, 2H), 3.80 (s, 3H), 3.47 (s, 2H), 1.89 (br. s., 2H). 
 
 
7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
oxo-7-(2-oxo-2-(phenylamino)ethylamino)heptanoate (13a): Compound 13a was 
prepared according to general procedure B and was obtained in 79% yield (0.45 g, 0.53 
mmol). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J1=2.3, J2=6, 1H), 7.81 (d, J=2, 1H), 7.64 
(d, J=8, 2H), 7.42-7.24 (m, 17H), 7.1 (t, J=7.78, 1H), 7.02 (d, J=9, 1H), 6.5 (d, J=2, 1H), 
6.44 (d, J=2, 1H), 5.14 (s, 2H), 5.13 (s, 2H), 5.04 (s, 2H), 4.08 (d, J=5, 2H), 2.55 (t, J=7, 
2H), 2.2 (t, J=7, 2H), 1.75-1.61 (m, 4H), 1.43-1.35 (m, 2H).   
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(4-((tert-butyldiphenylsilyloxy)methyl)phenylamino)-2-oxoethylamino)-7-
oxoheptanoate (13b): Compound 13b was prepared according to general procedure B 
and was obtained in 82% yield (0.582 g, 0.53 mmol). 1H NMR (400 MHz, CDCl3) δ 7.68 
(dd, J1=1, J2=7, 2H), 7.49 (d, J=8, 2H), 7.44-7.28 (m, 27H), 7.02 (d, J=9, 1H), 6.51 (d, 
J=2, 1H), 6.45 (d, J=2, 1H), 5.15 (s, 2H), 5.13 (s, 2H), 5.04 (s, 2H), 4.72 (s, 2H), 4.07 (d, 
J=6, 2H), 2.56 (t, J=7, 2H), 2.2 (t, J=8, 2H), 1.76-1.61 (m, 4H), 1.44-1.36 (m, 2H), 1.07 (s, 
9H). 
 
7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(4-(2-tert-butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate 
(13c): Compound 13c was prepared according to general procedure B and was obtained 
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in 77% yield (0.48 g, 0.5 mmol). 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J1=2.05, J2=6.65, 
1H), 7.8 (d, J=2, 1H), 7.48-7.2 (m, 19H), 7.02 (d, J=9, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2, 
1H), 5.15 (s, 2H), 5.13 (s, 2H), 5.06 (s, 2H), 4.07 (s, 2H), 3.47 (s, 2H), 2.54 (t, J=8, 2H), 
2.26 (t, J=8, 2H), 1.7-1.61 (m, 4H), 1.42 (s, 9H), 1.33-1.21 (m, 2H). 
 
7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
oxo-7-((2-oxo-2-(p-tolylamino)ethyl)amino)heptanoate (13d): Compound 13d was 
prepared according to general procedure B and was obtained in 53% yield (0.044 g, 
0.051 mmol). 
 
7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
((2-((4-ethylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13e): Compound 
13e was prepared according to general procedure B and was obtained in 83% yield 
(0.057 g, 0.058 mmol). 1H NMR (400 MHz, CDCl3) δ 8.48 (br. s., 1H), 7.77 - 7.90 (m, 1H), 
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7.23 - 7.51 (m, 17H), 7.14 (d, J = 8.28 Hz, 2H), 7.03 (d, J = 8.78 Hz, 1H), 6.51 (d, J = 2.30 
Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H), 5.15 (d, J = 10.79 Hz, 4H), 5.07 (s, 2H), 4.10 (br. s., 
2H), 2.47 - 2.68 (m, 4H), 2.28 (t, J = 7.50 Hz, 2H), 1.56 - 1.75 (m, 4H), 1.25 - 1.40 (m, 
2H), 1.21 (t, J = 7.53 Hz, 3H). 
 
7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
((2-((4-isopropylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13f): 
Compound 13f was prepared according to general procedure B and was obtained in 72% 
yield (0.05 g, 0.087 mmol). 1H NMR (400 MHz, CDCl3) δ 8.36 (br. s., 1H), 7.76 - 7.90 (m, 
1H), 7.25 - 7.49 (m, 17H), 7.15 - 7.24 (m, 2H), 6.98 - 7.11 (m, 1H), 6.48 - 6.54 (m, 1H), 
6.45 (d, J = 2.26 Hz, 1H), 5.15 (d, J = 10.54 Hz, 4H), 5.07 (s, 2H), 4.08 (br. s., 2H), 2.81 
- 2.95 (m, 1H), 2.55 (t, J = 7.53 Hz, 2H), 2.27 (t, J = 7.65 Hz, 2H), 1.58 - 1.79 (m, 4H), 
1.26 - 1.32 (m, 2H), 1.20 - 1.25 (m, 6H). 
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7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
((2-((4-chlorophenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13g): Compound 
13g was prepared according to general procedure B and was obtained in 46% yield 
(0.031 g, 0.035 mmol). 1H NMR (400 MHz, CDCl3) δ 12.61 (s, 1H), 8.69 (s, 1H), 7.76 - 
7.87 (m, 2H), 7.21 - 7.51 (m, 19H), 7.03 (d, J = 8.80 Hz, 1H), 6.52 (d, J = 2.20 Hz, 1H), 
6.46 (d, J = 2.20 Hz, 1H), 6.25 (t, J = 5.27 Hz, 1H), 5.06 - 5.20 (m, 4H), 5.03 (s, 2H), 4.06 
(d, J = 5.27 Hz, 2H), 2.58 (t, J = 7.20 Hz, 2H), 2.20 (t, J = 7.40 Hz, 2H), 1.52 - 1.80 (m, 
4H), 1.35 - 1.49 (m, 2H). 
 
 
7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(4-(tert-butyldiphenylsilyloxy)phenylamino)-2-oxoethylamino)-7-oxoheptanoate 
(13h): Compound 13h was prepared according to general procedure B and was obtained 
in 67% yield (0.61 g, 0.55 mmol). 1H NMR (400 MHz, CDCl3) δ 7.7-7.68 (m, 2H), 7.42-
7.21 (m, 29H), 6.7 (d, J=8, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.14 (s, 2H), 5.13 (s, 
2H), 5.03 (s, 2H), 3.98 (d, J=5, 2H), 2.54 (t, J=7, 2H), 2.17 (t, J=2, 2H), 1.73-1.58 (m, 4H), 
1.39-1.35 (m, 2H), 1.08 (s, 9H). 
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-ylamino)-2-oxoethylamino)-7-
oxoheptanoate (13i): Compound 13i was prepared according to general procedure B 
and was obtained in 81% yield (0.512 g, 0.55 mmol). 1H NMR (400 MHz, CDCl3) δ 7.85 
(dd, J1=2, J2=7, 1H), 7.8 (d, J=2, 1H), 7.42-7.3 (m, 17H), 7.12 (dd, J1=2, J2=6, 1H), 7.02 
(d, J=9, 1H), 6.75 (d, J=8, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.15 (s, 2H), 5.13 (s, 
2H), 5.05 (s, 2H), 4.79 (s, 2H), 4.04 (d, J=5, 2H), 2.54 (t, J=8, 2H), 2.25 (t, J=8, 2H), 1.72-
1.6 (m, 4H), 1.42-1.35 (m, 2H), 1.51 (s, 6H). 
 
7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-
((2-((4-methoxyphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13j): 
Compound 13j was prepared according to general procedure B and was obtained in 55% 
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yield (0.057 g, 0.065 mmol). 1H NMR (400 MHz, CDCl3) δ 12.64 (s, 1H), 8.74 (s, 1H), 
7.75 - 7.91 (m, 2H), 7.22 - 7.48 (m, 18H), 7.06 - 7.14 (m, 2H), 7.02 (d, J = 8.78 Hz, 1H), 
6.51 (d, J = 2.01 Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H), 5.03 - 5.17 (m, 6H), 4.10 (d, J = 5.02 
Hz, 2H), 2.55 (t, J = 7.40 Hz, 2H), 2.29 (s, 3H), 2.22 (t, J = 7.40 Hz, 2H), 1.59 - 1.78 (m, 
4H), 1.33 - 1.47 (m, 2H). 
 
7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate (14b): 
Compound 14b was prepared according to general procedure C and was obtained in 
67% yield (0.363 g, 0.41 mmol). 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J1=2, J2=7, 1H), 
7.73 (d, J=2, 1H), 7.43-7.18 (m, 19H), 6.96 (d, J=9, 1H), 6.44(d, J=2, 1H), 6.38 (d, J=2, 
1H), 5.09 (s, 2H), 5.07 (s, 2H), 4.99 (s, 2H), 4.56 (s, 2H), 4.01 (d, J=6, 2H), 2.47 (t, J=7, 
2H), 2.2 (t, J=8, 2H), 1.65-1.54 (m, 4H), 1.44-1.36 (m, 2H). 
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-
(4-hydroxyphenylamino)-2-oxoethylamino)-7-oxoheptanoate (14h): Compound 14h 
was prepared according to general procedure C and was obtained in 65% yield (0.317 g, 
0.367 mmol). 1H NMR (400 MHz, CD3OD) δ 7.88 (dd, J1=2, J2=7, 1H), 7.79 (d, J=2, 1H), 
7.53-7.2 (m, 20H), 6.71 (d, J=2, 1H), 6.43 (d, J=2, 1H), 3.98 (s, 2H), 2.56 (t, J=7, 2H), 
2.27 (t, J=7, 2H), 1.72-1.6 (m, 4H), 1.44-1.42 (m, 2H). 
 
 
 
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-oxo-7-(2-oxo-2-
(phenylamino)ethylamino)heptanoate (15a): Compound 15a was prepared according 
to general procedure D and was obtained in 43% yield (0.253 g, 0.44 mmol). 1H NMR 
(400 MHz, CD3OD) δ 7.99-7.96 (m, 1H), 7.89 (s, 1H), 7.52 (d, J=8, 2H), 7.28 (t, J=7, 2H), 
7.1 (t, J=7, 1H), 7.02 (d, J=9, 1H), 6.39 (s, 1H), 4.0 (s, 2H), 2.66 (t, J=7, 2H), 2.36 (t, J=7, 
2H), 1.82-1.71 (m, 4H) 1.57-1.51 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 177.3, 176.6, 
175.9, 169.7, 165.6, 162.5, 158.2, 148.7, 148.0, 146.2, 139.5, 137.2, 129.8, 125.3, 124.1, 
121.6, 121.2, 116.2, 116.0, 104.5, 99.2, 94.4, 70.6, 56.1, 44.0, 36.6, 34.6, 32.1, 30.6, 
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29.7, 29.5, 26.4, 25.6. HRMS (ESI) C30H28N2O10 m/z  [M-H]- found 575.1686, expected 
575.1665. 
 
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-
(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate (15b): 
Compound 15b was prepared according to general procedure D and was obtained in 
33% yield (0.241 g, 0.4 mmol). 1H NMR (400 MHz, CD3OD) δ 7.97 (dd, J1=2, J2=7, 1H), 
7.88 (d, J=2, 1H), 7.38 (d, J=8, 2H), 7.07 (d, J=8, 2H), 7.01 (d, J=9, 1H), 6.37 (m, 1H), 
6.17 (d, J=2, 1H), (3.98 (s, 2H), 2.64 (t, J=5, 2H), 2.35 (t, J=7, 2H), 1.81-1.71 (m, 4H), 
1.54-1.5 (m, 2H). 13C NMR (100MHz, DMSO-d6) δ 176.0, 172.5, 171.1, 164.0, 161.0, 
167.6, 156.1, 150.8, 138.3, 138.2, 136.3, 136.2, 126.4, 122.7, 119.1, 116.8, 115.5, 98.2, 
59.6, 54.8, 33.2, 33.1, 28.1, 28.0, 24.8, 24.2, 24.1, 20.3, 20.6. HRMS (ESI) C31H30N2O11 
m/z  [M-H]- found 605.1771, expected 605.1772. 
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2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-(2-tert-
butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate (14c): 
Compound 14c was prepared according to general procedure D and was obtained in 52% 
yield (0.248 g, 0.36 mmol). 1H NMR (400 MHz, CD3OD) δ 7.59 (d, J=9, 2H), 7.43 (d, J=2, 
1H), 7.38 (dd, J1=2, J2=6, 1H), 7.29 (d, J=8, 2H), 7.01 (d, J=8, 1H), 6.53 (d, J=2, 1H), 
6.339 (d, J=2, 1H), 4.09 (s, 2H), 3.58 (s, 2H), 2.76 (t, J=7, 2H), 2.4 (t, J=8, 2H), 1.86-1.76 
(m, 4H), 1.55-1.52 (m, 2H), 1.52 (s, 9H). 
 
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-oxo-7-((2-oxo-2-
(p-tolylamino)ethyl)amino)heptanoate (15d): Compound 15d was prepared according 
to general procedure D and was obtained in 31% yield (0.043 g, 0.073 mmol). 1H NMR 
(400 MHz, CD3OD) δ 7.98 (dd, J = 1.63, 8.66 Hz, 1H), 7.81 - 7.91 (m, 1H), 7.32 - 7.44 
(m, 2H), 6.95 - 7.15 (m, 3H), 6.39 (br. s., 1H), 6.12 - 6.22 (m, 1H), 3.99 (s, 2H), 2.66 (t, J 
= 7.30 Hz, 2H), 2.35 (t, J = 7.50 Hz, 2H), 2.27 (s, 3H), 1.67 - 1.85 (m, 4H), 1.47 - 1.60 (m, 
2H). 
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2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-
((4ethylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15e): Compound 15e 
was prepared according to general procedure D and was obtained in 41% yield (0.07 g, 
0.116 mmol). 1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 9.83 (s, 1H), 8.11 (t, J = 5.65 
Hz, 1H), 7.93 (dd, J = 2.26, 8.78 Hz, 1H), 7.85 (d, J = 2.26 Hz, 1H), 7.40 - 7.51 (m, 2H), 
7.00 - 7.14 (m, 3H), 6.39 - 6.46 (m, 1H), 6.13 - 6.22 (m, 1H), 3.84 (d, J = 5.77 Hz, 2H), 
2.50 - 2.63 (m, 4H), 2.18 (t, J = 7.40 Hz, 2H), 1.50 - 1.71 (m, 4H), 1.33 - 1.44 (m, 2H), 
1.13 (t, J = 7.53 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 175.8, 172.6, 171.2, 167.6, 
163.9, 160.5, 156.2, 150.8, 145.5, 138.6, 138.2, 136.5, 136.0, 127.9, 122.7, 122.1, 119.1, 
116.8, 103.1, 98.2, 93.6, 42.5, 35.0, 30.6, 28.0, 27.6, 24.9, 24.1, 15.6, 15.1. HRMS (ESI) 
C32H32N2O10 m/z  [M+H]+ found 605.2038, expected 605.2135. 
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2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4-
isopropylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15f): Compound 15f 
was prepared according to general procedure D and was obtained in 46 % yield (0.09 g, 
0.145 mmol). 1H NMR (400 MHz, CD3OD) δ 7.96 (dd, J = 2.26, 8.53 Hz, 1H), 7.80 - 7.89 
(m, 1H), 7.38 - 7.45 (m, 2H), 7.07 - 7.17 (m, 2H), 7.01 (d, J = 8.78 Hz, 1H), 6.37 (d, J = 
2.01 Hz, 1H), 6.12 - 6.21 (m, 1H), 3.99 (s, 2H), 2.78 - 2.89 (m, 1H), 2.65 (t, J = 7.30 Hz, 
2H), 2.35 (t, J = 7.53 Hz, 2H), 1.68 - 1.85 (m, 4H), 1.46 - 1.58 (m, 2H), 1.14 - 1.24 (m, 
6H). 13C NMR (101 MHz, DMSO-d6) δ 175.9, 172.5, 172.5, 172.5, 171.2, 171.0, 167.6, 
164.0, 160.7, 160.7, 156.1, 150.8, 145.5, 145.2, 143.2, 138.2, 136.6, 136.0, 129.2, 126.3, 
122.6, 122.0, 121.9, 119.2, 116.8, 103.0, 98.2, 93.5, 42.5, 34.9, 33.1, 33.1, 32.8, 28.0, 
24.8, 24.1, 23.8. HRMS (ESI) C33H34N2O10 m/z  [M+H]+ found 619.2260, expected 
619.2291. 
 
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4-
chlorophenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15g): Compound 15g 
was prepared according to general procedure D and was obtained in 15% yield (0.02 g, 
0.033 mmol). 1H NMR (400 MHz, CD3OD) δ 7.93 – 8.01 (m, 1H), 7.77 – 7.93 (m, 1H), 
7.44 – 7.58 (m, 2H), 7.18 – 7.33 (m, 2H), 6.96 – 7.15 (m, 2H), 6.32 – 6.43 (m, 1H), 6.11 
– 6.22 (m, 1H), 4.00 (d, J = 5.77 Hz, 2H), 2.66 (t, J = 7.30 Hz, 2H), 2.35 (t, J = 7.30 Hz, 
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2H), 1.64 – 1.87 (m, 4H), 1.54 (dt, J = 3.26, 7.53 Hz, 2H). 13C NMR (101 MHz, CD3OD) 
δ 177.5, 176.8, 176.8, 165.7, 162.6, 158.4, 148.9, 148.2, 146.4, 138.6, 137.4, 134.1, 
130.0, 129.9, 129.9, 125.4, 124.3, 122.7, 121.9, 121.4, 116.4, 116.2, 104.7, 99.4, 94.6, 
44.2, 36.7, 36.7, 34.8, 29.8, 29.8, 26.5, 25.8. 
 
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-
hydroxyphenylamino)-2-oxoethylamino)-7-oxoheptanoate (15h): Compound 15h 
was prepared according to general procedure D and was obtained in 34% yield (0.258 g, 
0.43 mmol). 1H NMR (400 MHz, CD3OD) δ 7.99 (dd, J1=2, J2=7, 1H), 7.89 (d, J=2, 1H), 
7.3 (d, J=9, 2H), 7.03 (d, J=9, 1H), 6.72 (d, J=9, 2H), 6.41 (d, J=2, 1H), 6.18 (d, J=2, 1H), 
3.97 (s, 2H), 2.67 (t, J=7, 2H), 2.35 (t, J=7, 2H), 1.82-1.72 (m, 4H), 1.55-1.51 (m, 2H). 13C 
NMR (100MHz, CD3OD) δ 177.1, 172.0, 165.1, 163.0, 158.7, 158.3, 153.2, 150.3, 148.1, 
146.6, 130.5, 125.3, 124.7, 123.3, 122.3, 121.4, 118.6, 116.2, 104.1, 100.5, 98.3, 96.0, 
94.1, 44.2, 36.7, 34.6, 26.3, 25.7, 25.5. HRMS (ESI) C30H28N2O11 m/z  [M-H]- found 
591.1591, expected 591.1615. 
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2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(2,2-dimethyl-
4H-benzo[d][1,3]dioxin-6-ylamino)-2-oxoethylamino)-7-oxoheptanoate (14i): 
Compound 14i was prepared according to general procedure D and was obtained in 57% 
yield (0.193 g, 0.29 mmol). 1H NMR (400 MHz, CD3OD) δ 7.32 (d, J=2, 1H), 7.28 (dd, 
J1=2, J2=6, 2H), 7.2 (dd, J1=2, J2=6, 1H), 6.91 (d, J=8, 1H), 6.7 (d, J=9, 1H), 6.42 (d, 
J=2, 1H), 6.23 (d, J=2, 1H), 4.91 (s, 2H), 3.97 (s, 2H), 2.66 (t, J=7, 2H), 2.3 (t, J=8, 2H), 
1.76-1.66 (m, 4H), 1.48 (s, 6H), 1.46-1.4 (m, 2H). 
 
2-(4-(2-(7-(2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yloxy)-7-
oxoheptanamido)acetamido)phenyl)acetic acid (15c): Compound 14c (0.1 g, 0.145 
mmol, 1.0 equiv) was dissolved in a mixture of triethylsilane (0.06 mL, 0.36 mmol, 2.5 
equiv) and DCM (1.45 mL, 0.1 M). To this mixture was added TFA (0.145 mL, 1.9 mmol, 
13.0 equiv) and was stirred overnight at room temperature. The reaction mixture was 
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concentrated and dried in vacuo to obtain pure 15c (0.085 g, 0.13 mmol, 92%). 1H NMR 
(400 MHz, CD3OD) δ 7.5 (d, J=8, 2H), 7.33 (d, J=2, 1H), 7.28 (dd, J1=2, J2=6, 1H), 7.22 
(d, J=8, 2H), 6.9 (d, J=8, 1H), 6.43 (d, J1=2, 1H), 6.24 (d, J=2, 1H), 3.99 (s, 2H), 3.56 (s, 
2H), 2.66 (t, J=7, 2H), 2.3 (t, J=7, 2H), 1.76-1.66 (m, 4H), 1.44-1.39 (m, 2H). 13C NMR 
(100MHz, CD3OD) δ 177.2, 176.7, 175.5, 172.5, 169.7, 166.2, 163.1, 158.7, 158.5, 150.3, 
146.6, 138.3, 132.0, 131.5, 122.2, 122.1, 116.6, 116.3, 105.4, 100.2, 95.1, 44.1, 41.3, 
36.6, 34.5, 29.5, 26.3, 25.5.  HRMS (ESI) C32H30N2O12 m/z  [M+H]+ found 635.1866, 
expected 635.1877. 
 
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-hydroxy-3-
(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate (15i): Compound 
14i (0.074 g, 0.111 mmol, 1.0 equiv) was dissolved in a mixture of 1 N HCl:THF (1:1, 0.6 
mL, 0.2 M). The mixture was stirred for 90 minutes and was concentrated in vacuo to 
obtain compound 15i (0.025 g, 0.04 mmol, 36% yield. 1H NMR (400 MHz, CD3OD) δ 7.39-
7.37 (m, 1H), 7.33 (d, J=2, 1H), 7.28 (dd, J1=2, J2=6, 2H), 6.91 (d, J=8, 1H), 6.71 (d, J=9, 
1H), 6.44 (d, J=2, 1H), 6.24 (d, J=2, 1H), 4.61 (s, 2H), 3.97 (s, 2H), 2.66 (t, J=7, 2H), 2.3 
(t, J=8, 2H), 1.76-1.64 (m, 4H), 1.15-1.41 (m, 2H). 13C NMR (100MHz, CD3OD) δ 177.2, 
172.6, 166.2, 163.1, 158.7, 158.5, 153.6, 150.3, 148.7, 146.6, 131.5, 125.7, 124.1, 123.3, 
122.2, 121.7, 116.6, 116.3, 116.1, 105.4, 100.2, 99.3, 95.1, 94.4, 70.9, 58.4, 44.0, 36.6, 
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34.6, 26.3, 25.7, 25.5.  HRMS (ESI) C31H30N2O12 m/z  [M-H]- found 621.1721, expected 
621.1720. 
 
 
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4-
methoxyphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15j): Compound 15j 
was prepared according to general procedure D and was obtained in 27% yield (0.034 g, 
0.056 mmol). 1H NMR (400 MHz, CD3OD) δ 7.98 (dd, J = 2.13, 8.66 Hz, 1H), 7.85 – 7.92 
(m, 2H), 7.74 (td, J = 1.00, 8.28 Hz, 1H), 7.46 – 7.58 (m, 2H), 7.37 – 7.44 (m, 2H), 7.02 
(d, J = 8.53 Hz, 1H), 6.81 – 6.86 (m, 2H), 6.37 – 6.41 (m, 1H), 6.16 – 6.21 (m, 1H), 3.98 
(s, 2H), 3.75 (s, 3H), 2.59 – 2.71 (m, 2H), 2.35 (t, J = 7.40 Hz, 2H), 1.67 – 1.87 (m, 4H), 
1.46 – 1.59 (m, 2H).  
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7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3,5-dihydroxy-4H-chromen-4-one (6): 
Quercetin (0.977 g, 3.23 mmol, 1.0 equiv) was dissolved in DMF (26 mL, 0.125M) and 
was cooled to 0 °C. To this mixture was added potassium carbonate (1.43 g, 10.34 mmol, 
3.2 equiv) and benzyl bromide (1.23 mL, 3.13 mmol, 3.5 equiv). The reaction mixture was 
allowed to slowly warm to room temperature and stirred overnight. The reaction was 
diluted with ethyl acetate and washed with copious amounts of 1N HCl. The ethyl acetate 
layer was dried over sodium sulfate and concentrated in vacuo.  The crude was purified 
by column chromatography (silica gel, acetone/hexane, 20% v/v) to give the desired 
compound 2 (0.925 g, 1.62 mmol, 50%). 1H NMR (400 MHz, DMSO-d6) δ 7.9 (d, J=2, 
1H), 7.84 (dd, J1=2, J2=2, 1H), 7.51-7.32 (m, 15H), 7.25 (d, J=9, 1H), 6.85 (d, J=2, 1H), 
6.44 (d, J=2, 1H), 5.24 (s, 4H), 5.2 (s, 2H). 
 
1-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl) 
7-tert-butyl heptanedioate (9): 7-tert-butoxy-7-oxoheptanoic acid (0.036 g, 0.168 mmol, 
1.2 equiv) was dissolved in THF (2.8 mL, 0.05M), after which was added EDCI (0.032 g, 
0.168 mmol, 1.2 equiv), Hunig’s base (0.03 mL, 0.168 mmol, 1.2 equiv) and DMAP 
(0.0017 g, 0.014 mmol, 0.1 equiv). To this solution was added compound 6 (0.08 g, 0.14 
mmol, 1.0 equiv) and the mixture was stirred overnight. The reaction mixture was washed 
with 1 N HCl and extracted into ethyl acetate. The ethyl acetate layer was dried over 
sodium sulfate and was purified by column chromatography (silica gel, ethyl 
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acetate/hexane, 25% v/v) to give the desired compound 9 (0.106 g, 0.13 mmol, 98%). 1H 
NMR (400 MHz, CDCl3) δ 7.54-7.29 (m, 17H), 6.36 (d, J=2, 1H), 6.48 (d, J=2, 1H), 5.6 
(dd, J1=2, J2=4, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 5.11 (s, 2H), 2.54 (t, J=8, 2H), 2.34 (t, 
J=8, 2H), 1.76-1.71 (m, 4H), 1.43 (s, 9H), 1.41-1.32 (m, 2H). 
 
 
7-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-
yloxy)-7-oxoheptanoic acid (10): To the solution of compound 9 (1.23 g, 1.6 mmol, 1.0 
equiv) in DCM (16.0 mL, 0.1M) was added triethylsilane (0.64mL, 4.0 mmol, 2.5 equiv) 
and trifluoroacetic acid (1.6 mL, 20.8 mmol, 13.0 equiv). The reaction mixture was stirred 
overnight, concentrated in vacuo and purified by column chromatography (silica gel, 
dichloromethane/methanol, 5% v/v) to give the desired compound 10 (0.876 g, 1.22 
mmol, 76%). 1H NMR (400 MHz, CDCl3) δ 7.47-7.33 (m, 17H), 7.01 (d, J=9, 1H), 6.49 (d, 
J=2, 1H), 6.45 (d, J=2, 1H), 5.24 (s, 2H), 5.2 (s, 2H), 5.13 (s, 2H), 2.54 (t, J=7, 2H), 2.36 
(t, J=7, 2H), 1.77-1.62 (m, 4H), 1.46-1.38 (m, 2H).  
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1-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-
yl)10-methyl decanedioate (14k): 10-methoxy-10-oxodecanoic acid (87 mg, 0.4 mmol, 
1.2 equiv) was dissolved in THF (8.0 mL 0.05M), after which was added EDCI (77 mg, 
0.4 mmol, 1.2 equiv),  Hunig’s base (0.07 mL, 0.4 mmol, 1.2 equiv) and DMAP (5 mg, 
0.04 mmol, 0.1 equiv). To this solution was added compound 6 (0.193 g, 0.34 mmol, 1.0 
equiv) and the mixture was stirred overnight. The reaction mixture was washed with 1N 
HCl and extracted into ethyl acetate. The ethyl acetate layer was dried over sodium 
sulfate and was purified by column chromatography (silica gel, ethyl acetate/hexane, 25% 
v/v) to give the desired compound 14k (0.152 g, 0.2 mmol, 58%). 1H NMR (400MHz, 
CDCl3) δ 7.5-7.32 (m, 17H), 6.48 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.59 (dd, J1=2, J2=4, 
1H), 5.24 (s, 2H), 5.19 (s, 2H), 5.13 (s, 2H), 3.66 (s, 3H), 2.53 (t, J=8, 2H), 2.34 (t, J=8, 
2H), 2.1-1.79 (m, 4H), 1.74-1.3 (m, 8H). 
 
1-(2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl) 10-methyl 
decanedioate (15k): Compound 15k was prepared from compound 14k according to 
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general procedure D and was obtained in 27% yield (0.041 g, 0.08 mmol). 1H NMR (400 
MHz, DMSO-d6) δ 7.3 (d, J=2, 1H), 7.25 (dd, J1=2, J2=6, 1H), 6.9 (d, J=9, 1H), 6.46 (d, 
J=2, 1H), 6.24 (d, J=2,1H), 3.56 (s, 3H), 2.62 (t, J=7, 2H), 2.28 (t, J=7, 2H), 1.64-1.58 (m, 
2H), 1.53-1.48 (m, 2H), 1.3-1.24 (m, 10H). 13C NMR (100 MHz, CD3OD) δ 177.2, 176.2, 
172.6, 166.2, 163.1, 158.7, 158.5, 150.3, 146.6, 131.5, 122.2, 122.1, 116.5, 116.3, 105.3, 
100.2, 95.1, 51.9, 34.8, 34.6, 30.1, 29.9, 25.9, 25.8. HRMS (ESI) C26H28O10 m/z  [M-H]-
found 499.1593, expected 499.1604. 
4.1.2: Biology Experimentals  
Negatively supercoiled pBR322 DNA was purchased from New England Biolabs, 
(Beverly, MA).  Relaxed plasmid DNA was prepared by incubating pBR322 with calf 
thymus Topo I (Life Technologies, Carlsbad, CA).  Human Topo II and kinetoplast (kDNA) 
were purchased from Topogen (Fort Orange, FL). 
E. coli Gyr A and Gyr B were overexpressed using the pET expression system186 and 
purified by unpublished protocols similar to those described previously187, 188.  Briefly, a 
soluble fraction containing GyrA was precipitated with ammonium sulfate (60% 
saturation), followed by chromatography on Q Sepharose FF, diethylaminoethyl cellulose 
DE52, and Sephacryl S-200.  A soluble fraction containing GyrB was also precipitated 
with ammonium sulfate (60% saturation), followed by chromatography on 
diethylaminoethyl cellulose DE52, Q Sepharose FF, and Sephacryl S-200.  The final 
preparations of GyrA and GyrB proteins were greater than 97% homogeneous for a single 
band on an SDS-polyacrylamide gel (data not shown).  Purified GyrA and GyrB were 
mixed at a molar ratio of 1:1 to reconstitute active gyrase.  All column resins were 
purchased from GE Healthcare (Chalfont St. Giles, UK).  
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Supercoiling assay 
The effect of the compounds on the supercoiling activity of E. coli gyrase was assessed 
as previously described189.  Reaction mixtures (20 µL) contained 50 mM Tris-HCl (pH 8.0 
at 23°C), 10 mM MgCl2, 100 mM potassium glutamate, 10 mM DTT, 50 µg/mL BSA, 1 
mM ATP, 0.3 g of relaxed plasmid pBR322, 5 µg/mL tRNA, 10 fmoles of E. coli gyrase, 
and various concentrations of the compounds (diluted in 50% DMSO from a 20 mM stock 
solution in 100% DMSO).  After incubating reaction mixtures at 37 °C for 15 minutes, 
reactions were terminated by addition of EDTA to 25 mM and further incubation at 37°C 
for 5 min. DNA products were analyzed by electrophoresis through vertical 1.2% agarose 
gels at 2 V/cm for 15 hours in TAE buffer.  Gels were stained with ethidium bromide prior 
to being photographed and quantified using an Eagle Eye system.  All reactions were 
performed at least in duplicate. 
 
Decatenation assays 
The effect of the compounds on the catalytic activity of the  form of human Topo II was 
assessed by a decatenation assay using kinetoplast DNA (kDNA) as the substrate as 
previously described27. Reaction mixtures (20 µL) contained 50 mM Tris-HCl (pH 8.0 at 
23°C), 10 mM MgCl2, 200 mM potassium glutamate, 10 mM DTT, 50 µg/mL BSA, 1 mM 
ATP, 0.3 g of kDNA, 5 µg/mL tRNA, 2 units of Topo II, and various concentrations of the 
compounds (diluted as described for the supercoiling assay). After incubating reaction 
mixtures at 37 °C for 15 min, reactions were terminated by addition of EDTA to 25 mM 
and further incubation at 37°C for 5 min.  Reaction products were analyzed by agarose 
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gel electrophoresis as described for the supercoiling assay.  All reactions were performed 
at least in duplicate. 
 
DNA cleavage assays  
DNA cleavage assays were performed as previously described190 to determine the ability 
of the analogues to act as a topoisomerase poison. DNA cleavage reaction mixtures (20 
µl) were as described for the supercoiling assay or decatenation assay, except that 
potassium glutamate was omitted, relaxed plasmid pBR322 was used as the substrate, 
and either 100 fmol of E. coli gyrase or 5 units of human Topo II was used.  Reaction 
mixtures were incubated for 10 minutes at 37°C, and then SDS was added to 1%, and 
reactions were continued at 37 °C for 10 min.  After addition of EDTA and proteinase K 
to a final concentration of 40 mM and 100 µg/mL, respectively, the reaction mixtures were 
further incubated at 37 C for 15 minutes (for E. coli gyrase) or 50 °C for one hour (human 
Topo II). The DNA products were purified by extraction with phenol/chloroform/isoamyl 
alcohol (25:24:1, v/v/v) and analyzed by electrophoresis through vertical 1.2% agarose 
gels at 2 V/cm for 12 hours in TAE buffer.  Ethidium bromide was present in both the 
agarose gels and the TAE buffer at a concentration of 0.5 µg/mL.  Gels were destained 
in water and then photographed and quantified using an Eagle Eye system.  All reactions 
were performed at least in duplicate. 
 
 
DNA unwinding assay 
A DNA unwinding assay37 was performed as previously described189 to determine the 
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ability of the compounds to intercalate into DNA.  Reaction mixtures (20 µl) contained 50 
mM Tris-HCl (pH 7.5 at 23°C), 1 mM MgCl2, 0.5 mM DTT, 50 μg/mL BSA, 0.3 g of 
relaxed pBR322, 0.8 units of calf thymus Topo I and the indicated concentrations of the 
compounds (diluted as described for the supercoiling assay).  Ethidium bromide was used 
as a positive control. Reaction mixtures were incubated at 37°C for 15 minutes.  DNA 
products were purified by extraction with phenol/chloroform/isoamyl alcohol (25:24:1, 
v/v/v) and analyzed by electrophoresis through vertical 1.2% agarose gels at 2 V/cm for 
15 hours in TAE buffer.  Gels were stained with ethidium bromide prior to being 
photographed and quantified using a Stratagene Eagle Eye gel documentation system 
(Agilent Technologies, Santa Clara, CA). All reactions were performed at least in 
duplicate.  Quercetin was purchased from Sigma-Aldrich (St. Louis, MO). 
 
SPR Experimental Procedure 
Linear, 5’ biotinylated DNA was dissolved in SPR buffer (10 mM HEPES pH 7.3, 3 mM 
EDTA, 0.005% surfactant P20) to give a concentration of 600 nM. The DNA was 
immobilized on the surface of flow cell two of a streptavidin-coated sensor chip by flowing 
50 μL of the solution through at a rate of 10 μL per minute. Flow cells one and two were 
then capped with 100 μL of a 1 mg/mL solution of biotin in SPR buffer. The BioCore T200 
instrument was then primed with SPR buffer containing 1% (v/v) DMSO, and the flow rate 
was increased to 50 μL/min. To test the compound’s ability to inhibit the DNA-DNA gyrase 
binding interaction, a premixed solution of DNA gyrase (100 nM) with or without 
compound (100 μM) was injected over flow cells one and two for 7 minutes. After allowing 
four minutes for dissociation, the surface of the flow cell was regenerated using 1 M NaCl 
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in 50 mM NaOH for 30 seconds (Figure 89). 
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Figure 89: SPR Sensograms 
 
4.2: Experimental for Studies toward Total Synthesis of SD8 
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), Alfa-
Aesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography 
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash 
chromatography was performed on a TELEDYNE ISCO CombiFlash® Rf instrument 
using RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm).  1H 
NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated chloroform 
(CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of parts per 
million (ppm) relative to chloroform and methanol residual peaks at 7.26 and 3.31 
respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra).  The 
data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and 
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integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin 
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer. 
 
 
(2E,4E)-hexa-2,4-dienedial 
A mixture of glyoxal trimer dihydrate (1.4 g, 6.7 mmol, 1.0 equiv) and 
(triphenylphospharanylidene) acetaldehyde (12.16 g, 40.0 mmol, 6.0 equiv) was heated 
to 80°C in DMF (80 mL, 0.08 M) for 12 hours. The reaction mixture was extracted into 
ethyl acetate and washed with water and the ethyl acetate was purified over silica gel to 
obtain the compound 46 (1.29 g, 11.7 mmol, 64%). 1H NMR (400 MHz, CDCl3) δ 9.73 
(dd, J = 0.75, 7.78 Hz, 2H), 7.23 - 7.37 (m, 2H), 6.43 - 6.63 (m, 2H). 
 
tert-butyl (2E,4E,6E)-8-oxoocta-2,4,6-trienoate 
To a solution of mucodialdehyde (0.062 g, 0.56 mmol, 1.2 equiv) in THF, cooled to 0°C 
was added a mixture of tert-Butyl diethylphosphonoacetate (0.118 g, 0.47 mmol, 1.0 
equiv) and barium hydroxide (0.121 g, 0.705 mmol, 1.5 equiv) in THF:H2O (5.6 mL, 0.1 
M, 40:1) over 30 minutes, after which the reaction was warmed up to room temperature 
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and stirred for 90 minutes. The reaction mixture was purified over silica gel to obtain the 
compound 48 (0.041 g, 0.197 mmol, 42%). 
 
(2E,4E,6E,8E)-10-(tert-butoxy)-10-oxodeca-2,4,6,8-tetraenoic acid 
To a solution of diethylphosphonoacetic acid (0.06 mL, 0.365 mmol, 1.1 equiv) in THF 
(0.8 mL, 0.4 M) cooled to -60°C was added n-BuLi (2.5 M soln in hexanes, 0.316 mL, 0.8 
mmol, 2.4 equiv) and the mixture was stirred for 30 minutes. To this solution was added 
the aldehyde (0.069 g, 0.331 mmol, 1.0 equiv) dropwise and the solution was stirred for 
30 minutes at -60°C and warmed to room temperature and stirred for 3 hours. The 
reaction was quenched by addition of 1 N HCl and the compound was purified over silica 
gel (0.075 g, 0.33 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J = 11.17, 15.18 
Hz, 1H), 7.13 - 7.24 (m, 1H), 6.41 - 6.71 (m, 4H), 5.94 (dd, J = 15.06, 18.57 Hz, 2H), 1.51 
(s, 9H). 
 
(2E,4E,6E,8E)-deca-2,4,6,8-tetraenedioic acid 
Fumagillin B (dicyclohexyammonium salt) from MEDIVET (0.021 g / 1.0 g, 5g, 0.229 
mmol) was taken up into saturated sodium bicarbonate solution and was extracted into 
DCM. The DCM layer was concentrated and was stirred with 1 N NaOH solution (excess) 
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overnight, followed by addition of 6 N HCl to precipitate out the tetraene diacid which was 
collected by flitration (0.04 g, 0.2 mmol, 90%). 1H NMR (400 MHz, DMSO-d6) δ 7.15 - 
7.32 (m, 2H), 6.73 - 6.85 (m, 2H), 6.53 - 6.70 (m, 2H), 5.99 (d, J = 15.31 Hz, 2H). 
 
1-(tert-butyl) 10-((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-
en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl) (2E,4E,6E,8E)-deca-2,4,6,8-
tetraenedioate 
Fumagillin (0.14 g, 0.3 mmol, 1.0 equiv), obtained from extraction of fumagillin B 
(MEDIVET) with sodium bicarbonate was dissolved in DMF (3.0 mL, 0.1 M). To this 
solution was added cesium carbonate (2.58 g, 7.93 mmol, 26.0 equiv), 
benzyltriethylammonium chloride (0.069 g, 0.305 g, 1.0 equiv) and tert-butyl bromide 
(1.64 mL, 14.65 mmol, 48 equiv). The solution was heated at 60°C overnight and was 
diluted with DCM and washed with saturated ammonium chloride solution. The DCM layer 
was purified over silica gel to obtain the compound 52 (0.091 g, 0.177 mmol, 60%). 1H 
NMR (400 MHz, CDCl3) δ 7.04 - 7.29 (m, 2H), 6.47 - 6.61 (m, 2H), 6.29 - 6.47 (m, 2H), 
5.93 (d, J = 15.31 Hz, 1H), 5.83 (d, J = 15.31 Hz, 1H), 5.59 - 5.69 (m, 1H), 5.16 (t, J = 
7.40 Hz, 1H), 3.62 (dd, J = 2.76, 11.04 Hz, 1H), 3.34 - 3.41 (m, 3H), 3.19 - 3.30 (m, 1H), 
2.88 - 2.97 (m, 2H), 2.76 - 2.83 (m, 1H), 2.46 - 2.58 (m, 2H), 2.24 - 2.37 (m, 1H), 1.89 - 
2.19 (m, 6H), 1.72 - 1.87 (m, 2H), 1.64 - 1.72 (m, 4H), 1.60 (s, 4H), 1.43 (s, 9H), 1.16 (s, 
3H). 
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(2E,4E,6E,8E)-10-(tert-butoxy)-10-oxodeca-2,4,6,8-tetraenoic acid 
The above obtained fumagillin tert-butyl ester (0.091 g, 0.176 mmol, 1.0 equiv) was 
dissolved in THF:EtOH (3:1, 1.76 mL, 0.1 M) and was added a solution of sodium 
hydroxide (1N, 1.76 mmol, 10.0 equiv) and stirred for 3 hours. The solution was stirred 
for 3 hours, followed by quenching with 1 N HCl and was purified over silica gel to obtain 
the compound 50 (0.042 g, 0.17 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J 
= 11.17, 15.18 Hz, 1H), 7.13 - 7.24 (m, 1H), 6.41 - 6.71 (m, 4H), 5.94 (dd, J = 15.06, 
18.57 Hz, 2H), 1.51 (s, 9H). 
 
 
  
(R)-1-(furan-2-yl)ethan-1-ol 
To a solution of the furan ketone 53 (0.11 mg, 1.0 mmol) in H2O (0.5 mL), formic 
acid/triethylamine (1:1, 0.5 mL) and Noyori asymmetric transfer hydrogenation catalyst 
(R)-Ru(η6-mesitylene)-(R, R)-TsDPEN A (0.0095 g, 0.5 mol%). The resulting solution was 
stirred at 40 °C for 8 hours. The reaction mixture was diluted with water and extracted 
with diethyl ether. The combined organic layers were washed with saturated NaHCO3, 
dried over Na2SO4, and concentrated under reduced pressure. The crude product was 
 164 
 
purified by silica gel to give furan alcohol 54 (0.089 g, 0.79 mmol, 79%). 1H NMR (400 
MHz, CDCl3) δ 7.34 (dd, J = 0.88, 1.88 Hz, 1H), 6.30 (dd, J = 1.76, 3.26 Hz, 1H), 6.20 (td, 
J = 0.75, 3.26 Hz, 1H), 4.85 (q, J = 6.69 Hz, 1H), 1.51 (d, J = 6.53 Hz, 3H). 
 
(2R)-6-hydroxy-2-methyl-2H-pyran-3(6H)-one 
Compound furan alcohol 54 (0.5 g, 4.46 mmol), 9.9 mL of THF, and 5.0 mL of H2O were 
added to a round bottom flask and cooled to 0oC.  Solid NaHCO3 (0.75 g, 8.9 mmol, 2.0 
equiv), NaOAc•3H2O (0.61 g, 4.46 mmol, 1.0 equiv), and NBS (0.53 g, 4.46 mmol, 1.0 
equiv) were added to the solution and the mixture was stirred for 1 hour at 0 oC.  The 
reaction was quenched with saturated NaHCO3, extracted with Et2O, dried (Na2SO4), 
concentrated under reduced pressure and purified by silica gel chromatography to give 
pyranone 55 (0.26 g, 2.01 mmol, 45%). 1H NMR (400 MHz, CDCl3) δ 6.73 (dd, J = 3.51, 
10.04 Hz, 1H), 5.99 (d, J = 10.29 Hz, 1H), 5.18 (d, J = 3.51 Hz, 1H), 4.74 (d, J = 11.80 
Hz, 1H), 4.59 (d, J = 11.80 Hz, 1H), 4.46 (q, J = 6.78 Hz, 1H), 1.27 (d, J = 6.78 Hz, 3H). 
 
tert-butyl ((2S,6R)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl) carbonate 
To a benzene solution (21 mL) of pyranone 55 (1.281 g, 10.0 mmol, 1.0 equiv) and 
(Boc)2O (3.5 g, 16.0 mmol) was added sodium acetate (0.985 g, 12.0 mmol). After stirring 
at 80 ºC for 2 hours, the mixture was cooled down to room temperature and was quenched 
by addition of saturated NaHCO3 solution, extracted with Et2O, dried (Na2SO4), and 
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concentrated under reduced pressure. The crude product was purified by silica gel flash 
chromatography to give two diastereomers of tert-butyl 5,6-dihydro-6-methyl-5-oxo-2H-
pyran-2-yl carbonate; β (0.55 g, 2.4 mmol, 24%). 1H NMR (400 MHz, CDCl3) δ 6.81 - 6.95 
(m, 1H), 6.36 (dd, J = 1.38, 2.64 Hz, 1H), 6.20 (dd, J = 1.25, 10.29 Hz, 1H), 4.37 (q, J = 
7.03 Hz, 1H), 1.51 (s, 12H). 
 
(2R,6R)-6-(benzyloxy)-2-methyl-2H-pyran-3(6H)-one 
A DCM (2.3 mL) solution of Boc pyranone 56β (0.52 g, 2.28 mmol, 1.0 equiv) and benzyl 
alcohol 0.48 mL, 4.56 mmol, 2.0 equiv) was cooled to 0° C. A DCM (1.4 mL) solution of 
Pd2(DBA)3•CHCl3 (0.055 g, 0.06 mmol, 2.5 mol%) and PPh3 (0.06 g, 0.23 mmol, 10 mol%) 
was added to the reaction mixture at 0°C. The reaction mixture was stirred at 0 °C for 2 
hours and was quenched with saturated NaHCO3 solution, extracted with diethyl ether, 
dried over sodium sulfate, and concentrated under reduced pressure. The crude product 
was purified by silica gel flash chromatography to give 57 (340 mg, 2.17 mmol, 95%). 1H 
NMR (400 MHz, CDCl3) δ 7.30 - 7.43 (m, 5H), 6.92 (dd, J = 2.01, 10.29 Hz, 1H), 6.15 (dd, 
J = 1.51, 10.29 Hz, 1H), 5.33 - 5.46 (m, 1H), 4.96 (d, J = 11.80 Hz, 1H), 4.70 (d, J = 11.80 
Hz, 1H), 4.25 (dq, J = 0.75, 6.86 Hz, 1H), 1.54 (d, J = 6.78 Hz, 3H). 
 
(2R,6R)-6-(benzyloxy)-2-methyl-3,6-dihydro-2H-pyran-3-ol 
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A DCM (1.5 mL) solution of enone 57 (0.3 g, 1.37 mmol, 1.0 equiv) and CeCl3 in MeOH 
solution (1.24 mL) was cooled to -78 °C. NaBH4 (0.052 g, 1.37 mmol) was added and the 
reaction mixture was stirred at -78 °C for 3 hours. The reaction mixture was diluted with 
diethyl ether and was quenched with saturated aqueous NaHCO3, extracted with Et2O 
and concentrated under reduced pressure. The crude product was purified by silica gel 
flash chromatography to give allylic alcohols 58 (0.17 g, 1.08 mmol, 79%). 1H NMR (400 
MHz, CDCl3) δ 7.14 - 7.33 (m, 5H), 5.67 - 5.80 (m, 1H), 5.00 - 5.12 (m, 1H), 4.80 (dd, J 
= 11.80, 18.57 Hz, 1H), 4.49 - 4.62 (m, 1H), 3.58 (quin, J = 6.46 Hz, 1H), 1.79 (br. s., 1H), 
1.23 - 1.33 (m, 3H). 
 
(2R,6R)-2-(benzyloxy)-6-methyl-3,6-dihydro-2H-pyran 
To a solution of dry N-methyl morpholine (NMM) (1.9 mL, 2.04 mmol, 3.0 equiv) triphenyl 
phosphine (0.59 g, 2.25 mmol, 3.3 equiv) and was cooled to -30 °C under Ar atmosphere. 
Diisopropylazodicarboxylate (0.41 mL, 2.04 mmol, 3.0 equiv) was added and the reaction 
was stirred for 5 minutes, allylic alcohol 58 (0.15 g, 0.68 mmol, 1.0 equiv) was added in 
a 1 M solution of NMM and the reaction mixture was stirred for 10 minutes, followed by 
addition of o-nitrobenzenesulfonyl hydrazide (NBSH) (0.444 g, 2.04 mmol, 3.0 equiv). 
The reaction was stirred at -30 °C for 2 hours and was monitored by TLC. Upon 
consumption of starting material, the reaction was warmed up to room temperature and 
stirred for another 2 hours. The reaction mixture was diluted with diethyl ether and was 
quenched with saturated aqueous NaHCO3, extracted with diethyl ether and concentrated 
under reduced pressure. The crude product was purified over silica gel to to give product 
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59 (0.133 g, 0.65 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 7.15 - 7.33 (m, 5H), 5.55 - 
5.66 (m, 1H), 5.52 (tdd, J = 1.38, 2.67, 10.13 Hz, 1H), 4.87 (d, J = 12.05 Hz, 1H), 4.67 
(dd, J = 3.51, 7.78 Hz, 1H), 4.55 (d, J = 12.05 Hz, 1H), 4.21 - 4.31 (m, 1H), 2.04 - 2.26 
(m, 2H), 1.25 (d, J = 6.78 Hz, 3H). 
 
(2R,3S,4S,6R)-6-(benzyloxy)-2-methyltetrahydro-2H-pyran-3,4-diol 
To a DCM (2.7 mL, 0.47 M) solution of olefin 17 (0.255g, 1.25 mmol, 1.0 equiv) at 0 °C 
was added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.57 mL). 
Crystalline OsO4 (0.00318 g, 1 mol %) was added and the reaction was stirred for 3 
hours. The reaction was quenched by adding EtOAc and saturated aqueous NaHCO3. 
The organic layer was separated and concentrated and was purified over silica gel to 
obtain the diol 60 (0.24 g, 1.007 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.25 - 7.40 
(m, 5H), 4.84 - 4.96 (m, 2H), 4.58 (d, J = 11.80 Hz, 1H), 4.08 - 4.17 (m, 1H), 3.76 (qd, J 
= 6.27, 9.29 Hz, 1H), 3.35 (dd, J = 3.26, 9.29 Hz, 1H), 2.14 (ddd, J = 2.26, 3.64, 13.93 
Hz, 1H), 1.80 (ddd, J = 3.01, 9.41, 13.93 Hz, 1H), 1.35 (d, J = 6.27 Hz, 3H). 
 
(2R,3R,4R,6R)-6-(benzyloxy)-4-methoxy-2-methyltetrahydro-2H-pyran-3-ol 
A THF (1.37 mL, 0.67M) solution of diol 60 (7.0 g, 29.4 mmol) at 0 °C were added PPh3 
(0.495 g, 1.88 mmol, 2.05 equiv) and p-nitrobenzoic acid (0.309 g, 1.85 mmol, 2.0 equiv). 
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DIAD (0.36 mL, 1.85 mmol, 2.0 equiv) in THF was added dropwise and the reaction 
mixture was warmed up to room temperature and stirred overnight. The solution was 
quenched with saturated aqueous NaHCO3, extracted with diethyl ether, and purified over 
silica gel to give compound 61, which was used directly for the next step. 
 
(((2R,3R,4R,6R)-6-(benzyloxy)-4-methoxy-2-methyltetrahydro-2H-pyran-3-
yl)oxy)(tert-butyl)dimethylsilane 
To the above obtained alcohol 61 (0.242 g, 0.625 mmol, 1.0 equiv) in DCM (3.9 mL, 0.16 
M) was added 2,6-lutidine (0.17 mL, 0.75 mmol, 1.2 equiv) and cooled to 0 °C. To this 
solution was added TBSOTf (0.12 mL, 1.0 mmol, 1.6 equiv) and the reaction was allowed 
to warm up to room temperature and stirred for 3 hours. The reaction mixture was 
quenched by addition of 1N HCl and purified over silica gel to obtain the tri-protected 
olivose sugar 62 (0.139 g, 0.38 mmol, 30% overall for 2 steps). 1H NMR (400 MHz, CDCl3) 
δ 8.26 - 8.35 (m, 2H), 8.16 - 8.24 (m, 2H), 7.28 - 7.40 (m, 5H), 5.14 (ddd, J = 5.27, 8.60, 
11.73 Hz, 1H), 4.91 (d, J = 12.05 Hz, 1H), 4.58 - 4.72 (m, 2H), 3.55 (t, J = 8.66 Hz, 1H), 
3.41 (qd, J = 6.18, 8.82 Hz, 1H), 2.40 (ddd, J = 2.01, 5.27, 12.30 Hz, 1H), 1.80 (dt, J = 
9.66, 12.11 Hz, 1H), 1.39 (d, J = 6.27 Hz, 3H), 0.77 (s, 9H), 0.09 (s, 3H), -0.13 (s, 3H). 
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1-(2-hydroxy-4-((4-methoxybenzyl)oxy)phenyl)ethan-1-one 
To a refluxing solution of 2’,4’-dihydroxyacetophenone (3 g, 19.72 mmol, 1.0 equiv) and 
potassium carbonate (6 g, 43.39 mmol, 2.2 equiv) in acetonitrile (40 mL, 0.5 M) was 
added PMBCl (2.67 mL, 19.72 mmol, 1.0 equiv) and the solution was refluxed for 16 
hours, following which it was quenched by 1N HCl, extracted into ethyl acetate and 
washed with 1N HCl solution. The ethyl acetate layer was dried and purified over silica 
gel to obtain the compound 64 (2.45 g, 9.07mmol, 46% yield). 1H NMR (400 MHz, CDCl3) 
δ 12.74 (s, 1H), 7.64 (d, J = 9.29 Hz, 1H), 7.35 (d, J = 8.80 Hz, 2H), 6.93 (d, J = 8.70 Hz, 
2H), 6.51 (qd, J = 2.49, 4.83 Hz, 2H), 5.03 (s, 2H), 3.83 (s, 3H), 2.56 (s, 3H). 
 
4-hydroxy-7-((4-methoxybenzyl)oxy)-2H-chromen-2-one 
To a refluxing suspension of sodium hydride (60%, 1.09 g, 27.24 mmol, 2.0 equiv) in 
toluene (91 mL, 0.1 M), was added a solution of compound 64 (2.47 g, 9.08 mmol, 1.0 
equiv) in toluene dropwise, followed by dimethyl carbonate (1.15 mL, 13.63 mmol, 1.5 
equiv) and the reaction was allowed to stir overnight under reflux. The following day, the 
reaction was cooled to 0 °C and quenched with 1 N HCl and diluted with ethyl acetate. 
The ethyl acetate layer was washed with 1 N HCl solution and concentrated. The product 
was precipitated out using methanol to get the coumarin 65 (2.79 g, 9.08 mmol, quant). 
1H NMR (400 MHz, DMSO-d6) δ 12.32 (br. s., 1H), 7.70 (d, J = 8.78 Hz, 1H), 7.40 (d, J = 
 170 
 
8.80 Hz, 2H), 7.01 (d, J = 2.51 Hz, 1H), 6.93 - 6.99 (m, 3H), 5.45 (s, 1H), 5.11 (s, 2H), 
3.75 (s, 3H). 
 
bis(2,2,2-trichloroethyl) 1-(4-hydroxy-7-((4-methoxybenzyl)oxy)-2-oxo-2H-
chromen-3-yl)hydrazine-1,2-dicarboxylate 
To a solution of the coumarin 65 (0.1 g, 0.335 mmol, 1.0 equiv) in acetonitrile (0.67 mL, 
0.5 M) was added ammonium acetate (0.00516 g, 0.067 mmol, 0.2 equiv) and bis(2,2,2-
trichloroethyl) azodicarboxylate (0.153 g, 0.4 mmol, 1.2 equiv). The reaction mixture was 
stirred for 2 hours and the product was purified over silica gel to obtain the compound 67 
(0.226 g, 0.335 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.95 (br. s., 1H), 7.85 (d, J = 
8.78 Hz, 1H), 7.37 (d, J = 8.53 Hz, 2H), 6.86 - 7.03 (m, 4H), 5.08 (s, 2H), 4.73 - 5.04 (m, 
4H), 3.84 (s, 3H). 
 
3-amino-4-hydroxy-7-((4-methoxybenzyl)oxy)-2H-chromen-2-one 
To a solution of the coumarin 67 (0.226 g, 0.333 mmol, 1.0 equiv) in acetic acid (2.38 mL, 
0.14 mL) was added acetone (238 µL) and zinc (0.68 g, 10.37 mmol, 31.0 equiv) and the 
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reaction was stirred overnight. The following day, the reaction was filtered through celite, 
basified with sodium bicarbonate solution and extracted into DCM. The DCM layer was 
purified over silica to obtain the aminocoumarin 68 (0.048 g, 0.15 mmol, 46%). 1H NMR 
(400 MHz, DMSO-d6) δ 7.75 (d, J = 8.53 Hz, 1H), 7.40 (d, J = 8.78 Hz, 2H), 6.79 - 7.00 
(m, 4H), 5.08 (s, 2H), 3.76 (s, 3H). 
 
4,7-dihydroxy-3-nitro-2H-chromen-2-one 
To a solution of the coumarin 68 (0.5 g, 2.108 mmol, 1.0 equiv) in DMF (10.54 mL, 0.2 
M), was added 1-dodecanethiol (3.54 mL, 14.76 mmol, 7.0 equiv) and potassium tert-
butoxide (0.592 g, 5.27 mmol, 2.5 equiv). The reaction mixture was heated at 120 °C 
overnight, followed by quenching the reaction with 1 N HCl and extracting the product 
into ethyl acetate, which was purified over silica gel to obtain the compound 70 (0.416 g, 
1.87 mmol, 88%). 1H NMR (400 MHz, DMSO-d6) δ 10.13 (br. s., 1H), 7.67 (d, J = 8.53 
Hz, 1H), 6.62 (dd, J = 2.26, 8.53 Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H). 
 
8-chloro-4,7-dihydroxy-3-nitro-2H-chromen-2-one 
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To a solution of the nitrocoumarin (0.055 g, 0.25 mmol, 1.0 equiv) in dioxane:water (1:1, 
1.23 mL, 0.2 M) was added chloramine-T hydrate (0.07 g, 0.25 mmol, 1.0 equiv). The 
reaction mixture was heated at reflux overnight and was extracted into ethyl acetate and 
dried. Analysis of the crude mixture by 1H NMR indicated a 50% conversion into product 
71. 1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 2H), 7.64 (d, J = 8.53 Hz, 1H), 6.83 (d, J = 
8.53 Hz, 1H). 
 
 
2-(hydroxymethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 
To a solution of n-butyllithium (0.7 mL, 1.7 mmol, 3.0 equiv) in THF (8.1 mL, 0.07M) was 
added 2,2,6,6-tetramethylpiperidine (0.29 mL, 1.7 mmol, 3.0 equiv) at -10 °C. The 
solution was stirred for 30 minutes and then cooled to -78 °C and compound 72 (0.1 g, 
0.57 mmol, 1.0 equiv) was added in THF dropwise and stirred for an additional one hour. 
To this, 1H-benzotriazole-methanol (0.17 g, 1.134 mmol, 2.0 equiv) was added dropwise 
over a period of 30 minutes and kept at this temperature for 2 hours. The solution was 
quenched with water and extracted into ethyl acetate and purified over silica gel to get 
the compound 73 (0.076 g, 0.37 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 
8.78 Hz, 1H), 6.79 - 6.87 (m, 1H), 6.71 (d, J = 2.51 Hz, 1H), 3.74 - 3.97 (m, 5H), 2.90 - 
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3.15 (m, 2H), 2.68 (tdd, J = 4.49, 7.65, 13.24 Hz, 1H), 2.04 - 2.15 (m, 1H), 1.84 - 2.01 (m, 
1H). 
 
2-hydroxy-2-(hydroxymethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 
To a solution of the alcohol 73 (1.012 g, 4.91 mmol, 1.0 equiv) and triethylamine (1.71 
mL, 12.27 mmol, 2.5 equiv) in DCM (9.82 mL, 0.5 M) was cooled to 0 °C was added 
TBSOTf (2.48 mL, 10.8 mmol, 2.2 equiv). The reaction was allowed to warm up to room 
temperature and stirred for 3 hours, following which the reaction was diluted with DCM 
and washed with water and concentrated and used for the next step without any further 
purification. 
The above obtained crude was dissolved in DCE (15.0 mL, 0.2 M) and cooled to 0 °C. To 
this solution was added 3-chloroperbenzoic acid (2.12 g, 12.27 mmol, 2.5 equiv) and was 
allowed to warm up to room temperature. The reaction mixture was stirred for 2 hours 
and was filtered over celite and washed with DCE. The mixture was diluted with DCM 
and washed with half saturated sodium carbonate and the DCM layer was concentrated 
and was used for the next step without purification. 
The crude was dissolved in THF (10.0 mL, 0.5 M) and was added TBAF (1 M in THF, 
14.7 mmol, 3.0 equiv) and was allowed to stir overnight. The following day, the reaction 
mixture was diluted with ethyl acetate and washed with water and then brine. The ethyl 
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acetate layer was concentrated and purified over silica gel to obtain the diol 74 (1.087 g, 
3.19 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.78 Hz, 1H), 6.87 (dd, J = 
2.51, 8.78 Hz, 1H), 6.71 (d, J = 2.51 Hz, 1H), 3.88 (s, 3H), 3.60 - 3.79 (m, 2H), 3.29 - 3.43 
(m, 1H), 2.95 - 3.11 (m, 2H), 2.34 - 2.50 (m, 1H), 2.11 (ddd, J = 6.53, 11.04, 13.30 Hz, 
2H), 1.62 - 1.75 (m, 1H), 1.41 - 1.53 (m, 1H), 1.02 (t, J = 7.40 Hz, 2H). 
 
6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-oxiran]-1-one 
To a solution of the diol 74 (0.320 g, 1.44 mmol, 1.0 equiv) in DMF (14.4 mL, 0.1M) was 
added DIAD (0.57 mL, 2.88 mmol, 2.0 equiv) and tributylphosphine (0.72 mL, 2.88 mmol, 
2.0 equiv). The reaction mixture was allowed to stir overnight and purified over silica gel 
to obtain the epoxide 75 (0.285 g, 1.39 mmol, 97%). 1H NMR (700 MHz, CDCl3) δ 8.07 
(d, J = 8.80 Hz, 1H), 6.88 (dd, J = 2.64, 8.80 Hz, 1H), 6.76 (d, J = 2.64 Hz, 1H), 3.89 (s, 
3H), 2.91 (d, J = 6.60 Hz, 1H), 2.44 - 2.59 (m, 1H), 1.95 - 2.10 (m, 2H). 
 
2-hydroxy-2-(iodomethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 
 175 
 
To a solution of the epoxide 75 (0.04 g, 0.196 mmol, 1.0 equiv) in THF (1.96 mL, 0.1 M) 
was added TBAI (0.145 g, 0.4 mmol, 2.0 equiv) and boron trifluoride etherate (0.05 mL, 
0.4 mmol, 2.0 equiv). The solution was stirred for one hour and was diluted by ethyl 
acetate. The ethyl acetate layer was washed with water, brine and purified over silica gel 
to obtain the compound 76 (0.042 g, 0.125 mmol, 64%). 1H NMR (700 MHz, CDCl3) δ 
8.00 (d, J = 8.80 Hz, 1H), 6.88 (dd, J = 2.64, 8.80 Hz, 1H), 6.62 - 6.74 (m, 1H), 3.99 (s, 
1H), 3.88 (s, 3H), 3.53 (d, J = 11.00 Hz, 1H), 3.30 (dd, J = 1.32, 11.00 Hz, 1H), 2.49 (ddd, 
J = 2.42, 4.95, 13.75 Hz, 1H), 2.16 - 2.28 (m, 1H), 1.90 - 2.01 (m, 1H), 1.65 - 1.75 (m, 
1H) 
 
6-methoxy-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-
dihydronaphthalen-1(2H)-one 
Compound 72 (1.47 g, 8.34 mmol, 1.0 equiv) was dissolved in THF (42.0 mL, 0.2 M) and 
cooled to -78°C. A solution of LiHMDS (1 M in THF, 12.5 mL, 1.5 equiv) was added 
dropwise, and the solution was stirred for 30 minutes, following which iodomethylpinacol 
boronate (12.5 mmol, 1.5 equiv) was added and the solution was stirred at the same 
temperature for 30 minutes. Then the mixture was allowed to warm to room temperature 
and was stirred for an additional 2 hours. The reaction mixture was quenched by addition 
of water and extracted into ethyl acetate and purified on silica gel to get the compound 
78 (1.423 g, 4.5 mmol, 55%). 1H NMR (700 MHz, CDCl3) δ 8.02 (d, J = 8.80 Hz, 1H), 6.83 
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(dd, J = 2.42, 8.58 Hz, 1H), 6.69 - 6.74 (m, 1H), 3.87 (s, 3H), 2.94 (t, J = 5.94 Hz, 2H), 
2.57 - 2.64 (m, 2H), 2.18 (s, 1H), 2.13 (td, J = 6.22, 12.65 Hz, 2H), 1.24 - 1.34 (m, 9H). 
 
potassium trifluoro((6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-
yl)methyl)borate 
The above obtained pinacol boronate (0.925 g, 2.925 mmol, 1.0 equiv) was dissolved in 
acetonitrile (14.6 mL, 0.2 M) and cooled to 0 °C. To this was added saturated aqueous 
KHF2 (4.5 M, 2.6 mL, 4.0 equiv) dropwise at 0 °C and the solution was stirred for 3 hours 
at room temprature. The resulting suspension was concentrated in vacuo and was 
purified by continuous Soxhlet extraction with acetone for 12 hours to provide the 
compound 79 (0.864 g, 2.92 mmol, quant). 1H NMR (400 MHz, DMSO-d6) δ 7.77 (d, J = 
8.78 Hz, 1H), 6.71 - 6.87 (m, 2H), 3.80 (s, 3H), 2.64 - 2.79 (m, 1H), 2.30 (tdd, J = 3.73, 
7.69, 11.45 Hz, 1H), 2.03 - 2.14 (m, 1H), 1.79 - 1.92 (m, 1H), 0.44 (ddd, J = 2.89, 6.78, 
13.43 Hz, 1H), -0.01 - 0.12 (m, 1H). 
 
N,N-diethyl-3-hydroxybenzamide 
 177 
 
To a solution of 3-hydroxybenzoic acid (2.5 g, 18.1 mmol, 1.0 equiv) in DCM (30.0 mL, 
0.6 M), cooled to 0 °C was added oxalyl chloride (1.84 mL, 22.0 mmol, 1.2 equiv) and 
DMF (0.35 mL, catalytic). The reaction was allowed to warm up to room temperature and 
stirred for 3 hours, followed by removal of all the solvents in vacuo. The crude was 
dissolved in DCM (30 mL, 0.6 M) and was cooled to 0 °C. To this was added a solution 
of diethylamine (2.81 mL, 26.89 mmol, 1.48 equiv) and triethylamine (5.04 mL, 36.2 equiv, 
2.0 equiv) in DCM (60 mL). The reaction mixture was allowed to warm up to room 
temperature and stirred overnight. The solution was concentrated in vacuo and the 
product was purified out over silica gel (3.2 g, 16.6 mmol, 92%). 
 
N,N-diethyl-3-methoxybenzamide 
The above prepared phenol (3.48 g, 18.1 mmol, 1.0 equiv) was dissolved in acetone (60 
mL, 0.3 M) and was added potassium carbonate (3.75 g, 27.15 mmol, 1.5 equiv) and was 
refluxed. To this solution was added methyl iodide (1.69 mL, 27.15 mmol, 1.5 equiv) and 
was allowed to react overnight. The crude mixture was allowed to cool down and 
quenched with 1 N HCl and extracted into ethyl acetate. The ethyl acetate layer was 
purified over silica gel to get compound 81’ (3.7 g, 18.0 mmol, quant). 
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N,N-diethyl-2-formyl-3-methoxybenzamide 
To a solution of the amide 81’ (1.7 g, 8.24 mmol, 1.0 equiv) in diethyl ether (22.0 mL, 0.4 
M) was cooled to -78 °C was added TMEDA (1.23 mL, 8.24 mmol, 1.0 equiv) and 
dropwise added s-BuLi (7.1 mL, 9.9 mmol, 1.2 equiv). The solution was allowed to stir for 
one hour followed by the dropwise addition of DMF (0.77 mL, 9.9 mmol, 1.2 equiv). The 
reaction was maintained for one hour at -78 °C followed by allowing it to warm up to room 
temperature overnight. The reaction was quenched by addition of 1N HCl and followed 
by extraction into ethyl acetate. The ethyl acetate layer was purified over silica gel to 
obtain compound 82 (1.22 g, 5.52 mmol, 67%). 1H NMR (400 MHz, CDCl3) δ 10.49 (s, 
1H), 7.55 (dd, J = 7.53, 8.53 Hz, 1H), 7.01 (dd, J = 0.75, 8.53 Hz, 1H), 6.85 (td, J = 0.75, 
7.53 Hz, 1H), 3.95 (s, 3H), 3.59 (q, J = 7.19 Hz, 2H), 3.07 (q, J = 7.03 Hz, 2H), 1.33 (t, J 
= 7.15 Hz, 3H), 1.01 (t, J = 7.15 Hz, 3H). 
 
N,N-diethyl-2-formyl-3-hydroxybenzamide 
To a solution of compound 82 (0.744 g, 3.162 mmol, 1.0 equiv) in DCM (16.0 mL, 0.2 M), 
cooled to -78 °C was added boron tribromide (1M in DCM, 2.5 equiv). The reaction was 
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allowed to warm to room temperature and kept overnight. Saturated solution of 
ammonium chloride was added to quench the reaction and the product was extracted into 
DCM and purified over silica gel to give compound 82’ (0.605 g, 2.73 mmol, 87%). 1H 
NMR (400 MHz, CDCl3) δ 11.58 (s, 1H), 9.95 (d, J = 0.50 Hz, 1H), 7.53 (dd, J = 7.40, 
8.41 Hz, 1H), 7.01 (td, J = 0.75, 8.53 Hz, 1H), 6.84 (dd, J = 1.00, 7.53 Hz, 1H), 3.62 (br. 
s., 2H), 3.21 (q, J = 7.11 Hz, 2H), 1.29 (t, J = 7.00 Hz, 3H), 1.10 (t, J = 7.00 Hz, 3H). 
 
3-(benzyloxy)-N,N-diethyl-2-formylbenzamide 
Benzyl bromide (0.483 mL, 4.065 mmol, 1.5 equiv) was added to a solution of the 
compound 81’ (0.6 g, 2.71 mmol, 1.0 equiv), sodium hydride (60%, 4.065 mmol, 1.5 
equiv) in DMF (13.5 mL, 0.2 M) cooled to 0 °C. The solution was allowed to warm up to 
room temperature over 4 hours and cooled to 0 °C again. The reaction was quenched by 
addition of 1N HCl followed by extraction of the product into ethyl acetate and purification 
over silica gel to obtain compound 83 (0.641 g, 2.05 mmol, 76%). 1H NMR (400 MHz, 
CDCl3) δ 10.56 (d, J = 0.75 Hz, 1H), 7.51 (dd, J = 7.53, 8.28 Hz, 1H), 7.33 - 7.47 (m, 5H), 
7.05 (dd, J = 0.88, 8.41 Hz, 1H), 6.78 - 6.90 (m, 1H), 5.21 (s, 2H), 3.59 (q, J = 7.11 Hz, 
2H), 3.07 (q, J = 7.28 Hz, 2H), 1.32 (t, J = 7.15 Hz, 3H), 1.01 (t, J = 7.20 Hz, 3H). 
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7-(benzyloxy)-3-oxo-1,3-dihydroisobenzofuran-1-carbonitrile 
To a solution of the compound 83 (0.37 g, 1.19 mmol, 1.0 equiv) in DCM (6.0 mL, 0.2 M) 
was added 18-crown-6 (0.063 g, 0.24 mmol, 0.2 equiv), potassium cyanide (0.016 g, 0.24 
mmol, 0.2 equiv), TMSCN (0.221 mL, 1.67 mmol, 1.4 equiv) and cooled to 0°C. To this 
solution, dropwise (CAUTION: EVOLUTION OF HCN GAS) was added glacial acetic acid 
(3.0 mL, 0.4 M). The solution was stirred at 0 °C for 3 hours, followed by stirring at room 
temperature overnight. The reaction was quenched by addition of 1 N HCl and extraction 
into DCM. The DCM layer was purified over silica gel to obtain the compound 84 (0.214 
g, 0.8 mmol, 68%). 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.64 (m, 2H), 7.32 - 7.48 (m, 5H), 
7.20 - 7.29 (m, 1H), 6.00 (s, 1H), 5.18 - 5.34 (m, 2H). 
 
 
2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-
pyran-2-yl)naphthalen-1-ol 
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To a solution of 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 (0.3 g, 0.55 mmol, 1.0 equiv) 
in DCM (12.0 mL, 0.023 M) was added trifluoroacetic anhydride (0.084 mL, 0.6 mmol, 
1.09 equiv) and stirred for 1h at room temperature. The reaction was concentrated in 
vacuo and dissolved in DCM (12.0 mL) and added 1-naphthol 85 (0.238 g, 1.65 mmol, 
2.97 equiv) and cooled to 0 °C. To this solution was added trifluoromethanesulfonic acid 
(0.09 mL, 1.021 mmol, 1.84 equiv) dropwise, and the solution was allowed to warm up to 
room temperature and stirred for 3 hours. The reaction was quenched by addition of 
water, extracted into DCM and purified over silica gel to obtain the product 87 (0.138 g, 
0.2 mmol, 37%). 1H NMR (400 MHz, CDCl3) δ 7.99 - 8.26 (m, 2H), 7.87 - 7.99 (m, 1H), 
7.65 - 7.87 (m, 1H), 7.38 - 7.51 (m, 3H), 7.06 - 7.36 (m, 18H), 5.15 (br. s., 1H), 5.03 - 5.12 
(m, 1H), 4.28 - 4.47 (m, 2H), 4.00 - 4.23 (m, 4H), 3.86 - 4.00 (m, 1H). 
 
2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-
pyran-2-yl)naphthalen-1-ol 
To a solution of 1-naphthol 85 (0.029 g, 0.2 mmol, 2.0 equiv) and 2,3,4,6-Tetra-O-benzyl-
D-glucopyranose 86 (0.054 g, 0.1 mmol, 1.0 equiv) and silver perchlorate (0.00415 g, 
0.02 mmol, 20 mol%) in DCM (1.0 mL, 0.1 M was added TMSOTf (4.0 µL, 0.02 mmol, 20 
mol%) at 0 °C. The reaction mixture was stirred for 2 hours, followed by quenching the 
reaction with triethylamine and purification over silica gel to give the compound 87 (0.021 
g, 0.032 mmol, 32% yield). 1H NMR (400 MHz, CDCl3) δ 7.99 - 8.26 (m, 2H), 7.87 - 7.99 
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(m, 1H), 7.65 - 7.87 (m, 1H), 7.38 - 7.51 (m, 3H), 7.06 - 7.36 (m, 18H), 5.15 (br. s., 1H), 
5.03 - 5.12 (m, 1H), 4.28 - 4.47 (m, 2H), 4.00 - 4.23 (m, 4H), 3.86 - 4.00 (m, 1H). 
 
3-hydroxy-13-methyl-2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)-6,7,8,9,11,12,13,14,15,16-decahydro-
17H-cyclopenta[a]phenanthren-17-one 
To a solution of estrone 88 (0.029 g, 0.2 mmol, 2.0 equiv) and 2,3,4,6-Tetra-O-benzyl-D-
glucopyranose 86 (0.054 g, 0.1 mmol, 1.0 equiv) and silver perchlorate (0.00415 g, 0.02 
mmol, 20 mol%) in DCM (1.0 mL, 0.1 M was added TMSOTf (4.0 µL, 0.02 mmol, 20 
mol%) at 0 °C. The reaction mixture was stirred for 2 hours, followed by quenching the 
reaction with triethylamine and purification over silica gel to give the compound 89 (0.029 
g, 0.037 mmol, 37% yield). 1H NMR (400 MHz, CDCl3) δ 6.91 - 7.19 (m, 15H), 6.82 - 6.90 
(m, 1H), 6.71 - 6.79 (m, 1H), 3.98 - 4.03 (m, 1H), 3.69 - 3.97 (m, 6H), 2.47 - 2.75 (m, 2H), 
2.24 - 2.47 (m, 2H), 1.91 - 2.10 (m, 6H), 1.73 - 1.90 (m, 3H), 1.23 - 1.49 (m, 7H), 1.11 - 
1.22 (m, 3H), 0.75 - 0.81 (m, 2H), 0.71 - 0.75 (m, 3H). 
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(2E,4E)-N-(2-oxo-2H-chromen-3-yl)hexa-2,4-dienamide 
To a solution of 3-aminocoumarin 90 (0.1 g, 0.621 mmol, 1.0 equiv) in pyridine:DCM 
(30%, 0.06 M) was added sorbic acid 91 (0.14 g, 1.241 mmol, 2.0 equiv) and EDCI (0.298 
g, 1.55 mmol, 2.5 equiv) and the solution was let stir overnight. The following day, reaction 
mixture was diluted with DCM, washed with copper sulfate solution, dried and purified 
over silica gel to obtain the amide 92 (0.094 g, 0.37 mmol, 59%). 1H NMR (400 MHz, 
CDCl3) δ 8.71 - 8.87 (m, 1H), 8.08 (br. s., 1H), 7.53 (dd, J = 1.51, 7.78 Hz, 1H), 7.42 - 
7.48 (m, 1H), 7.28 - 7.40 (m, 3H), 6.18 - 6.29 (m, 2H), 5.94 (d, J = 15.06 Hz, 1H), 1.90 (d, 
J = 5.27 Hz, 3H). 
 
4-(benzyloxy)cyclohexyl (2E,4E)-hexa-2,4-dienoate 
To a solution of sorbic acid 93 (0.163 g, 1.45 mmol, 1.5 equiv) in toluene (10.0 mL, 0.1 
M) cooled to 0 °C was added triethylamine (0.54 mL, 3.9 mmol, 4.0 equiv) and 2,4,6-
trichlorobenzoyl chloride (0.26 mL, 1.65 mmol, 1.7 equiv). The reaction was stirred for 1 
hour followed by addition of the alcohol 93 (0.2 g, 0.97 mmol, 1.0 equiv) and DMAP (0.24 
g, 1.94 mmol, 2.0 equiv) and was stirred overnight at room temperature. The following 
day, the reaction was quenched with sodium bicarbonate solution and extracted into 
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diethyl ether. The ether layer was purified over silica gel to give the compound 94 (0.15g, 
0.5 mmol, 51%). 1H NMR (400 MHz, CDCl3) δ 7.19 - 7.43 (m, 5H), 6.07 - 6.28 (m, 2H), 
5.70 - 5.83 (m, 1H), 4.82 - 4.98 (m, 1H), 4.51 - 4.59 (m, 2H), 3.40 - 3.58 (m, 1H), 1.99 - 
2.10 (m, 2H), 1.80 - 1.99 (m, 5H), 1.61 - 1.79 (m, 2H), 1.40 - 1.61 (m, 2H). 
4.3: Experimental for Design and Synthesis of Substrate-Competitive Covalent 
Inhibitors of AKT  
4.3.1: Chemistry Experimentals 
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), Alfa-
Aesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography 
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash 
chromatography was performed on TELEDYNE ISCO CombiFlash® Rf instrument using 
RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm).  1H NMR and 
13C NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated 
chloroform (CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of 
parts per million (ppm) relative to chloroform and methanol residual peaks at 7.26 and 
3.31 respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra).  
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and 
integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin 
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer. 
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2-Chloro-N-phenylacetamide 
To a stirred solution of aniline 123 (1.0 g, 10.74 mol, 1.0 equiv) and triethylamine (1.79 
mL, 12.9 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C, was added 
chloroacetyl chloride (1.03 mL, 12.9 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 125 (1.821 g, 10.73 
mmol, quant). 1H NMR (400 MHz, CDCl3) δ 8.24 (br. s., 1H), 7.56 (d, J = 8.53 Hz, 2H), 
7.38 (t, J = 7.91 Hz, 2H), 7.13 - 7.23 (m, 1H), 4.21 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
163.9, 136.6, 129.1, 125.3, 120.2, 42.9. HRMS (ESI) C8H9ClNO m/z [M+H] + found 
170.0338, expected 170.0373. 
 
2-bromo-N-phenylacetamide 
To a stirred solution of aniline 123 (0.2 g, 2.15 mmol, 1.0 equiv and triethylamine (0.36 
mL, 2.6 mmol, 1.2 equiv) in dichlomethane (2.5 mL, 1.0 M), cooled to 0 °C was added 
bromoacetyl chloride (0.215 mL, 2.6 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
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with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 129 (0.45 g, 2.13 mmol, 
quant). 1H NMR (400 MHz, CDCl3) δ 8.23 (br. s., 1H), 7.55 (t, J = 7.30 Hz, 2H), 7.37 (t, J 
= 8.03 Hz, 2H), 7.14 - 7.22 (m, 1H), 4.21 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 163.8, 
136.7, 129.1, 125.2, 120.1, 29.4. HRMS (ESI) C8H9BrNO m/z [M+H] + found 213.9827, 
expected 213.9867. 
 
 
2-iodo-N-phenylacetamide 
To a solution of the aniline 123 (0.5 g, 2.95 mmol, 1.0 equiv) in acetone (15.0 mL, 0.2 M) 
was added sodium iodide (1.76 g, 11.79 mmol, 4.0 equiv) and refluxed overnight, 
following which the solution was allowed to cool to room temp and the acetone was 
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium 
thiosulphate solution and was dried over anhydrous sodium sulphate and was purified 
over silica gel to get the compound 127 (0.645 g, 2.47 mmol, 84%). 1H NMR (400 MHz, 
CDCl3) δ 7.70 (br. s., 1H), 7.51 (d, J = 7.53 Hz, 2H), 7.36 (t, J = 8.03 Hz, 2H), 7.12 - 7.20 
(m, 1H), 3.87 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 164.9, 137.3, 129.1, 125.0, 120.0, -
0.1. HRMS (ESI) C8H9INO m/z [M+H] + found 261.9692, expected 261.9728. 
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2-chloro-N-(4-nitrophenyl)acetamide 
To a stirred solution of aniline 124 (1.5 g, 10.86 mmol, 1.0 equiv and triethylamine (1.81 
mL, 13.03 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C was added 
chloroacetyl chloride (1.04 mL, 13.03 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 126 (0.586 g, 2.73 mmol, 
25%). 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 9.29 Hz, 2H), 8.06 (br. s., 1H), 7.78 (d, J 
= 9.03 Hz, 2H), 4.25 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.5, 145.0, 143.7, 125.2, 
119.6, 40.5. 
 
 
2-bromo-N-(4-nitrophenyl)acetamide 
 To a stirred solution of aniline 124 (1.0 g, 7.24 mmol, 1.0 equiv and triethylamine (1.2 
mL, 8.7 mmol, 1.2 equiv) in dichlomethane (2.5 mL, 1.0 M), cooled to 0 °C was added 
bromoacetyl chloride (1.2 mL, 8.7 mmol, 1.2 equiv) dropwise and the mixture was allowed 
to warm up to room temperature overnight after which the mixture was washed with 1 N 
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HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo 
and purified over silica gel to get the desired compound 130 (0.882 g, 3.4 mmol, 47%). 
1H NMR (400 MHz, CDCl3) δ 8.49 (br. s., 1H), 8.27 (d, J = 9.00 Hz, 2H), 7.78 (d, J = 9.00 
Hz, 2H), 4.25 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 164.2, 144.4, 142.3, 125.1, 119.5, 
29.1 
 
 
2-iodo-N-(4-nitrophenyl)acetamide 
To a solution of the aniline 124 (0.586 g, 2.73 mmol, 1.0 equiv) in acetone (13.0 mL, 0.2 
M) was added sodium iodide (1.64 g, 10.92 mmol, 4.0 equiv) and refluxed overnight, 
following which the solution was allowed to cool to room temprature and the acetone was 
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium 
thiosulphate solution and was dried over anhydrous sodium sulphate and was purified 
over silica gel to get the compound 128 (0.468 g, 1.53 mmol, 56%). 1H NMR (400 MHz, 
CDCl3) δ 8.25 (d, J = 9.03 Hz, 2H), 7.72 (d, J = 9.29 Hz, 2H), 3.90 (s, 2H). 13C NMR (101 
MHz, CD6CO) δ 168.1, 146.0, 125.8, 120.0, 0.0. HRMS (ESI) C8H6IN2O3 m/z [M-H] - found 
304.9442, expected 304.9423. 
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4-(((4-nitrophenyl)amino)methyl)benzonitrile 
To a solution of the aniline 124 (0.1 g, 0.72 mmol, 1.0 equiv) and 4-formylbenzonitrile 
(0.095 g, 0.72 mmol, 1.0 equiv) in dichloroethane (2.42 mL, 0.3 M) was added glacial 
acetic acid (0.041 mL, 0.72 mmol, 1.0 equiv) and sodium triacetoxyborohydride (0.215 g, 
1.01 mmol, 1.4 equiv). The mixture was stirred for 2.5 hours at room temperature, 
following which DCE was removed in vacuo. The crude was taken in ethyl acetate and 
washed with sat. sodium bicarbonate solution. The ethyl acetate layer was dried over 
sodium sulphate and the product was crystallized from DCM to give 131 (0.096 g, 0.38 
mmol, 52%). 1H NMR (400 MHz, CD6CO) δ 8.02 (d, J = 9.00 Hz, 2H), 7.76 (d, J = 8.50 
Hz, 2H), 7.62 (d, J = 8.50 Hz, 2H), 6.75 (d, J = 9.00 Hz, 2H), 4.67 (s, 2H) 
 
 
2-chloro-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide 
To a stirred solution of aniline 131 (0.2 g, 0.79 mmol, 1.0 equiv and triethylamine (0.13 
mL, 0.95 mmol, 1.2 equiv) in dichlomethane (4.0 mL, 0.2 M), cooled to 0 °C, was added 
chloroacetyl chloride (0.075 mL, 0.95 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
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with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 132 (0.202 g, 0.61 mmol, 
77%). 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.03 Hz, 2H), 7.63 (d, J = 8.53 Hz, 2H), 
7.34 (d, J = 8.53 Hz, 2H), 7.29 (d, J = 8.78 Hz, 2H), 5.00 (s, 2H), 3.89 (s, 2H) 
 
 
2-bromo-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide 
To a stirred solution of aniline 131 (0.2 g, 0.79 mmol, 1.0 equiv and triethylamine (0.13 
mL, 0.95 mmol, 1.2 equiv) in dichlomethane (4.0 mL, 0.2 M), cooled to 0 °C, was added 
bromoacetyl chloride (0.08 mL, 0.95 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 134 (0.216 g, 0.58 mmol, 
69%). 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.78 Hz, 2H), 7.62 (d, J = 8.28 Hz, 2H), 
7.34 (d, J = 8.03 Hz, 2H), 7.29 (d, J = 9.03 Hz, 2H), 5.00 (s, 2H), 3.89 (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 166.1, 146.2, 141.0, 132.7, 129.2, 128.9, 125.5, 118.2, 112.3, 53.4, 
25.9.  
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2-iodo-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide 
To a solution of the aniline 132 (0.081 g, 0.246 mmol, 1.0 equiv) in acetone (13.0 mL, 0.2 
M) was added sodium iodide (0.148 g, 0.989 mmol, 4.0 equiv) and refluxed overnight, 
following which the solution was allowed to cool to room temprature and the acetone was 
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium 
thiosulphate solution, dried over anhydrous sodium sulphate, and was purified over silica 
gel to get the compound 133 (0.118 g, 0.24 mmol, quant). 1H NMR (400 MHz, CD6CO) δ 
8.30 (d, J = 9.03 Hz, 2H), 7.68 (d, J = 9.03 Hz, 2H), 7.73 (d, J = 8.53 Hz, 2H), 7.51 (d, J 
= 8.50 Hz, 2H), 5.11 (s, 2H), 3.83 (s, 2H). 13C NMR (101 MHz, CD6CO) δ 168.8, 149.2, 
144.1, 133.9, 130.6, 126.5, 119.8, 112.9, 54.3, -1.1. HRMS (ESI) C16H13IN3O3 m/z [M+H] 
+ found 421.9951, expected 422.0001. 
 
 
N-phenylacrylamide 
To a stirred solution of aniline 123 (1.0 g, 10.74 mmol, 1.0 equiv) and triethylamine (1.79 
mL, 12.9 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C was added 
acryloyl chloride (1.05 mL, 12.88 mmol, 1.2 equiv) dropwise and the mixture was allowed 
to warm up to room temperature overnight after which the mixture was washed with 1N 
HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo 
and purified over silica gel to get the desired compound 135 (1.182 g, 8.03 mmol, 75%). 
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1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 7.03 Hz, 2H), 7.31 - 7.40 (m, 2H), 7.09 - 7.18 
(m, 1H), 6.45 (dd, J = 1.25, 16.81 Hz, 1H), 6.26 (dd, J = 10.16, 16.94 Hz, 1H), 5.78 (dd, 
J = 1.25, 10.04 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 137.7, 131.2, 129.0, 127.7, 124.6, 
120.0. HRMS (ESI) C9H10NO m/z [M+H] + found 148.0741, expected 148.0762. 
 
N-(4-nitrophenyl)acrylamide 
To a stirred solution of aniline 124 (1.5 g, 10.86 mmol, 1.0 equiv) and triethylamine (1.81 
mL, 13.03 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0° was added 
acryloyl chloride (1.06 mL, 13.03 mmol, 1.2 equiv) dropwise and the mixture was allowed 
to warm up to room temperature overnight after which the mixture was washed with 1 N 
HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo 
and purified over silica gel to get the desired compound 136 (0.322 g, 1.68 mmol, 15%). 
1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 9.00 Hz, 2H), 7.79 (d, J = 9.00 Hz, 2H), 6.52 
(dd, J = 1.00, 16.81 Hz, 1H), 6.28 (dd, J = 10.29, 16.81 Hz, 1H), 5.90 (dd, J = 1.13, 10.16 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 143.5, 130.4, 129.6, 125.1, 119.3. 
 
N-(4-cyanobenzyl)-N-(4-nitrophenyl)acrylamide 
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To a stirred solution of aniline 131 (0.096 g, 0.38 mmol, 1.0 equiv) and triethylamine 
(0.064 mL, 0.46 mmol, 1.2 equiv) in dichlomethane (2.0 mL, 0.2 M), cooled to 0 °C was 
added acryloyl chloride (0.064 mL, 0.46 mmol, 1.2 equiv) dropwise and the mixture was 
allowed to warm up to room temperature overnight after which the mixture was washed 
with 1N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated 
in vacuo and purified over silica gel to get the desired compound 137 (0.076 g, 0.25 mmol, 
65%). 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.53 Hz, 2H), 7.61 (d, J = 8.28 Hz, 2H), 
7.35 (d, J = 8.03 Hz, 2H), 7.23 (d, J = 8.78 Hz, 2H), 6.53 (dd, J = 1.38, 16.94 Hz, 1H), 
6.06 (dd, J = 10.29, 16.56 Hz, 1H), 5.72 (dd, J = 1.51, 10.54 Hz, 1H), 5.09 (s, 2H). 13C 
NMR (101 MHz, CDCl3) δ 165.3, 147.2, 141.8, 132.6, 132.4, 130.1, 128.8, 128.3, 127.6, 
127.6, 127.0, 126.2, 125.9, 125.0, 118.3, 111.7, 111.4, 52.7. HRMS (ESI) C17H12N3O3 
m/z [M-H] - found 306.0819, expected 306.0878. 
 
 
N-phenyloxirane-2-carboxamide 
To a solution of aniline 135 (0.1 g, 0.68 mmol, 1.0 equiv) in dichloromethane (4.0 mL, 0.2 
M) was added m-CPBA (1.6 g, 6.8 mmol, 10.0 equiv). The mixture was refluxed overnight, 
followed by extracting the crude into ethylacetate and washing with sat. sodium 
bicarbonate solution. The ethylacetate layer was concentrated and purified on silica gel 
to give the desired compound 138 (0.020 g, 0.13 mmol, 18%). 1H NMR (400 MHz, CDCl3) 
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δ 7.79 (br. s., 1H), 7.49 - 7.56 (m, 2H), 7.35 (t, J = 8.00 Hz, 2H), 7.10 - 7.18 (m, 1H), 3.58 
(dd, J = 2.64, 4.64 Hz, 1H), 3.11 (dd, J = 4.64, 5.40 Hz, 1H), 2.93 (dd, J = 2.60, 4.50 Hz, 
1H). 13C NMR (101 MHz, CD6CO) δ 168.0, 130.1, 125.3, 125.1, 121.2, 120.9, 50.7, 47.6. 
HRMS (ESI) C9H10NO2 m/z [M+H] + found 164.0684, expected 164.0711. 
 
 
2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-yl)-N-
phenylacetamide 
To a stirred solution of aniline 127 (0.24 g, 0.9 mmol, 1.2 equiv) and imide 139 191(0.127 
g, 0.77 mmol, 1.0 equiv) in acetonitrile (8.0 mL, 0.1 M) was added potassium carbonate 
(0.212 g, 1.54 mmol, 2.0 equiv) and refluxed overnight. The ethyl acetate solution was 
cooled, washed with 1N HCl, dried over sodium sulphate and purified over silica gel to 
obtain compound 140 (0.059 mg, 0.2 mmol, 26%). 1H NMR (400 MHz, CDCl3) δ 7.64 (br. 
s., 1H), 7.49 (d, J = 7.53 Hz, 2H), 7.30 (d, J = 7.50 Hz, 2H), 7.11 (t, J = 7.53 Hz, 1H), 6.60 
(s, 2H), 5.41 (s, 2H), 4.34 (s, 2H), 3.03 (s, 2H) 
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2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-phenylacetamide 
Maleimide 140 (0.059 g, 0.26 mmol) was heated in anisole (0.5 mL, 0.5 M) at 140 °C for 
4 hours. The solution was purified over silica gel to obtain compound 141 (0.036 g, 0.16 
mmol, 60%). 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.78 Hz, 2H), 7.40 (br. s., 1H), 
7.33 (t, J = 7.65 Hz, 2H), 7.10 - 7.18 (m, 1H), 6.83 (s, 2H), 4.35 (s, 2H). 13C NMR (101 
MHz, CDCl3) δ 170.1, 134.6, 129.1, 124.9, 120.0, 41.3. HRMS (ESI) C12H11N2O3 m/z 
[M+H] + found 231.0724, expected 231.0769. 
 
2-((4-nitrophenyl)amino)ethan-1-ol 
To a solution of 1-fluoro-4-nitrobenzene 142 (0.2 g, 1.42 mmol, 1.0 equiv) in DMSO (3.0 
mL, 0.5 M) was added ethanolamine (0.096 g, 1.56 mmol, 1.1 equiv) and potassium 
carbonate (294 mg, 2.13 mmol, 1.5 equiv). The mixture was warmed to 45 °C and kept 
overnight. The crude solution in DMSO was taken up in ethyl acetate and washed with 
water. The ethyl acetate layer was dried on sodium sulfate and purified over sodium 
sulfate to give the compound 143 (0.225 g, 1.24 mmol, 87%). 1H NMR (400 MHz, CDCl3) 
δ 8.11 (d, J = 9.00 Hz, 2H), 6.59 (d, J = 9.00 Hz, 2H), 3.92 (t, J = 5.00 Hz, 2H), 3.41 (t, J 
= 5.00 Hz, 2H)    
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1-(2-((4-nitrophenyl)amino)ethyl)-1H-pyrrole-2,5-dione 
To a solution of compound 143 (0.1 g, 0.549 mmol, 1.1 equiv) in THF (5.5 mL, 0.15 M) at 
-78 °C was added DEAD (0.087 g, 0.5 mmol, 1.0 equiv), triphenylphosphine (0.131 g, 0.5 
mmol, 1.0 equiv) and tert-butanol (0.024 mL, 0.25 mmol, 0.5 equiv). The mixture was 
stirred for 30 minutes followed by addition of maleimide (0.049 g, 0.5 mmol, 1.0 equiv) 
and was raised to room temperature and stirred overnight. The crude mixture was taken 
up in ethyl acetate and washed with water and the ethyl acetate layer dried over sodium 
sulfate and purified over silica gel to obtain compound 144 (0.034 g, 0.13 mmol, 24%). 
1H NMR (400 MHz, CD6CO) δ 8.03 (d, J = 9.29 Hz, 2H), 6.87 (s, 2H), 6.73 (d, J = 9.29 
Hz, 2H), 3.68 - 3.78 (m, 2H), 3.53 (q, J = 6.44 Hz, 2H). 13C NMR (101 MHz, CD6CO) δ 
172.3, 155.5, 139.0, 135.9, 127.4, 112.5, 42.4. HRMS (ESI) C12H12N3O4 m/z [M+H] + 
found 262.0830, expected 262.0827. 
 
N-(4-cyanobenzyl)-2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-
yl)-N-(4-nitrophenyl)acetamide 
To a solution of the compound 133 (0.036 g, 0.085 mmol, 1.0 equiv) in acetonitrile (0.85 
mL, 0.1 M) was added compound 139 (0.027 g, 0.085 mmol, 1.0 equiv) and potassium 
carbonate (0.012 g, 0.085 mmol, 1.0 equiv). The mixture was stirred at 50 °C for 2 hours, 
followed by concentration of the solvent and washing the crude in ethyl acetate with 1 N 
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HCl to obtain the product 145’, which was sufficiently pure to be used for the next step. 
1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.53 Hz, 2H), 7.62 (d, J = 8.28 Hz, 2H), 7.30 - 
7.41 (m, 4H), 6.53 (s, 4H), 5.26 (s, 2H), 4.98 (s, 2H), 4.01 (s, 2H). 13C NMR (101 MHz, 
Acetone) δ 171.7, 167.5, 148.8, 148.2, 143.9, 136.3, 133.9, 130.9, 130.6, 126.7, 119.7, 
112.9, 54.1, 40.9. 
 
N-(4-cyanobenzyl)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(4-
nitrophenyl)acetamide 
The compound 145’ (0.066 g, 0.144 mmol, 1.0 equiv) was stirred in anisole (0.3 mL, 0.5 
M) at 140 °C overnight, after which the compound 145 was isolated by purification on 
silica gel (0.04 g, 0.1 mmol, 71%). 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 8.78 Hz, 2H), 
7.62 (d, J = 8.28 Hz, 2H), 7.38 (d, J = 8.78 Hz, 2H), 7.32 (d, J = 8.03 Hz, 2H), 6.80 (s, 
2H), 4.97 (s, 2H), 4.06 (s, 2H). HRMS (ESI) C20H15N4O5 m/z [M+H] + found 391.1045, 
expected 391.1042. 
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tert-Butyl(S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate: To 
a mixture of EDCI (0.920 g, 4.8 mmol) and HOBt (0.595 g, 4.4 mmol) in anhydrous 
dichloromethane (16.7 mL) was added 2-(tert-butoxycarbonylamino)-3-phenylpropanoic 
acid 146 (1.061 g, 4 mmol) and stirred at 0 oC for 30 min. N,O-Dimethylhydroxylamine 
hydrochloride (0.449 g, 4.6 mmol) and N-methylmorpholine (0.53 mL, 4.4 mmol) were 
added to the mixture and the reaction was stirred at room temperature for 16 hours. The 
reaction mixture was washed with 1 N HCl and then saturated NaHCO3. The organic 
layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The crude 
product was purified by column chromatography (silica gel, ethyl acetate:hexane 1:4) to 
give the desired product as colorless oil 147 (1.13 g, 96% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.28 (m, 2H) 7.22 (d, J=7.2, 1H), 7.17 (d, J=7.6, 2H), 5.14 (br, 1H), 4.95 (br, 
1H), 3.65 (s, 3H), 3.16 (s, 3H), 3.05 (dd, J1=6.2, J2=13.5, 1H), 2.89 (m, 1H), 1.39 (s, 
9H). 
 
tert-Butyl 3-oxo-1-phenylpent-4-en-2-ylcarbamate 
Weinreb amide 147 (0.13 g, 0.42 mmol) was dissolved in anhydrous THF (1.3 mL). The 
reaction mixture was cooled to -40 oC in a dry ice/acetonitrile bath and purged with argon 
before 1 M vinyl magnesium bromide in THF (1.26 mL, 1.26 mmol) was added dropwise. 
After 3 hours stirring at -40 oC, the reaction mixture was poured into cold 3 N HCl, and 
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extracted three times with ethyl acetate. The combined organic layers were dried over 
anhydrous sodium sulphate and concentrated in vacuo. The crude product was purified 
over silica gel chromatography to obtain the desired product as white solid 148 (0.081 g, 
70% yield). 1H NMR (400MHz, CDCl3) δ 7.25 (m, 3H) 7.10 (d, J=7.4, 2H), 6.41 (m, 2H), 
5.83 (d, J=10.4, 1H), 5.22 (m, 1H), 4.86 (q, J=9, 1H), 3.14 (dd, J1=6.4, J2=13.8, 1H), 2.98 
(dd, J1=8.0, J2=15.4, 1H), 1.42 (s, 9H). 13C NMR (100MHz, CDCl3) δ 197.9, 155.2, 136.0, 
133.5, 130.2, 129.6, 128.6, 127.1, 79.9, 58.3, 38.2, 28.4. HRMS (ESI) C16H21NO3 m/z  
[M+Na]+ found 298.1415, expected 298.1419. 
 
 
tert-butyl ((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)carbamate 
To the vinyl ketone 148 0.265 g, 0.962 mmol, 1.0 equiv) in methanol (3.21 mL, 0.3M) 
cooled to 0 °C was added sodium bohydride (0.109 g, 2.9 mmol, 3.0 equiv). The mixture 
was stirred for 2 hours, following which it was quenched with dilute acetic acid, taken up 
in ethyl acetate and washed with saturated sodium bicarbonate solution. The ethyl 
acetate layer was dried over anhydrous sodium sulfate and concentrated to get the 
compound 149 (0.267 g, 0.96 mmol, quant), which was sufficiently pure to use for the 
next step. 
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N-((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)-4-nitrobenzamide 
The a solution of the alcohol 149 (0.117 g, 0.422 mmol, 1.0 equiv) in DCM (0.9 mL, 0.5 
M), cooled to 0 °C was added 2,6-lutidine (0.16 mL, 1.5 M) and TMSOTf (0.163 mL, 1M). 
The solution was warmed to room temperature and stirred for 3 hours, following which it 
was concentrated in vacuo and was added into a solution of 4-nitrobenzoic acid (0.071 g, 
0.422 mmol, 1.0 equiv), PyBOP (0.221 g, 0.422 mmol, 1.0 equiv), DIPEA (0.15 mL, 0.844 
mmol, 2.0 equiv) in DCM (4.2 mL, 0.1 M). The mixture was stirred overnight and was 
diluted with DCM and washed with 1 N HCl. The DCM layer was dried on sodium sulfate 
and was purified over silica gel to get the alcohol 150 (0.103 g, 0.32 mmol, 75%). 1H NMR 
(400 MHz, CDCl3) δ 8.17 - 8.38 (m, 2H), 7.77 - 7.93 (m, 1H), 7.63 - 7.77 (m, 1H), 7.13 - 
7.40 (m, 5H), 5.84 - 6.11 (m, 1H), 5.46 (td, J = 1.47, 17.13 Hz, 1H), 5.28 - 5.39 (m, 1H), 
4.35 - 4.59 (m, 1H), 2.99 - 3.15 (m, 1H), 2.93 (dd, J = 9.41, 14.43 Hz, 1H) 
 
(S)-4-nitro-N-(3-oxo-1-phenylpent-4-en-2-yl)benzamide 
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The alcohol 150 (0.030 g, 0.092 mmol, 1.0 equiv) was dissolved in DCM (1.0 mL, 0.1 M) 
and Dess-Martin periodinane (0.039 g, 0.092 mmol, 1.0 equiv) was added. The mixture 
was stirred at room temprature overnight, followed by dilution with DCM and washing with 
sodium thiosulfate solution. The DCM layer was dried and purified over silica gel to get 
the vinyl ketone 151 (0.029 g, 0.089 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J 
= 9.00 Hz, 2H), 7.89 (d, J = 9.00 Hz, 2H), 7.20 - 7.37 (m, 5H), 7.03 - 7.18 (m, 2H), 6.94 
(d, J = 6.27 Hz, 1H), 6.40 - 6.61 (m, 2H), 5.99 (dd, J = 1.63, 9.91 Hz, 1H), 5.38 (dt, J = 
4.77, 6.90 Hz, 1H), 3.38 (dd, J = 6.78, 14.05 Hz, 1H), 3.14 - 3.30 (m, 1H). 13C NMR (101 
MHz, CD6CO) δ 197.7, 165.7, 150.6, 140.9, 138.7, 138.4, 134.5, 130.2, 130.1, 129.7, 
129.5, 129.2, 127.5, 124.4, 59.3, 36.9. HRMS (ESI) C18H17N2O4 m/z [M+H] + found 
325.1198, expected 325.1188. 
  
 
tert-butyl (S)-(3-oxo-1-phenylpentan-2-yl)carbamate 
To a solution of the vinyl ketone 148 (0.009 g, 0.032 mmol) in ethyl acetate (1 mL) was 
added 5% Pd/C (20% w/w). The reaction mixture was stirred under a hydrogen balloon 
at room temperature overnight. The catalyst was removed by filtration, and the filtrate was 
concentrated in vacuo to afford the desired product as white solid 152 (0.009 g, 
quantitative yield). 1H NMR (400MHz, CDCl3) δ 7.28 (m, 3H), 7.14 (d, J=6.8, 2H), 5.12 (s, 
1H), 4.54 (q, J=7.4, 1H), 3.00 (m, 2H), 2.38 (m, 2H), 1.41 (s, 9H), 1.00 (t, J= ,3H). 13C 
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NMR (100MHz, CDCl3) δ 209.9, 155.3, 136.4, 129.4, 128.8, 127.1, 80.0, 60.0, 38.3, 34.3, 
28.5, 7.5. HRMS (ESI) C16H23NO3 m/z [M+H] + found 278.1735, expected 278.1756; 
[M+Na] + found 300.1566, expected 300.1575. 
 
(S)-4-amino-N-(3-oxo-1-phenylpentan-2-yl)benzamide 
To a solution of the vinyl ketone 151 (0.01 g, 0.03 mmol) in ethyl acetate (0.3 mL, 0.1 M) 
was added 5% Pd/C (20% w/w). The reaction mixture was stirred under a hydrogen 
balloon at room temperature overnight. The catalyst was removed by filtration, and the 
filtrate was concentrated in vacuo to afford the desired product as white solid 153 (0.008 
g, 0.025 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.50 Hz, 2H), 7.20 - 7.33 
(m, 3H), 7.12 - 7.19 (m, 2H), 6.65 (d, J = 8.50 Hz, 2H), 5.04 (q, J = 6.78 Hz, 1H), 3.98 (br. 
s., 2H), 3.18 (dd, J = 3.26, 6.27 Hz, 2H), 2.37 - 2.55 (m, 2H), 1.04 (t, J = 7.28 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 209.6, 166.5, 149.8, 136.2, 129.3, 128.8, 128.6, 127.1, 
123.5, 114.1, 58.9, 37.9, 34.3, 7.4. HRMS (ESI) C18H21N2O2 m/z [M+H] + found 297.1590, 
expected 297.1603. 
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(Prop-2-yn-1-yloxy)carbonyl)-L-phenylalanine 
 To a solution of sodium hydroxide (0.467 g, 4 mmol) in water (8 mL) was added (L)-
phenylalanine 146, followed by propargyl chloroformate (0.39 mL, 4 mmol). The reaction 
was stirred at room temperature for 16 hours. The reaction mixture was then acidified to 
pH 4 with 2 N HCl, and extracted three times with ethyl acetate. The combined organic 
fractions were pooled, dried over anhydrous sodium sulfate, concentrated in vacuo to 
obtain compound 154 as white solid (0.438g, 44% yield). ). 1H NMR (400MHz, CD3OD) δ 
7.23-7.28 (m, 5H), 4.89 (m, 1H), 4.61 (s, 2H), 3.05 (dd, J1=5.80, J2=13.9, 1H), 2.86 (m, 
2H).  
 
Prop-2-yn-1-yl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate 
 To a solution of 154 (0.438 g, 1.8 mmol) in anhydrous DCM (9 mL) in an ice-water bath 
was added EDCI (0.479 g, 2.5 mmol) and HOBt (0.297 g, 2.2 mmol). After stirring at 0 oC 
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for 1 hour, the reaction mixture was added N,O-dimethylhydroxylamine hydrochloride 
(0.224 g, 2.3 mmol) and N-methylmorpholine (0.24 mL, 2.2 mmol). The reaction was 
warmed up to room temperate and stirred for 16 hours. The reaction mixture was washed 
with 1N HCl and then saturated NaHCO3 . The organic layer was dried over anhydrous 
sodium sulphate and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, ethyl acetate:hexane 1:4) to give the desired product 155 as 
yellow oil (0.312 g, 61% yield). 1H NMR (400 MHz, CD3OD) δ 7.23-7.29 (m, 5H), 4.89 (m, 
1H), 4.60 (s, 2H), 3.73 (s, 3H), 3.17 (s, 3H), 3.04 (dd, J1=5.9, J2=13.3, 1H), 2.86 (m, 2H). 
 
Prop-2-yn-1-yl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (36). A reaction mixture 
containing 155 (0.312 g, 1.1 mmol) in anhydrous THF (5.5 mL) was cooled to -40 oC in a 
dry ice/acetonitrile bath and purged with argon before 1 M vinyl magnesium bromide in 
THF (3.3 mL, 3.3 mmol) was added dropwise. After 3 hours stirring at -40 oC, the reaction 
mixture was poured into cold 3 N HCl, and extracted three times with ethyl acetate. The 
combined organic layers were dried over anhydrous sodium sulphate and concentrated 
in vacuo. The crude product was purified over silica gel chromatography to obtain the 
desired product as white solid 156 (0.136 g, 53% yield). 1H NMR (400 MHz, CD3OD) δ 
7.22-7.28 (m, 5H), 6.61 (dd, J1=10.1, J2=12.4, 1H), 6.36 (d, J=17.4, 1H), 5.87 (d, J=11.4, 
1H), 4.72 (m, 1H), 4.60 (s, 2H), 3.24 (dd, J1=5.5, J2=13.9, H), 2.87 (m, 2H). 
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4-(3-(5-azidopentyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid 
To a solution of fluorescein 5-isothiocynate 162 (0.050 g, 0.128 mmol, 1.13 equiv) and 
Hunigs base (0.073 mL, 0.42 mmol, 3.5 equiv) in DMF (1.2 mL, 0.1 M) was added 163 
(17 mg, 0.12 mmol, 1.0 equiv). The reaction mixture was stirred for 3 hours at room 
temperature, followed by dilution with ethyl acetate and washing with 1N HCl solution. 
The ethyl acetate layer was purified over silica to obtain compound 164 (43 mg, 0.088 
mmol, 69%). 1H NMR (400 MHz, CD3OD) δ 7.98 (s, 1H), 7.76 (dd, J = 1.63, 8.16 Hz, 1H), 
7.16 (d, J = 8.03 Hz, 1H), 6.69 (s, 4H), 6.56 (dd, J = 1.63, 9.41 Hz, 2H), 1.56 - 1.74 (m, 
4H), 1.39 - 1.53 (m, 4H), 1.26 - 1.33 (m, 2H) 
 
(S)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-4-(3-(4-(4-((((3-oxo-1-phenylpent-4-en-2-
yl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-1-yl)butyl)thioureido)benzoic acid 
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To a solution of CuSO4 (8 mg, 0.039 mmol) and sodium ascorbate (catalytic amount) in 
a mixture of 1:1 THF:water (1 mL) was added 156 (10 mg, 0.039 mmol) and Fluorescein 
Azide 145 (21 mg, 0.039 mmol). The reaction was stirred at room temperature for 1 hour. 
The reaction mixture then evaporated to dryness in vacuo and purified over silica gel 
chromatography to obtain the product as dark pink solid 165 (12 mg, 40% yield). MS (ESI) 
C94H97N11O21S m/z [M+H]+ 789.44. 
 
4-amino-N-((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)benzamide 
To a solution of the alcohol 150 (0.11 g, 0.34 mmol, 1.0 equiv) in ethyl acetate (2.0 mL, 
0.1 M) was added tin chloride dehydrate (0.228 g, 1.0 mmol, 3.0 equiv) and was refluxed 
for 3 hours. The reaction mixture was diluted with ethyl acetate and was washed with 
saturated sodium bicarbonate solution, following which it was dried over sodium sulfate 
and was concentrated in vacuo. The crude was sufficiently pure to be used in the next 
step without purification. 1H NMR (400 MHz, CDCl3) δ 7.48 - 7.55 (m, 1H), 7.40 - 7.46 (m, 
1H), 7.19 - 7.34 (m, 5H), 6.55 - 6.69 (m, 2H), 5.85 - 6.04 (m, 1H), 5.41 (td, J = 1.60, 17.13 
Hz, 1H), 5.23 - 5.36 (m, 1H), 4.21 - 4.48 (m, 2H), 2.82 - 3.09 (m, 2H). 
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4-amino-N-((2S)-3-((tert-butyldimethylsilyl)oxy)-1-phenylpent-4-en-2-yl)benzamide 
To the solution of the aniline from the previous step (0.1 g, 0.34 mmol, 1.0 equiv) in DCM 
(1.7 mL, 0.2 M) was added 2,6-lutidine (0.06 mL, 0.45 mmol, 1.5 equiv) and the solution 
was cooled to 0° C. To this mixture was added TBSOTf (0.086 mL, 0.37 mmol, 1.1 equiv) 
dropwise, the mixture was allowed to warm to room temperature and stirred overnight, 
following which the DCM layer was diluted and washed with 1 N HCl and purified over 
silica gel to get the compound 158 (0.063 g, 0.153 mmol, 45% overall yield for 2 steps). 
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.53 Hz, 1H), 7.45 (d, J = 8.78 Hz, 1H), 7.12 - 
7.32 (m, 5H), 6.55 - 6.70 (m, 2H), 5.78 - 6.05 (m, 2H), 5.38 (td, J = 1.73, 17.13 Hz, 1H), 
5.24 (td, J = 1.69, 10.42 Hz, 1H), 5.06 - 5.20 (m, 1H), 4.34 - 4.52 (m, 1H), 3.90 (d, J = 
3.26 Hz, 1H), 2.79 - 3.08 (m, 2H), 1.00 (s, 3H), 0.88 - 0.96 (m, 6H), 0.15 (s, 1H), 0.08 (s, 
2H), -0.02 (d, J = 19.32 Hz, 3H) 
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prop-2-yn-1-yl (4-(((2S)-3-((tert-butyldimethylsilyl)oxy)-1-phenylpent-4-en-2-
yl)carbamoyl)phenyl)carbamate 
To the solution of the aniline 158 (0.035 mg, 0.085 mmol, 1.0 equiv) in DCM (0.8 mL, 0.1 
M) was added triethylamine (0.013 mL, 0.09 mmol, 1.1 equiv) and the solution was cooled 
to 0 °C. To this solution was added propargyl chloroformate (0.01 mL, 0.09 mmol, 1.1 
equiv) and the mixture was allowed to warm to room temperature and kept overnight, 
followed which it was diluted with DCM and washed with 1 N HCl and concentrated in 
vacuo. The crude was sufficiently pure to be used for the next step without purification.  
 
prop-2-yn-1-yl (4-(((2S)-3-hydroxy-1-phenylpent-4-en-2-
yl)carbamoyl)phenyl)carbamate 
The above reaction crude (0.085 mmol, 1.0 equiv) was dissolved in THF (0.85 mL, 0.1 
M) and TBAF (1 M in THF, 1.5 equiv) was added. The mixture was stirred at room 
temperature overnight and was diluted with ethyl acetate and washed with 1 N HCl 
solution. The ethyl acetate layer was dried over sodium sulfate and purified over silica gel 
to obtain compound 160 (0.010 g, 0.026 mmol, 31% overall for 2 steps). 1H NMR (400 
MHz, CD6CO) δ 9.01 (br. s., 1H), 7.69 - 7.82 (m, 2H), 7.51 - 7.64 (m, 2H), 7.08 - 7.37 (m, 
5H), 5.88 - 6.13 (m, 1H), 5.23 - 5.41 (m, 2H), 5.03 - 5.20 (m, 1H), 4.74 - 4.82 (m, 2H), 
4.49 - 4.58 (m, 1H), 4.24 - 4.43 (m, 3H), 2.77 (br. s., 1H). 
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prop-2-yn-1-yl (S)-(4-((3-oxo-1-phenylpent-4-en-2-yl)carbamoyl)phenyl)carbamate 
To a solution of the above alcohol 160 (0.01 g, 0.026 mmol, 1.0 equiv) in DCM (0.3 mL, 
0.1 M) was added Dess – Martin periodinane (0.011 g, 0.026 mmol, 1.0 equiv) and the 
mixture was stirred at room temperature overnight, following which it was diluted with 
DCM and was washed with sodium thiosulfate solution. The DCM layer was dried over 
sodium sulfate and purified over silica gel to obtain compound 161 (0.007 g, 0.0186 mmol, 
71%). 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.53 Hz, 2H), 7.39 (d, J = 8.78 Hz, 2H), 
7.11 - 7.25 (m, 3H), 6.97 - 7.05 (m, 2H), 6.89 (s, 1H), 6.75 (d, J = 7.03 Hz, 1H), 6.28 - 
6.51 (m, 2H), 5.85 (dd, J = 1.51, 10.04 Hz, 1H), 5.29 (dt, J = 5.02, 6.90 Hz, 1H), 4.72 (d, 
J = 2.26 Hz, 2H), 3.25 (dd, J = 6.65, 13.93 Hz, 1H), 3.12 (dd, J = 4.89, 13.93 Hz, 1H), 
2.45 (t, J = 2.38 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 197.3, 166.0, 152.1, 140.7, 135.6, 
133.3, 130.6, 129.5, 129.2, 129.0, 128.7, 128.5, 128.3, 127.1, 118.1, 75.2, 57.4, 53.0, 
37.7. 
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N-(4-aminophenyl)-2-chloro-N-(4-cyanobenzyl)acetamide 
A solution of the compound 132 (0.115 g, 0.348 mmol, 1.0 equiv) in ethyl acetate (4.0 
mL, 0.1 M) was refluxed with tin chloride dihydrate (0.4 g, 1.745 mmol, 5.0 equiv) 
overnight, followed which the mixture was diluted with ethyl acetate, washed with 
saturated sodium bicarbonate solution and the ethyl acetate layer was purified over silica 
gel to obtain compound 166 (0.072 mg, 0.24 mmol, 69%). 1H NMR (400 MHz, CDCl3) δ 
7.58 (d, J = 8.50 Hz, 2H), 7.34 (d, J = 8.50 Hz, 2H), 6.76 (d, J = 8.50 Hz, 2H), 6.61 (d, J 
= 8.50 Hz, 2H), 4.87 (s, 2H), 3.89 (s, 2H). 
 
N-(4-(2-chloro-N-(4-cyanobenzyl)acetamido)phenyl)-4-nitrobenzamide 
To a solution of 4-nitrobenzoic acid (0.033 g, 0.192 mmol, 1.2 equiv) in DCM (0.2 mL, 0.1 
M) was added oxalyl chloride (0.06 mL, 0.64 mmol, 4.0 equiv). To this solution was added 
one drop of DMF (catalytic) and was stirred for an hour. The solution was concentrated 
in vacuo to get a white solid 167. The solid was dissolved in DCM (0.1 mL, 0.2 M) and 
was cooled to 0 °C. A solution of the aniline 166 (0.048 g, 0.16 mmol, 1.0 equiv) and 
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triethylamine (0.05 mL, 0.32 mmol, 2.0 equiv) in DCM (0.1 mL, 0.2 M) was slowly added 
to the acid chloride and the mixture was brought up to room temperature overnight. The 
reaction mixture was diluted with DCM and washed subsequently with 1 N HCl and 1 N 
NaOH solutions and dried over sodium sulfate. The DCM layer was concentrated in vacuo 
and purified over silica gel to obtain compound 168 (0.069 g, 0.154 mmol, 96%). 1H NMR 
(400 MHz, CDCl3) δ 8.38 (d, J = 8.78 Hz, 2H), 8.05 (d, J = 9.03 Hz, 2H), 7.71 (d, J = 8.80 
Hz, 2H), 7.61 (d, J = 8.28 Hz, 2H), 7.36 (d, J = 8.50 Hz, 2H), 7.09 (d, J = 8.78 Hz, 2H), 
4.95 (s, 2H), 3.90 (s, 2H). 
 
4-amino-N-(4-(2-chloro-N-(4-cyanobenzyl)acetamido)phenyl)benzamide 
The above prepared amide 168 (0.069 mg, 0.154 mmol, 1.0 equiv) was dissolved in ethyl 
acetate (1.6 mL, 0.1 M) and was refluxed overnight with tin chloride dihydrate (0.174 mg, 
0.77 mmol, 5.0 equiv), after which the mixture was diluted with ethyl acetate, washed with 
saturated sodium bicarbonate solution, dried with sodium sulfate and purified over silica 
gel to get compound 169 (0.041 mg, 0.094 mmol, 64%). 1H NMR (400 MHz, CDCl3) δ 
7.71 (d, J = 8.50 Hz, 2H), 7.66 (d, J = 8.80 Hz, 2H), 7.60 (d, J = 8.28 Hz, 2H), 7.35 (d, J 
= 8.30 Hz, 2H), 7.02 (d, J = 8.80 Hz, 2H), 6.72 (d, J = 8.53 Hz, 2H), 4.93 (s, 2H), 4.09 (br. 
s., 2H), 3.89 (s, 2H). 
 212 
 
 
(9H-fluoren-9-yl)methyl (2-((4-((4-(2-chloro-N-(4-
cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)carbamate 
To a solution of the aniline 169 (0.031 mg, 0.074 mmol, 1.0 equiv) in chloroform (0.6 mL, 
0.1 M) was added Fmoc glycyl chloride (0.035 g, 0.11 mmol, 1.5 equiv) and a solution of 
NaHCO3 in water (10%, 10.0 equiv) and the mixture was stirred vigorously for 90 minutes. 
The mixture was diluted with DCM and washed with 1N HCl and purified over silica gel to 
obtain the title compound 170 (0.05 g, 0.07 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 
8.37 (br. s., 1H), 8.07 (s, 1H), 7.77 (d, J = 7.53 Hz, 2H), 7.80 (d, J = 8.53 Hz, 2H), 7.70 
(d, J = 8.80 Hz, 2H), 7.51 - 7.63 (m, 6H), 7.25 - 7.44 (m, 6H), 7.03 (d, J = 8.50 Hz, 2H), 
5.57 (br. s., 1H), 4.93 (s, 2H), 4.52 (d, J = 6.80 Hz, 2H), 4.24 (t, J = 6.78 Hz, 1H), 4.00 (d, 
J = 5.27 Hz, 2H), 3.88 (s, 2H). 
 
4-(2-aminoacetamido)-N-(4-(2-chloro-N-(4-
cyanobenzyl)acetamido)phenyl)benzamide 
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To a solution of the above Fmoc protected amide 170 (0.05 g, 0.072 mmol, 1.0 equiv) in 
DMF (0.3 mL, 0.33 M) was added DBU:piperidine (0.012 mL, 1:1, 4% v/v) and the mixture 
was stirred for 30 minutes. The mixture was passed over a short plug of silica to obtain 
the compound 171 (0.034 mg, 0.07 mmol, quant) and was used for the next step without 
any further purification. 
 
N-(4-(N-(4-cyanobenzyl)-2-chloroacetamido)phenyl)-4-(2-(N,N-Di-Boc-1H-
guanidino)acetamido))benzamide 
To a solution of the primary amine 171 (0.036 g, 0.076 mmol, 1.0 equiv) and triethylamine 
(0.042 mL, 0.3 mmol, 4.0 equiv) in methanol (0.8 mL, 0.1 M) was added N,N’-Di-Boc-1H-
pyrazole-1-carboxamidine (0.036 g, 0.113 mmol, 1.5 equiv). The reaction mixture was 
stirred at room temperature overnight and was purified over silica gel to obtain compound 
172 (0.046 g, 0.064 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 10.34 (s, 
1H), 8.99 (t, J = 5.90 Hz, 1H), 8.31 (s, 1H), 7.71 (d, J = 8.78 Hz, 2H), 7.74 (d, J = 8.53 
Hz, 2H), 7.49 - 7.65 (m, 4H), 7.34 (d, J = 8.03 Hz, 2H), 6.99 (d, J = 8.78 Hz, 2H), 4.90 (s, 
2H), 4.17 (d, J = 6.02 Hz, 2H), 2.92 (s, 2H), 2.38 (br. s., 2H), 1.51 (s, 18H). 
 214 
 
 
1-(2-((4-((4-(2-chloro-N-(4-
cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)guanidinium 
2,2,2-trifluoroacetate 
To a solution of the above compound 172 (0.02 g, 0.027 mmol, 1.0 equiv) in DCM (0.15 
mL, 0.2 M) was added TFA (0.15 mL, 0.2 M) and stirred overnight. The reaction mixture 
was dried in vacuo to obtain the title compound 173. (0.016 mg, 0.027 mmol, quant). 1H 
NMR (400 MHz, CD3OD) δ 7.93 (d, J = 8.78 Hz, 2H), 7.76 (d, J = 8.78 Hz, 2H), 7.80 (d, 
J = 8.78 Hz, 2H), 7.68 (d, J = 8.30 Hz, 2H), 7.44 (d, J = 8.30 Hz, 2H), 7.18 (d, J = 8.78 
Hz, 2H), 5.04 (s, 2H), 3.87 (s, 2H), 3.51 - 3.66 (m, 3H). 13C NMR (101 MHz, CD3OD) δ 
173.2, 168.3, 168.2, 165.7, 159.8, 143.4, 143.2, 141.3, 135.9, 133.7, 131.2, 131.0, 130.0, 
129.9, 123.6, 120.5, 119.6, 112.9, 61.7, 21.0, 14.6. 
 
N-(4-(N-(4-cyanobenzyl)-2-bromoacetamido)phenyl)-4-(2-(N,N-Di-Boc-1H-
guanidino)acetamido))benzamide 
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The acetamide 172 (0.048 g, 0.0067 mmol, 1.0 equiv) was dissolved in acetone (1.0 mL, 
0.1 M) and refluxed with sodium bromide (0.207 g, 2.0 mmol, 30.0 equiv) overnight. The 
reaction mixture was concentrated and taken up in ethyl acetate, washed with sodium 
thiosulfate solution and purified over silica gel to obtain the compound 174 (0.026 mg, 
0.034 mmol, 51%). 1H NMR (400 MHz, CDCl3) δ 11.37 (s, 1H), 10.37 (br. s., 1H), 8.99 
(br. s., 1H), 8.26 (br. s., 1H), 7.70 (d, J = 7.53 Hz, 2H), 7.75 (d, J = 8.03 Hz, 2H), 7.44 - 
7.65 (m, 4H), 7.34 (d, J = 7.78 Hz, 2H), 6.99 (d, J = 8.03 Hz, 2H), 5.30 (s, 1H), 4.90 (br. 
s., 2H), 4.17 (d, J = 5.27 Hz, 2H), 2.92 (br. s., 2H), 2.38 (br. s., 2H), 1.51 (br. s., 18H). 
 
1-(2-((4-((4-(2-bromo-N-(4-
cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)guanidinium 
2,2,2-trifluoroacetate 
To a solution of the above compound 174 (0.026 g, 0.034 mmol, 1.0 equiv) in DCM (0.17 
mL, 0.2 M) was added TFA (0.17 mL, 0.2 M) and stirred overnight. The reaction mixture 
was dried in vacuo to obtain the title compound 175. (0.019 mg, 0.03 mmol, quant). 1H 
NMR (700 MHz, CD3OD) δ 7.93 (d, J = 8.36 Hz, 2H), 7.80 (d, J = 8.40 Hz, 2H), 7.76 (d, 
J = 8.80 Hz, 2H), 7.67 (d, J = 7.90 Hz, 2H), 7.44 (d, J = 7.90 Hz, 2H), 7.18 (d, J = 8.80 
Hz, 2H), 5.03 (s, 2H), 4.14 (s, 2H), 3.87 (s, 2H), 3.57 (d, J = 11.88 Hz, 2H). 13C NMR (101 
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MHz, CD3OD) δ 168.3, 168.1, 165.7, 154.4, 153.2, 151.7, 151.3, 147.1, 143.4, 141.3, 
135.9, 133.7, 130.9, 130.7, 130.0, 129.9, 123.6, 120.5, 115.5, 112.9, 92.9, 89.0, 85.9, 
85.6, 63.5, 55.6, 45.5, 28.1. 
 
N-(4-(N-(4-cyanobenzyl)-2-iodoacetamido)phenyl)-4-(2-(N,N-Di-Boc-1H-
guanidino)acetamido))benzamide 
The acetamide 172 (0.043 g, 0.006 mmol, 1.0 equiv) was dissolved in acetone (1.0 mL, 
0.1 M) and refluxed with sodium iodide (0.3 g, 0.6 mmol, 30.0 equiv) overnight. The 
reaction mixture was concentrated and taken up in ethyl acetate, washed with sodium 
thiosulfate solution and purified over silica gel to obtain the compound 176 (0.041 mg, 
0.05 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 12.30 (br. s., 1H), 9.12 (br. s., 1H), 8.59 
(br. s., 1H), 8.24 (br. s., 1H), 7.79 (d, J = 6.78 Hz, 2H), 7.53 - 7.69 (m, 3H), 7.41 - 7.53 
(m, 2H), 7.29 (br. s., 2H), 7.21 (d, J = 2.26 Hz, 1H), 6.92 (d, J = 6.78 Hz, 2H), 4.83 (br. s., 
2H), 4.08 (d, J = 3.51 Hz, 2H), 3.61 (br. s., 2H), 3.44 (br. s., 2H), 2.88 (br. s., 2H), 2.34 
(br. s., 2H), 1.19 (s, 18H). 
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1-(2-((4-((4-(N-(4-cyanobenzyl)-2-iodoacetamido)phenyl)carbamoyl)phenyl)amino)-
2-oxoethyl)guanidinium 2,2,2-trifluoroacetate 
To a solution of the above compound 176 (0.041 g, 0.05 mmol, 1.0 equiv) in DCM (0.25 
mL, 0.2 M) was added TFA (0.25 mL, 0.2 M) and stirred overnight. The reaction mixture 
was dried in vacuo to obtain the title compound 177. (0.03 mg, 0.05 mmol, quant). 1H 
NMR (700 MHz, CD3OD) δ 7.93 (d, J = 8.80 Hz, 2H), 7.81 (d, J = 8.80 Hz, 2H), 7.76 (d, 
J = 8.80 Hz, 2H), 7.67 (d, J = 8.36 Hz, 2H), 7.43 (d, J = 8.36 Hz, 2H), 7.18 (d, J = 8.80 
Hz, 2H), 4.29 (s, 2H), 3.88 (s, 2H), 3.57 (d, J = 11.88 Hz, 2H). 13C NMR (101 MHz, 
CD3OD) δ 168.3, 165.8, 159.4, 158.9, 154.1, 143.5, 141.3, 136.0, 133.7, 130.9, 130.0, 
129.9, 129.3, 127.9, 123.6, 120.6, 119.6, 117.6, 114.8, 112.9, 58.6, 55.6, 45.9, 0.1 
 
tert-butyl 3-bromo-4-nitrobenzoate 
To a solution of 3-bromo-4-nitrobenzoic acid 178 (0.435 g, 1.77 mmol, 1.0 equiv) and tert-
butyl 2,2,2-trichloroacetamidate (0.38 mL, 2.122 mmol, 1.2 equiv) in diethyl ether (9.0 mL, 
0.2 M) cooled to 0°C, was slowly added boron trifluoride diethyl etherate (0.022 mL, 0.177 
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mmol, 0.1 equiv). The reaction was slowly allowed to warm up to room temperature 
overnight, followed which it was washed with saturated sodium bicarbonate solution and 
the ether layer was purified over silica gel to obtain the compound 179 (0.373 g, 1.23 
mmol, 70%). 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 1.76 Hz, 1H), 8.04 (dd, J = 1.76, 
8.28 Hz, 1H), 7.83 (d, J = 8.53 Hz, 1H), 1.62 (s, 9H).  
 
tert-butyl 6-nitro-[1,1'-biphenyl]-3-carboxylate 
A solution of the ester 179 (0.03 g, 0.1 mmol, 1.0 equiv), phenylboronic acid (0.013 g, 0.1 
mmol, 1.0 equiv), tetrakis(triphenylphosphine)palladium(0) (0.006 g, 0.005 mmol, 5 
mol%), sodium carbonate (0.027 g, 0.25 mmol, 2.5 equiv) in DME:H2O (0.5 mL, 3:1, 0.2 
M) was stirred vigorously overnight at 95 °C. The following day, the reaction mixture was 
diluted with diethyl ether and washed with 1 N HCl and purified over silica gel to get the 
compound 180 (0.028 g, 0.095 mmol, 96%). 1H NMR (400 MHz, CDCl3) δ 8.00 - 8.14 (m, 
2H), 7.85 (d, J = 8.28 Hz, 1H), 7.40 - 7.50 (m, 3H), 7.28 - 7.40 (m, 2H), 1.62 (s, 9H) 
 
6-nitro-[1,1'-biphenyl]-3-carboxylic acid 
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The above prepared ester 180 (0.02 g, 0.067 mmol, 1.0 equiv) was dissolved in DCM 
(0.35 mL, 0.2 M) and was added TFA (0.35 mL, 0.2 M). The reaction mixture was stirred 
for 4 hours followed by removal of the excess TFA by vacuum to yield the compound 181 
(0.016 mg, 0.066 mmol, quant). 1H NMR (400 MHz, CD3OD) δ 8.17 (dd, J = 1.88, 8.41 
Hz, 1H), 8.09 (d, J = 1.51 Hz, 1H), 7.93 (d, J = 8.28 Hz, 1H), 7.40 - 7.49 (m, 3H), 7.30 - 
7.37 (m, 2H) 
 
benzyl 4-(6-nitro-[1,1'-biphenyl]-3-carboxamido)benzoate 
To a solution of the acid 181 (0.07 g, 0.29 mmol, 1.0 equiv) in DCM (3.0 mL, 0.2 M) was 
added thionyl chloride (0.21 mL, 2.9 mmol, 10.0 equiv) and was refluxed for 4 hours, after 
which the excess thionyl chloride was removed under vacuum to obtain the acid chloride 
.The acyl chloride was taken in DCM (1.5 mL, 0.4 M) and cooled to 0 °C. To this solution 
was added a solution of benzyl 4-amino benzoate (0.066 g, 0.288 mmol, 1.0 equiv), 
triethylamine (0.06 mL, 0.432 mL, 1.5 equiv) in DCM (1.5 mL, 0.4 M). The reaction mixture 
was allowed to warm up to room temperature and stirred overnight, after which the 
reaction was diluted by DCM, washed subsequently with 1 N HCl and 1 N NaOH and 
purified on silica gel to obtain the compound 182. (0.118 g, 0.26 mmol, 90%). 1H NMR 
(400 MHz, CDCl3) δ 8.27 (s, 1H), 8.10 (d, J = 8.80 Hz, 2H), 7.85 - 8.02 (m, 3H), 7.75 (d, 
J = 8.80 Hz, 2H), 7.28 - 7.51 (m, 10H), 5.37 (s, 2H). 
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benzyl 4-(6-amino-[1,1'-biphenyl]-3-carboxamido)benzoate 
To a solution of the benzyl ester 182 (0.182 g, 0.4 mmol, 1.0 equiv) in ethyl acetate (4.0 
mL, 0.1 M) was added tin chloride dehydrate (0.273 g, 1.21 mmol, 3.0 equiv) and refluxed 
for 90 minutes. The reaction mixture was diluted with ethyl acetate and washed with 
saturated sodium bicarbonate solution and the ethyl acetate layer was purified over silica 
gel to obtain the compound 183 (0.119 g, 0.281 mmol, 69%). 1H NMR (400 MHz, CDCl3) 
δ 8.07 (d, J = 8.70 Hz, 2H), 7.96 (s, 1H), 7.68 - 7.77 (m, 3H), 7.66 (d, J = 2.26 Hz, 1H), 
7.31 - 7.51 (m, 10H), 6.79 (d, J = 8.53 Hz, 1H), 5.36 (s, 2H), 4.18 (s, 2H). 
 
benzyl 4-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-
carboxamido)benzoate 
To the solution of the above prepared aniline 183 (0.086 g, 0.203 mmol, 1.0 equiv) in 
methanol (2.0 mL, 0.1 M) with molecular seives was added N-Boc-2-aminoacetaldehyde 
(0.012 mg, 0.203 mmol, 1.0 equiv), glacial acetic acid (0.21 mL, 0.203 mmol, 1.0 equiv) 
and was stirred for one hour. To this solution was added sodium cyanoborohydride (0.013 
g, 0.203 mmol, 1.0 equiv) and the mixture was stirred overnight. The reaction mixture was 
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concentrated under vacuum and was taken into DCM and washed with saturated sodium 
bicarbonate solution. The DCM layer was concentrated and used for the next step without 
purification. 1H NMR (400 MHz, CDCl3) δ 8.03 - 8.12 (m, 2H), 7.89 (s, 1H), 7.82 (dd, J = 
2.26, 8.53 Hz, 1H), 7.72 (d, J = 8.78 Hz, 2H), 7.57 - 7.68 (m, 1H), 7.30 - 7.54 (m, 10H), 
6.79 (dd, J = 8.41, 19.20 Hz, 1H), 5.36 (s, 2H), 3.72 (t, J = 5.02 Hz, 1H), 3.32 (s, 3H), 
1.47 (d, J = 6.02 Hz, 9H). 
 
2-((5-((4-((benzyloxy)carbonyl)phenyl)carbamoyl)-[1,1'-biphenyl]-2-yl)amino)ethan-
1-aminium 
The compound from the above step (0.108 g, 0.191 mmol, 1.0 equiv) was dissolved in 
DCM (1.0 mL, 0.2 M) and TFA (1.0 mL, 0.2 M) was added and the mixture was stirred for 
3 hours, followed by purification of the compound on silica gel to obtain compound 185 
(0.099 g, 0.171 mmol, 84% for 2 steps). 1H NMR (400 MHz, CD6CO) δ 7.93 - 8.05 (m, 
5H), 7.75 (d, J = 2.26 Hz, 1H), 7.31 - 7.54 (m, 10H), 7.04 (d, J = 8.78 Hz, 1H), 5.36 (s, 
2H), 4.02 (t, J = 5.90 Hz, 2H), 3.81 (t, J = 5.90 Hz, 2H). 
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benzyl (Z)-4-(6-((2-(2,3-bis(tert-butoxycarbonyl)guanidino)ethyl)amino)-[1,1'-
biphenyl]-3-carboxamido)benzoate 
To a solution of the primary amine TFA salt 185 (0.099 g, 0.071 mmol, 1.0 equiv) and 
triethylamine (0.1 mL, 0.684 mmol, 4.0 equiv) in methanol (2.0 mL, 0.1 M) was added 
N,N’-Di-Boc-1H-pyrazole-1-carboxamidine (0.08 g, 0.26 mmol, 1.5 equiv). The reaction 
mixture was stirred at room temperature overnight and was purified over silica gel to 
obtain compound 186 (0.051 g, 0.071 mmol, quant). 1H NMR (400 MHz, CD6CO) δ 11.61 
(s, 1H), 9.58 (s, 1H), 8.46 (d, J = 5.52 Hz, 1H), 7.84 - 8.07 (m, 5H), 7.72 (d, J = 2.51 Hz, 
1H), 7.27 - 7.55 (m, 10H), 7.17 (d, J = 8.78 Hz, 1H), 5.36 (s, 2H), 3.60 - 3.71 (m, 2H), 
3.45 - 3.57 (m, 2H), 2.78 (br. s., 1H), 1.53 (s, 9H), 1.47 (s, 9H). 
 
 (Z)-4-(6-((2-(2,3-bis(tert-butoxycarbonyl)guanidino)ethyl)amino)-[1,1'-biphenyl]-3-
carboxamido)benzoic acid 
To the solution of the above prepared guanidine 186 (0.051 g, 0.072 mmol, 1.0 equiv) in 
ethyl acetate (1.0 mL, 0.1 M) was added 5% Pd/C (25% w/w). The reaction mixture was 
stirred under a hydrogen balloon at room temperature overnight. The product was eluted 
by filtration using copious amounts of acetone, and the filtrate was concentrated in vacuo 
to afford the desired product as white solid 187 (0.045 g, 0.072 mmol, quant). 1H NMR 
(400 MHz, CD6CO) δ 11.61 (br. s., 1H), 9.55 (br. s., 1H), 8.47 (br. s., 1H), 7.81 - 8.07 (m, 
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5H), 7.73 (s, 1H), 7.43 - 7.52 (m, 3H), 7.27 - 7.43 (m, 2H), 7.16 (d, J = 6.78 Hz, 1H), 5.19 
(t, J = 4.89 Hz, 1H), 3.58 - 3.70 (m, 2H), 3.52 (d, J = 6.02 Hz, 2H), 1.53 (s, 9H), 1.47 (s, 
9H). 
 
(S)-(3-((tert-butoxycarbonyl)amino)-2-oxo-4-phenylbutyl)diazen-1-ide 
To a solution of Boc-Phe-OH 146 (1.326 g, 5.0 mmol, 1.0 equiv) and 4-methyl morpholine 
(0.58 mL, 5.25 mmol, 1.05 equiv) in THF (7.14 mL, 0.7 M) cooled to 0 °C was slowly 
added isobutyl chloroformate (0.68 mL, 5.25 mmol, 1.05 equiv). The reaction was stirred 
for one hour followed by the addition of a solution of diazomethane in diethyl ether. The 
reaction was allowed to warm to room temperature and stirred overnight, followed by 
purification of the product over silica gel to obtain brown crystals of 188. (1.378 g, 4.74 
mmol, 95%). 1H NMR (400 MHz, CDCl3) δ 7.15 - 7.35 (m, 5H), 5.22 (br. s., 1H), 5.09 (br. 
s., 1H), 4.42 (br. s., 1H), 3.03 (d, J = 6.78 Hz, 2H), 1.42 (s, 9H). 
 
tert-butyl (S)-(4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate 
The above prepared diazo ketone 188 (0.1 g. 0.35 mmol, 1.0 equiv) was dissolved in 
diethyl ether (4.0 mL, 0.1 M) and cooled to -20 °C. To this solution was added HCl in 
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dioxane (4 N, 0.13 mL, 1.5 equiv) slowly and the reaction was allowed to stir for 4 hours, 
after which the pH of the solution was adjusted to 7.0 using triethyl amine and the reaction 
was diluted with ether. The ether layer was washed with 1 N HCl, dried and purified over 
silica gel to obtain the product 190. (0.102 mg, 0.34 mmol, quant). 1H NMR (400 MHz, 
CDCl3) δ 7.24 - 7.38 (m, 3H), 7.13 - 7.21 (m, 2H), 5.02 (br. s., 1H), 4.68 (d, J = 7.28 Hz, 
1H), 4.17 (d, J = 16.31 Hz, 1H), 3.99 (d, J = 16.31 Hz, 1H), 2.95 - 3.16 (m, 2H), 1.42 (s, 
9H). 
 
tert-butyl ((2S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate 
To a solution of the α-chloro ketone 190 (0.043 g, 0.144 mmol, 1.0 equiv) in methanol 
(0.8 mL, 0.2 M) cooled to 0 °C, was added sodium borohydride (0.011 g, 0.29 mmol, 2.0 
equiv). The reaction mixture was stirred for 2 hours at 0 °C, followed by quenching the 
mixture with dilute acetic acid. The reaction was taken up in ethyl acetate, washed with 1 
N HCl and dried in vacuo to obtain the product 191 (0.043 g, 0.14 mmol, quant).  
 
(2S)-4-chloro-3-hydroxy-1-phenylbutan-2-aminium 2,2,2-trifluoroacetate 
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To the solution of the above compound 191 (0.043 g, 0.14 mmol, 1.0 equiv) in DCM (0.7 
mL, 0.2 M) was added TFA (0.7 mL, 0.2 M). The reaction was stirred at room temperature 
for 3 hours, after which the solvents were removed vacuo to obtain the compound 192. 
(0.044 g, 0.14 mmol, quant). 1H NMR (400 MHz, CD6CO) δ 7.83 (br. s., 2H), 7.11 - 7.39 
(m, 5H), 4.22 - 4.41 (m, 1H), 4.01 - 4.17 (m, 1H), 3.60 - 3.87 (m, 2H), 2.99 - 3.28 (m, 2H). 
 
 
To a solution of the acid 187 (0.053 g, 0.86 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M) was 
added PyBOP (0.045 g, 0.86 mmol, 1.0 equiv), DIPEA (0.03 mL, 0.17 mmol, 2.0 equiv) 
and stirred for 30 minutes, followed by the addition of the amine 192 (0.034 g, 0.086 
mmol, 1.0 equiv). The reaction was stirred overnight, after which it was washed with 1 N 
HCl and the DCM layer was purified over silica gel to get the compound 193 (0.062 g, 
0.078 mmol, 90%). 1H NMR (400 MHz, CDCl3) δ 11.47 (br. s., 1H), 8.50 (t, J = 5.40 Hz, 
1H), 8.25 (s, 1H), 7.77 - 7.85 (m, 1H), 7.61 - 7.73 (m, 6H), 7.51 - 7.60 (m, 3H), 7.33 - 7.50 
(m, 8H), 7.15 - 7.33 (m, 7H), 6.78 (d, J = 8.53 Hz, 1H), 6.37 (d, J = 8.03 Hz, 1H), 4.32 - 
4.53 (m, 2H), 3.93 - 4.18 (m, 2H), 3.49 - 3.69 (m, 4H), 3.37 (t, J = 6.53 Hz, 2H), 3.01 - 
3.16 (m, 2H), 1.49 (s, 9H), 1.52 (s, 9H) 
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To the above prepared alcohol 193 (0.062 g, 0.078 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 
M) was added Dess Martin periodinane (0.04 g, 0.093 mmol, 1.2 equiv). The reaction 
mixture was stirred for one hour at room temperature, followed by dilution of the reaction 
with DCM, washing with sodium thiosulfate solution and purification of the DCM layer over 
silica gel to obtain the α-chloro ketone 194 (0.022 g, 0.028 mmol, 67%). 1H NMR (400 
MHz, CDCl3) δ 8.50 (t, J = 5.40 Hz, 1H), 8.18 (s, 1H), 7.81 (dd, J = 2.26, 8.53 Hz, 1H), 
7.59 - 7.76 (m, 5H), 7.25 - 7.48 (m, 10H), 7.15 - 7.23 (m, 3H), 6.80 (d, J = 8.53 Hz, 1H), 
6.70 (d, J = 7.03 Hz, 1H), 5.12 (q, J = 7.03 Hz, 1H), 4.24 (d, J = 16.06 Hz, 1H), 4.05 (d, J 
= 16.06 Hz, 1H), 3.60 (q, J = 6.11 Hz, 2H), 3.38 (t, J = 6.30 Hz, 2H), 3.21 (tt, J = 6.93, 
14.40 Hz, 2H), 1.49 (s, 9H), 1.52 (s, 9H). 
 
To a solution of the α-chloro ketone 194 (0.022 g, 0.028 mmol, 1.0 equiv) in dioxane (0.3 
mL, 0.1M) was added HCl in dioxane (4 N, 0.07 mL, 10.0 equiv). The solution was stirred 
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overnight and the solvents were removed in vacuo to obtain the compound 195 (0.017 g, 
0.026 mmol, 95%). 1H NMR (400 MHz, CD3OD) δ 7.88 (d, J = 6.78 Hz, 1H), 7.65 - 7.80 
(m, 5H), 7.30 - 7.53 (m, 7H), 7.23 (s, 4H), 7.17 (br. s., 2H), 6.87 (d, J = 7.78 Hz, 1H), 4.45 
(d, J = 16.31 Hz, 1H), 4.23 (d, J = 16.31 Hz, 1H), 3.58 - 3.77 (m, 2H), 3.34 - 3.57 (m, 6H), 
2.97 - 3.11 (m, 1H). 13C NMR (101 MHz, CD3OD) δ 170.2, 168.7, 159.0, 149.2, 144.1, 
139.8, 138.5, 131.6, 130.6, 130.4, 130.4, 130.4, 129.8, 129.5, 129.5, 129.3, 129.2, 129.1, 
128.0, 123.9, 121.4, 111.2, 60.3, 43.4, 41.8, 37.0. HRMS (ESI) C33H35ClN6O3 m/z [M+H] 
+ found 598.2388, expected 598.2459. 
 
N-((2S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)-4-methoxybenzamide 
To a solution of the acid 196 (0.048 g, 0.154 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M) 
was added PyBOP (0.08 g, 0.154 mmol, 1.0 equiv), DIPEA (0.06 mL, 0.154 mmol, 2.0 
equiv) and stirred for 30 minutes, followed by the addition of the amine 192 (0.024 g, 
0.154 mmol, 1.0 equiv). The reaction was stirred overnight, after which it was washed 
with 1 N HCl and the DCM layer was purified over silica gel to get the compound 197 
(0.047 g, 0.14 mmol, 91%). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.78 Hz, 2H), 7.18 
- 7.38 (m, 5H), 6.89 (d, J = 8.80 Hz, 2H), 6.12 (d, J = 7.78 Hz, 1H), 4.34 - 4.47 (m, 1H), 
3.98 - 4.06 (m, 1H), 3.79 - 3.91 (m, 5H), 3.61 - 3.69 (m, 2H), 3.01 - 3.22 (m, 3H). 
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(S)-N-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methoxybenzamide 
To the above prepared alcohol 197 (0.020 g, 0.06 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 
M) was added Dess Martin periodinane (0.031 g, 0.072 mmol, 1.2 equiv). The reaction 
mixture was stirred for one hour at room temperature, followed by dilution of the reaction 
with DCM, washing with sodium thiosulfate solution and purification of the DCM layer over 
silica gel to obtain the α-chloro ketone 198 (0.01 g, 0.03 mmol, 50%). 1H NMR (400 MHz, 
CDCl3) δ 7.68 (d, J = 9.00 Hz, 2H), 7.25 - 7.39 (m, 3H), 7.18 - 7.25 (m, 2H), 6.92 (d, J = 
9.00 Hz, 2H), 6.55 (d, J = 6.02 Hz, 1H), 5.14 (q, J = 7.03 Hz, 1H), 4.24 (d, J = 16.06 Hz, 
1H), 4.06 (d, J = 16.06 Hz, 1H), 3.86 (s, 3H), 3.14 - 3.28 (m, 2H). 13C NMR (101 MHz, 
CD6CO) δ 200.9, 167.4, 163.4, 142.1, 138.5, 133.5, 132.5, 131.6, 130.1, 130.1, 129.3, 
127.5, 114.4, 59.4, 55.8, 48.6, 36.5. HRMS (ESI) C18H19ClNO3 m/z [M+H] + found 
332.1063, expected 332.1053. 
 
 
tert-butyl (S)-(1-(benzylamino)-1-oxo-3-phenylpropan-2-yl)carbamate 
 229 
 
To a solution of Boc-Phe-OH 146 (0.5g, 1.9 mmol, 1.0 equiv) in DCM (9.0 mL, 0.2 M) was 
added 1-hydroxybenzotriazole hydrate (0.306 g, 2.26 mmol, 1.2 equiv), EDCI (0.362 g, 
1.89 mmol, 1.0 equiv) and NMM (0.25 mL, 2.26 mmol, 1.2 equiv). The solution was stirred 
for 30 minutes, followed by addition of benzylamine 199 (0.2 mL, 1.89 mmol, 1.0 equiv) 
and the reaction was allowed to stir overnight. The following day, the solution was diluted 
with DCM and washed with 1 N HCl. The DCM layer was purified over silica gel to obtain 
the compound 200 (0.502 g, 1.42 mmol, 75%). 1H NMR (400 MHz, CDCl3) δ 7.17 - 7.34 
(m, 7H), 7.11 (d, J = 6.27 Hz, 2H), 6.05 (br. s., 1H), 5.04 (br. s., 1H), 4.37 (d, J = 6.00 Hz, 
2H), 2.98 - 3.18 (m, 3H), 1.40 (s, 9H). 
 
(S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-aminium 
To the solution of the amide 200 (0.1 g, 0.282 mmol, 1.0 equiv) in DCM (0.7 mL, 0.4 M) 
was added TFA (0.7 mL, 0.4 M) and the solution was stirred overnight. The following day, 
solvents were removed in vacuo to obtain compound 201 that was sufficiently pure to use 
for the next step. 
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To the solution of the acid 187 (0.027 g, 0.044 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M) 
was added PyBOP (0.023 g, 0.044 mmol, 1.0 equiv) and DIPEA (0.015 mL, 0.084 mmol, 
2.0 equiv). The mixture was stirred for 30 minutes, followed by addition of the amine 201 
(0.023 g, 0.044 mmol, 1.0 equiv). The solution was stirred overnight, followed by dilution 
with DCM, washing with 1 N HCl and purification over silica gel to obtain compound 202 
(0.035 g, 0.041 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 11.47 (s, 1H), 8.50 (t, J = 5.52 
Hz, 1H), 8.20 (s, 1H), 7.83 (dd, J = 2.13, 8.66 Hz, 1H), 7.62 - 7.74 (m, 5H), 7.35 - 7.50 
(m, 5H), 7.16 - 7.32 (m, 10H), 7.02 - 7.12 (m, 2H), 6.92 (d, J = 7.78 Hz, 1H), 6.81 (d, J = 
8.53 Hz, 1H), 6.34 (t, J = 5.65 Hz, 1H), 4.81 - 4.92 (m, 1H), 4.47 (br. s., 1H), 4.39 (dd, J 
= 6.15, 14.93 Hz, 1H), 4.28 (dd, J = 5.52, 14.81 Hz, 1H), 3.60 (q, J = 6.11 Hz, 2H), 3.34 
- 3.44 (m, 2H), 3.26 (dd, J = 6.02, 13.55 Hz, 1H), 3.14 (dd, J = 8.03, 13.55 Hz, 1H), 1.51 
(d, J = 8.78 Hz, 18H). 
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(S)-1-(2-((5-((4-((1-(benzylamino)-1-oxo-3-phenylpropan-2-
yl)carbamoyl)phenyl)carbamoyl)-[1,1'-biphenyl]-2-yl)amino)ethyl)guanidinium 
chloride 
To a solution of the above prepared amide 202 (0.035 g, 0.041 mmol, 1.0 equiv) in 
dioxane (0.4 mL, 0.1 M) was added HCl in dioxane (4 N, 0.1 mL, 10.0 equiv). The solution 
was stirred overnight and the solvents were removed in vacuo to obtain the compound 
203 (0.026 g, 0.04 mmol, quant). 1H NMR (400 MHz, CD3OD) δ 7.92 (br. s., 1H), 7.65 - 
7.85 (m, 5H), 7.34 - 7.55 (m, 6H), 7.07 - 7.33 (m, 12H), 6.95 (br. s., 1H), 4.74 - 4.88 (m, 
2H), 4.25 - 4.43 (m, 2H), 3.69 - 3.76 (m, 1H), 3.59 (s, 2H), 3.37 - 3.48 (m, 4H), 3.23 (dd, 
J = 6.15, 13.43 Hz, 1H), 3.03 - 3.14 (m, 1H). 13C NMR (101 MHz, CD3OD) δ 169.4, 168.3, 
158.7, 148.2, 143.6, 139.3, 138.3, 131.4, 130.3, 130.3, 130.2, 130.1, 129.9, 129.5, 129.4, 
129.3, 129.1, 128.9, 128.4, 128.0, 127.7, 124.5, 121.1, 111.8, 56.8, 44.1, 41.6, 38.9. 
HRMS (ESI) C39H41N7O3 m/z [M+H] + found 655.3187, expected 655.3270. 
 
4.3.2: Biological Experimentals 
Assays of AKT1 were performed using Z’-LYTE Kinase Assay Kit – Ser/Thr 6 peptide 
(Invitrogen, NY, USA) in non-binding low-volume 384-well plates (Cat. No 3676, Corning, 
NY, USA). All the reagents were diluted in kinase buffer (50 mM HEPES pH 7.5, 0.01% 
BRIJ-35, 10 mM MgCl2, 1 mM EDTA). All compounds were prepared as 10 mM soulutions 
in DMSO and diluted to 0.8% final DMSO concentrations in the assay. A typical 10 µL 
assay contained 6 ng of AKT1, 75 µM ATP and 2 µM peptide substrate in kinase buffer 
in the presence/absence of tested compounds. The assays were incubated at room 
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temperature for 1 h, following by the addition of 5 µL of development reagent and further 
incubation at room temperature for another hour. The kinase reaction was terminated by 
the addition of 5 µL of stop reagent. The FRET signal was measured using Flexstation 3 
microplate reader (molecular Devices, CA, USA) with an excitation wavelength of 410 nm 
and emission wavelengths of 458 nm and 522 nm.  The percent inhibition was calculated 
according to the kit guidelines. Staurosporine (CalBiochem) was used as the control 
compound. Data analysis, curve fitting and calculation of error was performed using Prism 
software from GraphPad. The IC50s (Table 11) were calculated from the graphs obtained 
below (Figure 90); 
Table 11: IC50s (µM) of compounds  
Compound IC50 (µM) 95% Confidence 
Interval 
125 >100  
129 10.59 7.53 – 14.89 
127 3.25 2.32 – 4.55 
141 1.55 1.35 – 1.79 
135 >100  
138 >100  
128 2.33 1.84 – 2.96 
133 1.11 1.00 – 1.24 
144 1.79 1.53 – 2.09 
145 1.97 1.44 – 4.11 
 233 
 
151 0.32 0.26 – 0.40 
152 >100  
156 2.44 1.23 – 2.76 
153 > 100  
161 0.82 0.68 – 0.98 
173 > 100  
175 > 100  
177 > 100  
198 >25  
195 0.578 0.314 – 1.065  
203 >25  
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Figure 90: Graphs used to calculate IC50s for compounds 
 
The assays of PKAα were performed using Z′-LYTE Kinase Assay Kit – Ser/Thr 1 Peptide 
(Invitrogen, NY, USA) in non-binding low-volume 384-well plates (Cat. No 3676, Corning, 
NY,USA). All the reagents were diluted in kinase buffer (50 mM HEPES pH 7.5, 0.01% 
BRIJ-35, 10mM MgCl2, 1 mM EDTA). The compounds were prepared as 10 mM solutions 
in DMSO and diluted to 0.8% final DMSO concentration in the assay. A typical 10 μL 
assay contained 0.3 ng of PKAα, 4 μM ATP and 2 μM peptide substrate in kinase buffer 
in the presence/absence of tested compounds. The assays were incubated at room 
temperature for 1 h. 5 μL of development reagent was then added and the assay mixture 
was incubated at room temperature for further 1 h. The kinase reaction was terminated 
by the addition of 5 μL of stop reagent. The FRET signal was measured using a 
Flexstation 3 microplate reader (Molecular Devices, CA, USA) using an excitation 
wavelength of 410 nm and emission wavelengths of 458 nm and 522 nm. The percent 
inhibition was calculated according to the kit guidelines. Staurosporine (CalBiochem) was 
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used as a control compound. The IC50s (Table 12) were calculated from the graphs 
obtained below (Figure 91) 
Table 12: IC50 of compounds against PKAα 
Compound IC50 (µM) Confidence interval 
151 >100  
161 13.47 11.75 – 15.43 
 
 
Figure 91: Graphs used to calculate IC50s for PKAα 
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